[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5536
1. Haenssle HA, Krueger U, Vente C, Thoms KM, Bertsch HP, Zutt M, Rosenberger A, Neumann C, Emmert S: Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J Invest Dermatol; 2006 May;126(5):980-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma.
  • We analyzed the value of digital epiluminescence microscopy (DELM) for the long-term follow-up of atypical nevi.
  • Atypical nevi (n=7001) were additionally followed by DELM.
  • Excisions due to mere DELM changes detected 66.7% of melanomas in familial atypical mole and multiple melanoma (FAMMM) and 32.5% of melanomas in atypical mole syndrome (AMS) patients.
  • We conclude that DELM is a valuable tool for the long-term follow-up of atypical nevi, especially in the high-risk groups of FAMMM and AMS patients.
  • [MeSH-major] Image Processing, Computer-Assisted. Melanoma / diagnosis. Microscopy. Nevus, Pigmented / pathology. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514414.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, Kirkwood JM: STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol; 2008 Aug;128(8):1997-2002
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
  • Atypical nevi are nonobligate risk markers of melanoma, affording investigators a target for evaluation of progression biomarkers in vivo. pSTAT1tyr701 (pSTAT1) and pSTAT3tyr705 (pSTAT3) oppose one another in biological function.
  • Therefore, an analysis of phosphorylated STAT1 (pSTAT1) and pSTAT3 signaling was performed simultaneously using double-immunohistochemistry in biopsies of 168 atypical nevi from 42 patients receiving high- or low-dose IFNalpha (HDI and LDI).
  • With maturation of melanocytes from junctional into dermal components of nevi, pSTAT1 expression increased, whereas pSTAT3 expression decreased.
  • The percentage of pSTAT3-positive melanocytes was positively associated with the atypical degree of nevi (P<0.0001).
  • In the junctional component of nevomelanocytic lesions, HDI and LDI downregulated the percentage of pSTAT3-positive melanocytes (P=0.008 and P=0.0003, respectively) while upregulating the percentage of pSTAT1-positive melanocytes (P=0.016 and P=0.0059, respectively) and augmented the pSTAT1/pSTAT3 ratio (P=0.008 and P=0.0040, respectively).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Interferon-alpha / therapeutic use. Melanoma / metabolism. Nevus / metabolism. STAT3 Transcription Factor / metabolism. Skin Neoplasms / drug therapy. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18305569.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / STAT1 Transcription Factor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


3. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, van der Drift C, van Leeuwen I, van Mourik L, Huurne JA, Frants RR, Willemze R, Breuning MH, Trent JM, Gruis NA: Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families. Eur J Hum Genet; 2008 Sep;16(9):1135-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide linkage scan for atypical nevi in p16-Leiden melanoma families.
  • However, it does not account for the Atypical Nevus (AN) phenotype that segregates in both p16-Leiden carriers and non-carriers.
  • The AN-affected p16-Leiden family members are therefore a unique valuable resource for unraveling the genetic etiology of the AN phenotype, which is considered both a risk factor and a precursor lesion for melanoma.
  • The strongest evidence for an atypical nevus susceptibility gene was mapped to chromosome band 7q21.3 (two-point LOD score=2.751), a region containing candidate gene CDK6.
  • [MeSH-major] Dysplastic Nevus Syndrome / genetics. Genes, p16. Genetic Linkage / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18398432.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


Advertisement
4. Fuller SR, Bowen GM, Tanner B, Florell SR, Grossman D: Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma. Dermatol Surg; 2007 Oct;33(10):1198-206; discussion 1205-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital dermoscopic monitoring of atypical nevi in patients at risk for melanoma.
  • BACKGROUND: Atypical nevi are a common risk factor for melanoma.
  • OBJECTIVES: The objective was to determine the utility of monitoring dermoscopic photographs of atypical nevi in a high-risk population.
  • METHODS: Over a 4.5-year period, digital dermoscopic photographs were taken of clinically atypical nevi at initial and follow-up visits, such that side-by-side comparisons could be made.
  • Photographic (dermoscopic) changes were noted in 96 of 5,945 (1.6%) lesions, which included 64 dysplastic nevi (67%), 25 common nevi (26%), and 1 melanoma (1.0%).
  • CONCLUSIONS: Most clinically atypical melanocytic nevi are stable over time, and lesions exhibiting dermoscopic changes are most likely to be dysplastic nevi.
  • Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 2000 Sep;43(3):467-76 [10954658.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):980-5 [16514414.001]
  • [Cites] Arch Dermatol. 2001 Dec;137(12):1583-9 [11735708.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):282-8 [12622618.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):663-71 [12734494.001]
  • [Cites] J Am Acad Dermatol. 2004 Jan;50(1):15-20 [14699359.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):49-56 [14732660.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):683-9 [15097950.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):706-14 [15099367.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):466-70 [15337995.001]
  • [Cites] Ann Surg. 1991 Apr;213(4):308-14 [2009012.001]
  • [Cites] Australas J Dermatol. 1990;31(2):77-80 [2095738.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):286-91 [7887657.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):87-92 [15656806.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):998-1006 [16103329.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1008-14 [16103330.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1032-4 [16103334.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):979-86 [11369910.001]
  • (PMID = 17903152.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR050102; United States / NIAMS NIH HHS / AR / AR50102; United States / NCI NIH HHS / CA / CA125761; United States / NIAMS NIH HHS / AR / R01 AR050102-04; United States / NIAMS NIH HHS / AR / AR050102-04
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS44276; NLM/ PMC2292405
  •  go-up   go-down


5. Cebulla CM, Alegret AM, Feuer WJ, Shi W, Schefler AC, Murray TG: Tumor volume reduction using combined phacoemulsification and intravitreal triamcinolone injection for the management of cataract with treated uveal melanoma and atypical nevi. J Cataract Refract Surg; 2008 Oct;34(10):1669-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor volume reduction using combined phacoemulsification and intravitreal triamcinolone injection for the management of cataract with treated uveal melanoma and atypical nevi.
  • PURPOSE: To study the reduction in tumor size and the safety and efficacy of combined phacoemulsification and intravitreal triamcinolone acetonide injection (phaco-IVTA) in patients with treated melanoma and atypical nevi.
  • METHODS: The medical records of 49 consecutive patients (51 eyes) with treated melanoma or atypical nevi treated with phaco-IVTA were evaluated retrospectively for changes in Snellen visual acuity, tumor volume, and frequency of complications.
  • Treated uveal melanomas (n=30) and atypical choroidal nevi (n=21) were stable with combined therapy, and echographic measurements improved in 12 eyes.
  • CONCLUSIONS: Combined phacoemulsification and IVTA was reasonably safe in patients with treated melanoma and atypical nevi.
  • Intravitreal triamcinolone acetonide injection at the time of cataract surgery in patients with treated melanoma or nevus may reduce rates of tumor progression in these patients.
  • [MeSH-major] Glucocorticoids / administration & dosage. Melanoma / pathology. Nevus, Pigmented / pathology. Phacoemulsification / methods. Triamcinolone Acetonide / administration & dosage. Tumor Burden. Uveal Neoplasms / pathology

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812116.001).
  • [ISSN] 0886-3350
  • [Journal-full-title] Journal of cataract and refractive surgery
  • [ISO-abbreviation] J Cataract Refract Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; F446C597KA / Triamcinolone Acetonide
  •  go-up   go-down


6. Schäfer T, Merkl J, Klemm E, Wichmann HE, Ring J, KORA Study Group: The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000. J Invest Dermatol; 2006 Jul;126(7):1490-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000.
  • Nevi can approximate the melanoma risk and demographic changes will increase the meaning of signs of skin aging (SSA).
  • However, little is known about the epidemiology of nevi and SSA in the general adult population.
  • We aimed to estimate the prevalence and age distribution of common and atypical nevi and SSA as well as gender differences in a large population-based sample.
  • Most subjects (60.3%) exhibited 11 to 50 common nevi and 5.2% had at least one atypical nevus.
  • All signs of skin aging increased significantly with age and so did lentigines solaris, seniles, and actinic keratoses.
  • In contrast, common and atypical nevi and ephelides decreased significantly with age.
  • Signs of skin aging are frequent and increase, in contrast to common and atypical nevi, with age.
  • [MeSH-major] Nevus / epidemiology. Nevus / pathology. Skin Aging / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology


7. Fabrizi G, Pagliarello C, Parente P, Massi G: Atypical nevi of the scalp in adolescents. J Cutan Pathol; 2007 May;34(5):365-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical nevi of the scalp in adolescents.
  • BACKGROUND: A few reports in the literature point out that in special areas of the body, nevi can have peculiar pseudomelanomatous features.
  • In our routine work, we have met few examples of atypical nevi with peculiar features on the scalp of teenagers.
  • MATERIALS AND METHODS: Thirty-nine nevi of the scalp were from adolescents (12-18 years), 160 from adults, and 30 from children below the age of 12 years.
  • RESULTS: About 10% of the melanocytic nevi of the scalp of adolescents have atypical cytological and architectural aspects that are different from those seen in Clark's dysplastic nevus.
  • Other findings were pagetoid spread of cells above the junction and the discohesive pattern of the melanocytes in the nests.
  • Mild cytological atypia was present but less significant.
  • Such distinctive aspects are not found in nevi of the same site in adults or younger children.
  • The general pattern of these atypical nevi of the scalp of adolescents closely recalls that of the so-called atypical nevi on special sites, i.e. nevi on mammary line, genitalia and body's folds.
  • Despite the architectural and cytological atypia, clinical follow-up does not show any tendency to recur or proclivity to malignant behaviour.
  • CONCLUSIONS: Despite their similarities with melanoma, the nevi with atypical features of the scalp of adolescents are probably an entirely benign entity, at least at the moment of their excision.
  • However, although benign, the relationship of this peculiar group of nevi with melanomas developed in adulthood remains entirely unknown, and the complete excision with conservative margins seems a recommendable procedure.
  • [MeSH-major] Nevus, Pigmented / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448189.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


8. Rezze GG, Leon A, Duprat J: Dysplastic nevus (atypical nevus). An Bras Dermatol; 2010 Nov-Dec;85(6):863-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplastic nevus (atypical nevus).
  • Atypical nevum (dysplastic) is considered an important factor associated with increased risk of developing cutaneous melanoma.
  • It is believed that atypical nevi are precursor lesions of cutaneous melanoma.
  • They may be present in patients with multiple melanocytic nevi (atypical nevus syndrome) or isolated and in small numbers in a non-familial context.
  • The major challenge in relation to atypical nevi lies in the controversy of defining its nomenclature, clinical diagnosis, dermoscopic criteria, histopathological diagnosis and molecular aspects.
  • This review aims at bringing knowledge, facilitating comprehension and clarifying doubts about atypical nevus.
  • [MeSH-major] Dysplastic Nevus Syndrome / pathology. Melanoma / pathology. Precancerous Conditions / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] An Bras Dermatol. 2011 Feb;86(1):182
  • (PMID = 21308311.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  •  go-up   go-down


9. Haimovic A, Hamilton HK, Tay S, Stein JA, Polsky D: Association between thin melanomas and atypical nevi in middle-aged and older men possibly attributable to heightened patient awareness. Arch Dermatol; 2009 Dec;145(12):1457-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between thin melanomas and atypical nevi in middle-aged and older men possibly attributable to heightened patient awareness.
  • [MeSH-major] Early Detection of Cancer. Health Knowledge, Attitudes, Practice. Melanoma / pathology. Nevus / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Dermatol. 2006 Dec;142(12):1551-8 [17178980.001]
  • [CommentOn] Arch Dermatol. 2009 Apr;145(4):397-404 [19380661.001]
  • (PMID = 20026863.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Seidenari S, Pellacani G, Grana C: Colors in atypical nevi: a computer description reproducing clinical assessment. Skin Res Technol; 2005 Feb;11(1):36-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colors in atypical nevi: a computer description reproducing clinical assessment.
  • BACKGROUND/PURPOSE: Atypical nevi (AN) share some dermoscopic features with early melanoma (MM), and computer elaboration of digital images could represent a useful support to diagnosis to assess automatically colors in AN, and to compare the data with those referring to clearly benign nevi (BN) and MMs.
  • [MeSH-major] Colorimetry / methods. Dermoscopy / methods. Expert Systems. Image Interpretation, Computer-Assisted / methods. Melanoma / pathology. Nevus / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691257.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


11. Molven A, Grimstvedt MB, Steine SJ, Harland M, Avril MF, Hayward NK, Akslen LA: A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer; 2005 Sep;44(1):10-8
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
  • In the 1960s, a large Norwegian pedigree with multiple atypical nevi and malignant melanomas was identified.
  • Thus, the case of ocular melanoma in this family was sporadic, suggesting an etiology different from that of the skin tumors.
  • In addition to resulting from selection pressure, this observation may be explained by the CG dinucleotide of codon 24 representing a mutational hot spot in the CDK4 gene.
  • [MeSH-major] Cyclin-Dependent Kinases / genetics. Dysplastic Nevus Syndrome / genetics. Melanoma / genetics. Mutation, Missense. Proto-Oncogene Proteins / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15880589.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 9007-49-2 / DNA; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


12. Hanson MS, Steffen A, Danobeitia JS, Ludwig B, Fernandez LA: Flow Cytometric Quantification of Glucose-Stimulated β-Cell Metabolic Flux Can Reveal Impaired Islet Functional Potency. Cell Transplant; 2008 Dec;17(12):1337-1347

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucose-induced metabolic activity was indicated by changes in Fura Red fluorescence and the autofluorescence of the pyridine [NAD(P)H] and flavin (FAD/FMN) nucleotides.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876094.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Diabetes / Flow cytometry / Glucose / Islet; β-Cell / Mitochondria / Pancreas / Transplantation
  •  go-up   go-down


13. Kmetz EC, Sanders H, Fisher G, Lang PG, Maize JC Sr: The role of observation in the management of atypical nevi. South Med J; 2009 Jan;102(1):45-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of observation in the management of atypical nevi.
  • OBJECTIVE: The definition and management of the atypical nevus remains a controversial issue.
  • Some believe that atypical nevi are common variants of benign melanocytic nevi while others believe they are lesions intermediate between benign melanocytic nevi and melanoma.
  • Therefore, the question of whether or not partially removed atypical nevi should be re-excised with clear margins in order to prevent their evolution into melanoma remains unanswered.
  • Although studies have shown that most atypical nevi will never progress into melanoma, re-excision, when biopsy margins are positive, is commonly practiced.
  • METHODS: Our cohort study includes 55 previously biopsied atypical nevi that were not re-excised and which were followed for at least 5 years with a mean follow up time of 6.12 years.
  • RESULTS: The experimental group included 26 atypical nevi whose biopsy revealed at least one involved margin.
  • The control group included 29 atypical nevi whose biopsy revealed clear margins.
  • No melanomas were observed to arise in association with a pre-existing atypical nevus in either the experimental or control group during the follow-up period.
  • CONCLUSIONS: The results of our study support observation as a safe alternative to re-excision for incompletely removed atypical nevi.
  • A large prospective study with longer follow up would be necessary to better answer the question of how often atypical nevi evolve into melanoma and over what time period this occurs.
  • [MeSH-major] Dysplastic Nevus Syndrome / surgery. Neoplasm Recurrence, Local / prevention & control. Observation. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077745.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pishvaian MJ, Marshall JL, Hwang JJ, Malik S, He AR, Deeken JF, Kelso CB, Cotarla I, Berger MS: A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. J Clin Oncol; 2009 May 20;27(15_suppl):3581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion.
  • : 3581 Background: GMX1777 is a pro-drug which converts to GMX1778, a potent and specific small molecule inhibitor of NAMPRT, the rate-limiting enzyme in NAD+ synthesis.
  • Thrombocytopenia, GI hemorrhage, and skin rash (the last occurring after multiple cycles) were encountered at higher doses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Mazzone PJ, Videtic G, Murthy S, Mason D, Rice T, Pennell N, Rich T, Machuzak M, Mekhail T: The serial effects of multimodality therapy for stage III non-small cell carcinoma on lung function. J Clin Oncol; 2009 May 20;27(15_suppl):7551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7551 Purpose: To describe the effects of multimodality treatment on lung function in patients with stage III non-small cell carcinoma of the lung (NSCLC) Methods: Pulmonary function tests (PFTs) were reviewed for 32 patients with stage III NSCLC who were enrolled in a multimodality protocol that included neoadjuvant (NAd) combined chemoradiotherapy (taxol 50 mg/m2, carboplatin AUC 2 weekly X 3, radiation (XRT) 1.8 Gy BID to 30 Gy + erlotinib 150 mg/d for 28 days, followed by resection (R) and adjuvant (Ad) chemoradiotherapy (same as induction) followed by erlotinib 150mg/d maintenance (M) for 2 years.
  • Changes in PFTs were analyzed at multiple time points (baseline to after NAd, after NAd to after R, after R to after Ad) and for the overall effect of treatment (baseline to the end of treatment).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963339.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Frankenthaler A, Lee M, Seery V, Renzi S, Kinnaman M, Liu V, Friedman E, Atkins MB, Cutaneous Oncology Program: Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We examined the Beth Israel Deaconess Medical Center Cutaneous Oncology Program database for pts with immune suppression at the time of melanoma diagnosis.
  • Melanoma stages at diagnosis were in situ 1, IB 7, IIA 1, IIB 1, IIIB 3, IIIC 5, and IV 1.
  • In addition, more cases appeared to have an amelanotic primary (21% vs. 5.4%) or an atypical mole syndrome (21% vs 10.2%).
  • At a median f/up of 52 mos, 37% of the cases had relapsed and all of these pts had died.
  • At a median f/up of 76 mos, 30% of the controls had relapsed yet only 47% of these pts had died.
  • CONCLUSIONS: Compared to the general melanoma population, pts with concomitant immune suppression appear more likely to be female, have an amelanotic primary or atypical mole syndrome and more advanced disease at presentation.
  • Thus, diagnosis and treatment of a primary melanoma at an early stage appears especially important in an immunosuppressed population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to gather data on the epidemiology of AIDS-defining (AD) and non-AIDS-defining (NAD) malignancies in HIV-positive patients (pts) in Germany in the past decade.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • The high proportion of NAD malignancies has remained constant over all observation periods, as well as the relative incidence of most of the different subentities.
  • CONCLUSIONS: Our observations show a high incidence of NAD malignomas over the past 8 years in Germany.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Uribe P, Wistuba II, Gonzalez S: Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol; 2009 Jun;31(4):354-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas.
  • Loss of heterozygosity (LOH) in several chromosomal regions is found in melanoma, and it has been partially studied in nevi.
  • BRAF mutations are found in melanoma and nevi and in colorectal cancer are linked to mismatch repair deficiency.
  • DNA extracted from microdissected cells of 22 common nevi, 23 atypical nevi, and 25 primary cutaneous melanomas were examined for LOH and MSI by polymerase chain reaction-based analysis of 24 microsatellite markers and BRAF mutation.
  • Allelic loss index was higher in atypical nevi (0.20) and melanomas (0.27) than common nevi (0.07).
  • LOH at any of this loci occurred in 27% of common nevi, 57% of atypical nevi, and 68% of melanomas.
  • Similar genetic alterations in atypical nevi and melanomas support the concept of atypical nevus as melanoma precursor.
  • Novel deletion loci at 5q35 and 17q21 (BRCA1) in atypical nevi and melanomas were identified.
  • [MeSH-major] Loss of Heterozygosity. Microsatellite Instability. Nevus, Pigmented / genetics. Proto-Oncogene Proteins B-raf / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461239.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


19. Wang H, Presland RB, Piepkorn M: A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection. Arch Dermatol; 2005 Feb;141(2):177-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection.
  • OBJECTIVE: To determine the frequency at which the CDKN2A coding region is mutated in the atypical nevi of persons with sporadic melanoma.
  • DESIGN: DNA samples, isolated by laser-captured microdissection of atypical nevi from 10 patients with newly incident cases of sporadic melanoma and their spouses as matched controls, were used as templates for nested polymerase chain reaction amplification of CDKN2A exons 1 and 2.
  • RESULTS: No point mutations in the coding region of CDKN2A were observed in any of the melanocytic nevi.
  • CONCLUSIONS: Point mutations in CDKN2A are an uncommon event in the atypical nevi of persons with melanoma.
  • As such, the data may support a hypothesis of melanocytic nevus histogenesis, in which the melanocytic nevus and malignant melanoma represent separate, pleiotropic pathways resulting from common stimuli, such as genomic damage from UV radiation.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Genetic Predisposition to Disease. Melanoma / genetics. Nevus, Pigmented / genetics. Point Mutation. Skin Neoplasms / genetics
  • [MeSH-minor] Alleles. Base Sequence. Case-Control Studies. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Laser Therapy / methods. Male. Microdissection / methods. Molecular Sequence Data. Paraffin Embedding. Polymerase Chain Reaction / methods. Probability. Reference Values. Sampling Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724013.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / T32 AR07019
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm
  •  go-up   go-down


20. Miracco C, De Nisi MC, Arcuri F, Cosci E, Pacenti L, Toscano M, Lalinga AV, Biagioli M, Rubegni P, Vatti R, Maellaro E, Del Bello B, Massi D, Luzi P, Tosi P: Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int J Oncol; 2006 Feb;28(2):345-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated MIF protein expression in 126 skin lesions, including benign and atypical nevi, melanoma and melanoma metastases.
  • Benign nevi were subdivided into nevocytic and Spitz/blue types; and melanomas into the radial, and vertical growth phase.
  • A strong cytoplasmic MIF positivity was found in most samples, although it was more heterogeneous in malignant tumours; MIF nuclear expression characterized Spitz/blue nevi, atypical nevi, melanomas and metastases.
  • All samples expressed MIF mRNA but it was significantly lower in benign nevi vs atypical nevi, melanomas and metastases (p=0.001; p<0.0001; p=0.002, respectively).
  • Whereas we observed a trend towards higher expression levels of mRNA in atypical and malignant tumours, MIF protein was highly expressed in all lesions, although limited to the cytoplasm in most benign nevi.
  • These observations suggest differences in MIF protein storage, subcellular location and properties in most benign nevi vs atypical and malignant tumours that should be confirmed by further investigation and correlation with clinical outcome.
  • [MeSH-major] Macrophage Migration-Inhibitory Factors / metabolism. Melanoma / metabolism. Nevus, Pigmented / metabolism. RNA, Messenger / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391788.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger
  •  go-up   go-down


21. Sharma BK, Smith CC, Laing JM, Rucker DA, Burnett JW, Aurelian L: Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions. Dermatology; 2006;213(3):192-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To examine whether H11 is silenced by aberrant DNA methylation in melanoma as compared to nevi and normal skin tissues.
  • METHODS: Cell suspensions from benign intradermal nevi, atypical nevi and malignant melanoma tissues were used in reverse-transcriptase PCR and methylation-specific PCR.
  • RESULTS: H11 is methylated in 60-75% of melanoma and atypical nevi, but not in normal skin or most benign nevi.
  • CONCLUSION: The heat shock protein H11 is silenced by aberrant DNA methylation in melanoma, but not benign melanocytic lesions or normal skin melanocytes.
  • [MeSH-major] DNA Methylation. Heat-Shock Proteins / genetics. Melanocytes / pathology. Melanoma / genetics. Protein-Serine-Threonine Kinases / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Apoptosis. Dysplastic Nevus Syndrome / genetics. Dysplastic Nevus Syndrome / metabolism. Dysplastic Nevus Syndrome / pathology. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Nevus, Intradermal / genetics. Nevus, Intradermal / metabolism. Nevus, Intradermal / pathology. Nevus, Pigmented / genetics. Nevus, Pigmented / metabolism. Nevus, Pigmented / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033167.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR-42647; United States / NIEHS NIH HHS / ES / ES07263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Heat-Shock Proteins; EC 2.7.1.- / HSPB8 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


22. Gächter T, Mühleisen B, Schärer L, Dummer R, Burg G, Hofbauer GF: Weight of decision-making impairs clinical assessment of melanocytic lesions. J Cutan Med Surg; 2007 Jan-Feb;11(1):9-18
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: We studied the weight of decision-making on clinical assessment of melanocytic lesions judging benign, atypical, and malignant lesions; common mistakes; and total removal rates, comparing dermatologists with nondermatologists.
  • Histopathologic diagnosis served as the gold standard.
  • RESULTS: Benign nevi were assessed most accurately (77%).
  • Dermatologists assessed benign nevi better (p < .0001).
  • The accuracy of clinical assessment in atypical nevi and melanoma was lower (23% and 42%, respectively).
  • Seborrheic keratosis was the most common mistaken diagnosis.
  • Complete removal of clinically benign nevi, atypical nevi, and melanoma was 84%, 90%, and 89%.
  • CONCLUSION: The accuracy of clinical assessment of melanocytic lesions is high for benign nevi, with dermatologists outperforming nondermatologists.
  • [MeSH-major] Decision Making. Keratosis, Seborrheic / diagnosis. Melanoma / diagnosis. Nevus / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Clinical Competence. Dermatology. Diagnosis, Differential. Humans. Risk Assessment

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274934.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Pellacani G, Cesinaro AM, Longo C, Grana C, Seidenari S: Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas. Arch Dermatol; 2005 Feb;141(2):147-54
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas.
  • Some confocal architectural and cytologic features, as observed at the dermoepidermal junction, were morphologically described and quantified by means of a dedicated program.
  • STUDY POPULATION: We studied confocal images of 15 melanomas, 15 dermoscopic atypical nevi, and 15 common nevi.
  • MAIN OUTCOME MEASURES: Features referring to aspect, size, regularity, homogeneity, and infiltration of dermal papillae and to cellular size, regularity, and atypia were described by 2 observers on confocal images.
  • Mean dermal papillary diameter, mean cell area, and shape irregularity were quantified by drawing papillae and cell contours on confocal images and measured with the use of a computer program.
  • RESULTS: Pigment network in melanomas consisted of large basal cells that circumscribed small to medium-sized dermal papillae with marked cellular atypia, sometimes infiltrating dermal papillae.
  • On the other hand, common acquired nevi were characterized by lack of atypical cells and edged dermal papillae.
  • Atypical nevi presented intermediate characteristics between clearly benign and malignant lesions.
  • CONCLUSION: Cellular atypia was the most sensitive feature for melanoma diagnosis, whereas the presence of nucleated cells infiltrating dermal papillae was the most specific one.
  • [MeSH-major] Melanoma / pathology. Microscopy, Confocal. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cohort Studies. Dermoscopy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Melanocytes / pathology. Melanocytes / ultrastructure. Probability. Sampling Studies. Sensitivity and Specificity. Skin Pigmentation. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2005 Feb;141(2):212-5 [15724018.001]
  • (PMID = 15724010.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Soares TF, Laman SD, Yiannias JA, Connolly SM, Lim KK, Wu Q, Swanson DL: Factors leading to the biopsy of 1547 pigmented lesions at Mayo Clinic, Scottsdale, Arizona, in 2005. Int J Dermatol; 2009 Oct;48(10):1053-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We identified 1398 nevi, 147 invasive and in situ melanomas, and two lesions interpreted as atypical melanocytic proliferations.
  • Prior histories of melanoma, atypical nevi, or nonmelanoma skin cancer were common.
  • Physician-directed biopsies more commonly yielded atypical nevi, but there was no difference in the likelihood of melanoma.
  • The ratio of removed nevi to melanomas was 9.2 : 1.
  • CONCLUSIONS: Both patient-driven and physician-driven indications lead to skin biopsies.
  • [MeSH-major] Melanoma / pathology. Nevus / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775399.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Brod C, Schippert W, Breuninger H: Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis. J Dtsch Dermatol Ges; 2009 Sep;7(9):773-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplastic nevus syndrome with development of multiple melanomas. A surgical concept for prophylaxis.
  • A 58-year-old man presented in 2001 with dysplastic nevus syndrome with at least 300 nevi and about 100 clinically highly atypical nevi.
  • Between 2002 and 2003, 117 nevi which were atypical on dermatoscopy were removed; most by horizontal (shave) excision.
  • Adequate clinical and dermatoscopic control was not feasible due to the large number of atypical nevi.
  • In order to reduce the number of nevus cells, we treated test sites with both dermabrasion and split-thickness excision.
  • The latter proved to be more efficient and was used to completely excise the skin of the back, as well as parts of the arms and chest in two sessions under general anesthesia.
  • Following these procedures, adequate clinical and dermatoscopic monitoring of the remaining nevi was possible and only a few had to be removed.
  • [MeSH-major] Dysplastic Nevus Syndrome / prevention & control. Dysplastic Nevus Syndrome / surgery. Melanoma / prevention & control. Nevus / surgery. Precancerous Conditions / surgery. Skin Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Dtsch Dermatol Ges. 2010 Apr;8(4):279-80 [20409087.001]
  • (PMID = 19456853.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Fikrle T, Pizinger K: Digital computer analysis of dermatoscopical images of 260 melanocytic skin lesions; perimeter/area ratio for the differentiation between malignant melanomas and melanocytic nevi. J Eur Acad Dermatol Venereol; 2007 Jan;21(1):48-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital computer analysis of dermatoscopical images of 260 melanocytic skin lesions; perimeter/area ratio for the differentiation between malignant melanomas and melanocytic nevi.
  • BACKGROUND: Digital computer analysis of dermatoscopical images has been reported to facilitate the differential diagnosis of pigmented skin lesions in recent years.
  • OBJECTIVE: The aim of our study was to perform digital computer analysis of a set of different melanocytic lesions and compare the objective results.
  • METHODS: The set of 260 melanocytic lesions (150 excised difficult cases (46 melanomas, 47 atypical nevi, 57 common nevi and 110 unexcised common nevi) was automatically analysed by the digital dermatoscopical system microDERM.
  • RESULTS: The perimeter/area ratio was detected as the most important criterion for differentiation between malignant and benign melanocytic lesions (sensitivity 91.3% and specificity 90.7% for malignant melanomas vs. all benign nevi; sensitivity 91.3% and specificity 80.8% for melanomas vs. clinically atypical nevi).
  • CONCLUSION: The perimeter/area ratio is a simple parameter for the differential diagnosis of melanocytic skin lesions.
  • [MeSH-major] Image Processing, Computer-Assisted. Melanoma / diagnosis. Nevus / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207167.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Goodson AG, Grossman D: Strategies for early melanoma detection: Approaches to the patient with nevi. J Am Acad Dermatol; 2009 May;60(5):719-35; quiz 736-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for early melanoma detection: Approaches to the patient with nevi.
  • Although there are no noninvasive techniques for the definitive diagnosis of melanoma, and the "gold standard" remains biopsy with histologic examination, a variety of modalities may facilitate early melanoma diagnosis and the detection of new and changing nevi.
  • This article reviews the general clinical principles of early melanoma detection and various modalities that are currently available or on the horizon, providing the clinician with an up to date understanding of management strategies for their patients with numerous or atypical nevi.
  • LEARNING OBJECTIVE: After completing this learning activity, participants should understand the clinical importance of early melanoma detection, appreciate the challenges of early melanoma diagnosis and which patients are at highest risk, know the general principles of early melanoma detection, be familiar with current and emerging modalities that may facilitate early melanoma diagnosis and the detection of new and changing nevi, know the advantages and limitations of each modality, and be able to practice a combined approach to the patient with numerous or clinically atypical nevi.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Dermatol. 2005 Jan;14(1):56-9 [15660920.001]
  • [Cites] J Cutan Med Surg. 2004 Jan-Feb;8(1):1-5 [15688095.001]
  • [Cites] Arch Dermatol. 2005 Feb;141(2):155-60 [15724011.001]
  • [Cites] J Invest Dermatol. 2005 Mar;124(3):493-8 [15737188.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):434-8 [15837860.001]
  • [Cites] Curr Opin Ophthalmol. 2005 Jun;16(3):141-54 [15870570.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):998-1006 [16103329.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1008-14 [16103330.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1032-4 [16103334.001]
  • [Cites] J Am Acad Dermatol. 2005 Sep;53(3):393-406 [16112344.001]
  • [Cites] J Invest Dermatol. 2005 Sep;125(3):532-7 [16117795.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2040-59 [16125929.001]
  • [Cites] Arch Dermatol. 2005 Nov;141(11):1388-96 [16301386.001]
  • [Cites] Arch Dermatol. 2005 Nov;141(11):1401-12 [16301387.001]
  • [Cites] Skin Res Technol. 2006 Feb;12(1):50-9 [16420539.001]
  • [Cites] Arch Dermatol. 2006 Apr;142(4):508 [16618873.001]
  • [Cites] J Invest Dermatol. 2006 May;126(5):980-5 [16514414.001]
  • [Cites] J Am Acad Dermatol. 2006 May;54(5):783-92 [16635658.001]
  • [Cites] J Gen Intern Med. 2006 Jul;21(7):678-82 [16808765.001]
  • [Cites] J Am Acad Dermatol. 2006 Aug;55(2):245-50 [16844506.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):044012 [16965169.001]
  • [Cites] Arch Dermatol. 2006 Sep;142(9):1113-9 [16982998.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1214-9 [17062034.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):189-95 [17068484.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):45-52 [17190620.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):144-5 [17190631.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):72-6 [17199569.001]
  • [Cites] Dermatol Surg. 2006 Dec;32(12):1497-504 [17199661.001]
  • [Cites] Arch Dermatol. 2007 Jan;143(1):21-8 [17224538.001]
  • [Cites] Arch Dermatol. 2007 Feb;143(2):176-85 [17309998.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):508-13 [17113189.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):413-6 [17156892.001]
  • [Cites] Arch Dermatol. 2007 Mar;143(3):329-38 [17372097.001]
  • [Cites] Am J Dermatopathol. 2007 Apr;29(2):134-6 [17414433.001]
  • [Cites] Arch Dermatol. 2007 Apr;143(4):488-94 [17438181.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):759-67 [17316894.001]
  • [Cites] Arch Dermatol. 2007 Jun;143(6):727-34 [17576938.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2819-24 [17602087.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1086-90 [17714130.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):629-37 [17610989.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):555-72; quiz 573-6 [17870429.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1213-5; author reply 1215-6 [17875894.001]
  • [Cites] Dermatol Surg. 2007 Oct;33(10):1198-206; discussion 1205-6 [17903152.001]
  • [Cites] Int J Dermatol. 2007 Dec;46(12):1253-7 [18173518.001]
  • [Cites] Actas Dermosifiliogr. 2008 Jan-Feb;99(1):44-53 [18206086.001]
  • [Cites] Arch Dermatol. 2008 Jan;144(1):58-64 [18209169.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):420-1; author reply 423-4 [18047522.001]
  • [Cites] J Investig Dermatol Symp Proc. 2008 Apr;13(1):6-9 [18369332.001]
  • [Cites] Int J Cosmet Sci. 2008 Feb;30(1):1-17 [18377626.001]
  • [Cites] Br J Dermatol. 2008 May;158(5):1000-7 [18284380.001]
  • [Cites] Arch Dermatol. 2008 Apr;144(4):476-82 [18427041.001]
  • [Cites] Arch Dermatol. 2008 Apr;144(4):502-6 [18427044.001]
  • [Cites] Arch Dermatol. 2008 Apr;144(4):509-13 [18427045.001]
  • [Cites] Inform Prim Care. 2008;16(1):41-50 [18534076.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):671-9 [18307049.001]
  • [Cites] Arch Dermatol. 1995 Mar;131(3):286-91 [7887657.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):79-86 [12890198.001]
  • [Cites] J Am Acad Dermatol. 2003 Oct;49(4):593-8 [14512902.001]
  • [Cites] J Am Acad Dermatol. 2003 Nov;49(5):777-97; quiz 798-9 [14576657.001]
  • [Cites] Arch Dermatol. 2003 Dec;139(12):1620-4; discussion 1624 [14676081.001]
  • [Cites] J Am Acad Dermatol. 2004 Jan;50(1):15-20 [14699359.001]
  • [Cites] J Am Acad Dermatol. 2004 Jan;50(1):50-4 [14699364.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):49-56 [14732660.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):57-62 [14732661.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):683-9 [15097950.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):687-92 [15099364.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):706-14 [15099367.001]
  • [Cites] Skin Res Technol. 2004 Aug;10(3):169-73 [15225266.001]
  • [Cites] J Am Acad Dermatol. 2004 Sep;51(3):466-70 [15337995.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Arch Dermatol. 1972 Jan;105(1):129-30 [5009616.001]
  • [Cites] Acta Derm Venereol. 1976;56(5):345-52 [78618.001]
  • [Cites] Arch Dermatol. 1978 Sep;114(9):1400-1 [686763.001]
  • [Cites] J Am Acad Dermatol. 1979 Dec;1(6):503-5 [528699.001]
  • [Cites] Acta Derm Venereol. 1980;60(4):360-3 [6163289.001]
  • [Cites] J Cutan Pathol. 1984 Aug;11(4):296-9 [6491007.001]
  • [Cites] Am J Dermatopathol. 1984 Summer;6 Suppl:89-91 [6528946.001]
  • [Cites] CA Cancer J Clin. 1985 May-Jun;35(3):130-51 [3921200.001]
  • [Cites] Br J Dermatol. 1985 Aug;113(2):167-74 [4027184.001]
  • [Cites] J Am Acad Dermatol. 1986 Jan;14(1):25-31 [3950111.001]
  • [Cites] J Am Acad Dermatol. 1987 Sep;17(3):459-68 [3655025.001]
  • [Cites] J Am Acad Dermatol. 1987 Oct;17(4):571-83 [3668002.001]
  • [Cites] Arch Dermatol. 1989 Mar;125(3):397-401 [2923449.001]
  • [Cites] J Am Acad Dermatol. 1990 Jun;22(6 Pt 1):1042-8 [2370329.001]
  • [Cites] Australas J Dermatol. 1990;31(2):77-80 [2095738.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2064-8 [1913555.001]
  • [Cites] Arch Dermatol. 1992 Apr;128(4):514-7 [1580659.001]
  • [Cites] Arch Dermatol. 1992 Jul;128(7):934-40 [1626960.001]
  • [Cites] Dermatology. 1992;185(1):49-55 [1638071.001]
  • [Cites] Arch Dermatol. 1993 Feb;129(2):157-74 [8434973.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):350S-355S [8440923.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):356S-362S [8440924.001]
  • [Cites] J Am Acad Dermatol. 1994 Apr;30(4):551-9 [8157780.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1013-7 [8053697.001]
  • [Cites] J Cutan Pathol. 1994 Aug;21(4):302-11 [7798386.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):946-52 [7769264.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):17-23 [8847720.001]
  • [Cites] J Am Acad Dermatol. 1996 Mar;34(3):460-4 [8609260.001]
  • [Cites] Melanoma Res. 1996 Feb;6(1):55-62 [8640071.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):649 [8859308.001]
  • [Cites] Dermatology. 1997;194(1):17-9 [9031785.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):378-82 [9091467.001]
  • [Cites] JAMA. 1997 May 14;277(18):1439-44 [9145715.001]
  • [Cites] Med J Aust. 1997 Aug 18;167(4):191-4 [9293264.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):198-203 [9335442.001]
  • [Cites] Arch Dermatol. 1998 Jan;134(1):103-4 [9449921.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):669-80 [9591809.001]
  • [Cites] Br J Dermatol. 1998 Feb;138(2):283-7 [9602875.001]
  • [Cites] Arch Dermatol. 1998 Dec;134(12):1563-70 [9875194.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):457-61 [9930803.001]
  • [Cites] JAMA. 1999 Feb 17;281(7):640-3 [10029126.001]
  • [Cites] Arch Dermatol. 1999 Mar;135(3):275-80 [10086448.001]
  • [Cites] J Am Acad Dermatol. 1999 Apr;40(4):558-62 [10188673.001]
  • [Cites] Br J Dermatol. 2004 Nov;151(5):1029-38 [15541081.001]
  • [Cites] Int J Dermatol. 2004 Dec;43(12):882-5 [15569007.001]
  • [Cites] J Am Board Fam Pract. 2004 Nov-Dec;17(6):416-23 [15575033.001]
  • [Cites] JAMA. 2004 Dec 8;292(22):2771-6 [15585738.001]
  • [Cites] Dermatology. 2005;210(1):39-44 [15604544.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):93-8 [15655153.001]
  • [Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):738-45 [10534637.001]
  • [Cites] Arch Dermatol. 2000 Mar;136(3):316-20 [10724192.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 1):731-4 [10775846.001]
  • [Cites] J Am Acad Dermatol. 2000 May;42(5 Pt 1):754-9 [10775850.001]
  • [Cites] Arch Dermatol. 2000 May;136(5):647-51 [10815858.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):811-8 [10814676.001]
  • [Cites] J Am Acad Dermatol. 2000 Jun;42(6):988-91 [10827401.001]
  • [Cites] J Pathol. 2000 Jun;191(2):115-9 [10861568.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):271-9 [10861504.001]
  • [Cites] J Am Acad Dermatol. 2000 Sep;43(3):467-76 [10954658.001]
  • [Cites] Hautarzt. 2000 Aug;51(8):561-6 [10997310.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):207-18 [11174377.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):979-86 [11369910.001]
  • [Cites] Dermatology. 2001;202(4):324-7 [11455145.001]
  • [Cites] Arch Dermatol. 2001 Oct;137(10):1343-50 [11594860.001]
  • [Cites] Arch Dermatol. 2001 Dec;137(12):1583-9 [11735708.001]
  • [Cites] Arch Dermatol. 2001 Dec;137(12):1590-5 [11735709.001]
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2):260-3 [11807439.001]
  • [Cites] J Invest Dermatol. 2002 Mar;118(3):500-4 [11874490.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):1023-6 [11899128.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):159-65 [11902502.001]
  • [Cites] Br J Dermatol. 2002 Mar;146(3):448-57 [11952545.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):674-82 [12004306.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):710-4 [12004312.001]
  • [Cites] J Am Acad Dermatol. 2002 Jun;46(6):957-9 [12063500.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):349-55 [12170184.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):389-94 [12170189.001]
  • [Cites] Br J Dermatol. 2002 Sep;147(3):481-6 [12207587.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1562-8 [12237926.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):639-43 [12548605.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):282-8 [12622618.001]
  • [Cites] Eur J Dermatol. 2003 Mar-Apr;13(2):183-8 [12695136.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):663-71 [12734494.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):672-8 [12734495.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):694-701 [12734497.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):707-13 [12734499.001]
  • [Cites] Arch Dermatol. 2003 May;139(5):607-12 [12756097.001]
  • [Cites] Br J Dermatol. 2003 May;148(5):981-4 [12786829.001]
  • (PMID = 19389517.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR050102-05; United States / NIAMS NIH HHS / AR / R01 AR050102; United States / NIAMS NIH HHS / AR / R01 AR050102-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  • [Other-IDs] NLM/ NIHMS114603; NLM/ PMC2690513
  •  go-up   go-down


28. Alexandrescu DT, Kauffman CL, Jatkoe TA, Hartmann DP, Vener T, Wang H, Derecho C, Rajpurohit Y, Wang Y, Palma JF: Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis. J Invest Dermatol; 2010 Jul;130(7):1887-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma-specific marker expression in skin biopsy tissues as a tool to facilitate melanoma diagnosis.
  • Diagnosis of cutaneous melanoma requires accurate differentiation of true malignant tumors from highly atypical lesions, which lack the capacity to develop uncontrolled proliferation and to metastasize.
  • We used melanoma markers from previous work to differentiate benign and atypical lesions from melanoma using paraffin-embedded tissue.
  • This critical step in diagnosis generates the most uncertainty and discrepancy between dermatopathologists.
  • A total of 193 biopsy tissues were selected: 47 melanomas, 48 benign nevi, and 98 atypical/suspicious, including 48 atypical nevi and 50 melanomas as later assigned by expert dermatopathologists.
  • Performance for SILV, GDF15, and L1CAM normalized to TYR in unequivocal melanoma versus benign nevi resulted in an area under the curve (AUC) of 0.94, 0.67, and 0.5, respectively.
  • SILV also differentiated atypical cases classified as melanoma from atypical nevi with an AUC=0.74.
  • Furthermore, SILV showed a significant difference between suspicious melanoma and each suspicious atypia group: melanoma versus severe atypia and melanoma versus moderate atypia had P-values of 0.0077 and 0.0009, respectively.
  • SILV showed clear discrimination between melanoma and benign unequivocal cases as well as between different atypia subgroups in the group of suspicious samples.
  • The role and potential utility of this molecular assay as an adjunct to the morphological diagnosis of melanoma are discussed.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genetic Testing. Melanoma / genetics. Melanoma / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Area Under Curve. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Nevus / metabolism. Nevus / pathology. Paraffin Embedding. Reverse Transcriptase Polymerase Chain Reaction. Skin Diseases / metabolism. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Invest Dermatol. 2010 Jul;130(7):1763 [20548313.001]
  • (PMID = 20357814.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Silva Idos S, Higgins CD, Abramsky T, Swanwick MA, Frazer J, Whitaker LM, Blanshard ME, Bradshaw J, Apps JM, Bishop DT, Newton-Bishop JA, Swerdlow AJ: Overseas sun exposure, nevus counts, and premature skin aging in young English women: a population-based survey. J Invest Dermatol; 2009 Jan;129(1):50-9
MedlinePlus Health Information. consumer health - Skin Aging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overseas sun exposure, nevus counts, and premature skin aging in young English women: a population-based survey.
  • A large number of melanocytic nevi is the strongest known risk factor for melanoma in whites, but its relationship to sun exposure overseas among young white women living in temperate climates is unclear.
  • A total of 754 white English women aged 18-46 years were recruited into a cross-sectional study in 1997-2000 to investigate the effect of ultraviolet exposures on numbers of nevi and atypical nevi, and on skin aging as measured by microtopography.
  • Having ever holidayed in hotter countries was associated with a greater age- and phenotype-adjusted mean number of whole-body nevi (percent increase=74; 95% confidence interval: 24, 144; P=0.001), particularly for holidays taken at ages 18-29 years and for counts of the trunk and lower limbs.
  • Having ever lived overseas was not associated with nevus counts, but was inversely associated with number of atypical nevi (P=0.02).
  • Skin aging was not associated with residence or holidays abroad.
  • The association of holidays overseas with an increased nevus count in young white women, which was stronger in the anatomical sites intermittently exposed to sunlight, supports the hypothesis that intermittent sun exposure is of relevance in the etiology of nevi and, hence, melanoma.
  • [MeSH-major] Nevus / etiology. Skin Aging. Sunlight
  • [MeSH-minor] Adolescent. Adult. Aging. England. Female. Humans. Melanoma / etiology. Melanoma / prevention & control. Middle Aged. Risk Factors. Skin Neoplasms / etiology. Skin Neoplasms / prevention & control. Surveys and Questionnaires. Travel

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Premature aging.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18615111.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10589; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Seidenari S, Pellacani G, Martella A: Acquired melanocytic lesions and the decision to excise: role of color variegation and distribution as assessed by dermoscopy. Dermatol Surg; 2005 Feb;31(2):184-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Because melanoma may sometimes be difficult to differentiate from nevi with clinical atypia, many benign lesions also undergo surgical removal.
  • METHODS: Overall, 603 images, referring to 112 melanomas and 491 nevi, were retrospectively subdivided into four groups: "clearly benign," "follow-up," "dermoscopic atypical nevi," and "dermoscopic melanomas," according to their dermoscopic aspects.
  • RESULTS: With respect to lesions not eligible for excision according to dermoscopy (but excised for cosmetic reasons), those excised with a suspicion of malignancy showed a higher number of colors, whose distribution was also more asymmetric.
  • Moreover, the frequency of the presence of black and blue-gray progressively increased from clearly benign lesions to atypical nevi and dermoscopic melanomas.
  • CONCLUSION: In dermoscopic images, color parameters are essential elements for the diagnosis of atypical nevus, which can be differentiated from both a clearly benign lesion and a melanoma.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / surgery. Microscopy / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery
  • [MeSH-minor] Decision Support Techniques. Humans. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Nevus, Pigmented / surgery. Predictive Value of Tests. ROC Curve. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762212.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, Tarantini F, Ketabchi S, Cirino G, Hollenberg MD, Geppetti P, Santucci M: Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol; 2005 Jun;36(6):676-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
  • Here, we have investigated the expression of PAR-1 and PAR-2 proteins by immunohistochemistry in a series of benign and malignant melanocytic lesions: 20 melanocytic lesions (10 common melanocytic nevi and 10 atypical or "dysplastic" melanocytic nevi) and 50 melanomas (10 in situ melanomas, 10 melanomas T1, 10 melanomas T2, 10 melanomas T3 to T4, and 10 metastatic melanomas).
  • PAR-1 was significantly overexpressed in atypical nevi and melanomas in comparison with common melanocytic nevi.
  • PAR-2 was strongly and diffusely expressed by immunohistochemistry in all melanocytic lesions, with no statistically significant differences between nevi and melanomas.
  • Similarly to immunohistochemical results, PAR-1 mRNA expression was significantly higher in atypical nevi and melanomas in comparison with common nevi and controls.
  • Overexpression of PAR-1 in atypical nevi and melanomas supports a role for PAR-1 in the initial phases of melanoma development as well as in tumor progression and metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Melanoma / metabolism. Nevus, Pigmented / metabolism. Receptor, PAR-1 / biosynthesis. Receptor, PAR-2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021575.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1; 0 / Receptor, PAR-2
  •  go-up   go-down


32. Nagore E, Botella-Estrada R, Garcia-Casado Z, Requena C, Serra-Guillen C, Llombart B, Sanmartin O, Guillen C: Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain. J Eur Acad Dermatol Venereol; 2008 Aug;22(8):931-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some clinical, pathological and genetic features have been associated to familial melanoma, particularly multiple melanoma and earlier age at diagnosis.
  • To compare the clinical, epidemiological and pathological differences between familial and sporadic melanoma patients in Valencia, Spain, a series of 959 patients with cutaneous melanoma were selected at a single institution.
  • For this study the following variables were selected: age, sex, melanoma site and presence of solar lentigines on the melanoma surrounding skin, histological subtype, tumor thickness, stage, family and personal history of cutaneous melanoma and of other neoplasias, personal history of non-melanoma skin cancer, past personal history of severe sunburns, cutaneous phenotype (phototype, hair and eyes colors number of common nevus, number of atypical nevi, presence of solar lentigines).
  • Among the multiple variables studied, a younger age at diagnosis (median age of 42 vs 53 years), higher frequency of the presence of at least one clinically atypical nevus (36.1% vs 17.7%), multiple melanomas (12.2% vs 3.4%) and red/blonde hair (33.3% vs 18.9%), and a lower rate of cases with solar lentigines in melanoma site (33.3% vs 56.3%) were found for familial cases.
  • In summary, phenotypic risk factors for familial melanoma are a tendency to develop multiple melanomas, to have clinically atypical nevi and to present less actinic damage at the melanoma site.
  • All these results enhance the relevancy of genetic susceptibility associated to the ability to produce atypical nevi and partly to a higher sensitivity to the sun.
  • [MeSH-major] Melanoma / genetics. Melanoma / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Melanoma, familial.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18355200.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Jen M, Murphy M, Grant-Kels JM: Childhood melanoma. Clin Dermatol; 2009 Nov-Dec;27(6):529-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because early diagnosis and treatment improves prognosis, clinicians need to include it as a possible diagnosis when evaluating a pigmented lesion in a pediatric patient.
  • Some risk factors for melanoma include xeroderma pigmentosum, giant congenital melanocytic nevi, dysplastic nevus syndrome, atypical nevi, many acquired melanocytic nevi, family history of melanoma, and immunosuppression.
  • [MeSH-major] Melanoma / pathology. Neoplasm Invasiveness / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880040.001).
  • [ISSN] 1879-1131
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 117
  •  go-up   go-down


34. Smith AP, Hoek K, Becker D: Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther; 2005 Sep;4(9):1018-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.
  • To gain insights into the genetic profile of every stage of the melanoma progression pathway, and to determine to what extent these profiles are similar or distinct, we performed whole-genome expression profiling of tissue specimens representing normal skin, benign and atypical nevi, and early and advanced-stage melanomas.
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma in Situ / pathology. Cell Line, Tumor. Disease Progression. Humans. Neoplasm Staging. Nevus / chemistry. Nevus / genetics. Nevus / pathology. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251803.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Koller J: [Pigment nevi in children]. Hautarzt; 2010 May;61(5):443-51; quiz 452
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pigment nevi in children].
  • Almost all fair-skinned children demonstrate one or more pigment nevi at the integument.
  • While most pigmented nevi are per se harmless, congenital and atypical (dysplastic) nevi are considered as precursors of melanoma and risk indicators.
  • Although one normal nevus in isolation generally presents no risk, children and adults with multiple pigment nevi are at increased risk of developing a melanoma in the course of their life.
  • Since the onset of pigment nevi is undisputedly triggered by ultraviolet light, appropriate prevention and protection is crucial.
  • The differential diagnosis between nevus cell nevi and melanoma is particularly challenging, especially in the case of atypical nevi.
  • [MeSH-major] Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Nevus, Pigmented / diagnosis. Skin Neoplasms / diagnosis. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Adolescent. Child. Dermatologic Surgical Procedures. Diagnosis, Differential. Humans. Skin / pathology. Wound Healing / physiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437126.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Borsari S, Longo C, Ferrari C, Benati E, Bassoli S, Schianchi S, Giusti F, Cesinaro AM, Pellacani G, Seidenari S: Dermoscopic island: a new descriptor for thin melanoma. Arch Dermatol; 2010 Nov;146(11):1257-62
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To determine the frequency and the features of the dermoscopic island (DI) in melanocytic lesions and to assess its specificity for the diagnosis of melanoma.
  • DESIGN: Dermoscopic images of 96 in situ melanomas, 266 invasive melanomas, and 612 dermoscopic atypical nevi were evaluated to establish the presence and the main pattern of the DI.
  • MAIN OUTCOME MEASURES: Specificity and odds ratio for melanoma; dermoscopic and histologic characteristics of lesions with a DI.
  • RESULTS: The DI was present in 10.4% of in situ melanomas, 4.1% of invasive melanomas, and 3.1% of dermoscopic atypical nevi.
  • Invasive melanomas with a DI were thinner than those lacking this descriptor.
  • In addition, more than half of the melanomas with a DI arose on a nevus.
  • CONCLUSION: The DI is characteristic of thin melanoma arising in a nevus; thus, it can be considered a potential early sign of transformation of a nevus into a melanoma.
  • [MeSH-major] Dermoscopy. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Nevus / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21079063.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Swetter SM, Johnson TM, Miller DR, Layton CJ, Brooks KR, Geller AC: Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol; 2009 Apr;145(4):397-404
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: Differences in melanoma awareness, skin examination practices, discovery patterns, and social/medical care factors relative to tumor thickness.
  • RESULTS: Two hundred twenty-seven men completed surveys within 3 months of melanoma diagnosis; 57 (25.1%) had thicker tumors (>2.00 mm).
  • Thicker tumors were associated with nodular histologic features (43.9%), a lack of atypical nevi, having less than a high school education, and patient vs physician (dermatologist or nondermatologist) detection.
  • Knowledge of melanoma (P = .007), attention to skin cancer detection information (P = .02), an interest in health topics (P = .003), and knowing the importance of physician skin examination (P = .05) were more common in those with thin tumors.
  • Tumor thickness did not correlate with age, anatomic location, marital/cohabitation status, prior skin cancer, or sun sensitivity.
  • Overall patient awareness of melanoma warning signs, skin self-examination practices, and Internet use were poor (<20%, <50%, and <14%, respectively).
  • CONCLUSIONS: Physician discovery, the patient's higher level of education and detection-promoting awareness and attitudes, and the presence of clinically atypical nevi were related to thinner melanomas.
  • [MeSH-major] Melanoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2009 Dec;145(12):1457-8 [20026863.001]
  • (PMID = 19380661.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Berwick M, Wiggins C: The current epidemiology of cutaneous malignant melanoma. Front Biosci; 2006;11:1244-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major host factors associated with the development of melanoma include skin type and numbers of nevi (as well as atypical nevi).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genetic Predisposition to Disease. Melanoma / epidemiology. Melanoma / genetics. Polymorphism, Genetic. Skin Neoplasms / epidemiology. Skin Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Animals. Child. Child, Preschool. Cohort Studies. Environment. Female. Genetic Variation. Humans. Incidence. Infant. Infant, Newborn. Light. Male. Middle Aged. Nevus. Phenotype. Risk. Sex Factors. Sunlight. Treatment Outcome. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368510.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


39. Kolman O, Hoang MP, Piris A, Mihm MC Jr, Duncan LM: Histologic processing and reporting of cutaneous pigmented lesions: recommendations based on a survey of 94 dermatopathologists. J Am Acad Dermatol; 2010 Oct;63(4):661-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) determine the impact of the procedure, intent to excise, and histologic diagnosis on the process of margin evaluation; and (3) propose guidelines based on these findings.
  • METHODS: The survey consisted of 44 questions focused on the impact of procedure (punch, shave, or ellipse), intent (excision or biopsy), and histologic diagnosis (common nevus, congenital nevus, atypical nevus, melanoma) on processing and margin reporting.
  • Although more than 90% of observers report the margins on all melanomas and atypical nevi, fewer than 50% of respondents report margins on all nonatypical nevi.
  • LIMITATIONS: The study consists of a survey sample of dermatopathologists and does not represent the practices of those who did not respond to the survey.
  • (3) obtain levels in cases with tumor in the tip but not at ink if the specimen is an ellipse or excision and the diagnosis is atypical nevus or melanoma; and (4) report margins on all atypical nevi and melanomas.
  • [MeSH-major] Dermatology / methods. Dermatology / statistics & numerical data. Dysplastic Nevus Syndrome / pathology. Melanoma / pathology. Pathology, Surgical / methods. Practice Patterns, Physicians' / statistics & numerical data. Skin Neoplasms / pathology
  • [MeSH-minor] Academic Medical Centers. Attitude of Health Personnel. Biopsy, Needle. Diagnosis, Differential. Female. Health Care Surveys. Humans. Immunohistochemistry. Male. Massachusetts. Practice Guidelines as Topic. Risk Assessment. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20846568.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ: WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Arch Ophthalmol; 2009 Aug;127(8):964-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Recent studies indicate that WT1 and Bcl2 protein are detected in melanocytic lesions of the skin.
  • METHODS: Protein expression and localization of WT1 and Bcl2 were studied by means of immunolabeling and semiquantification in 123 conjunctival melanocytic lesions (71 benign nevi, 21 atypical nevi, 11 primary acquired melanosis, and 20 malignant melanomas).
  • RESULTS: WT1 showed a graded increase in expression in lesions with increasing atypia.
  • Higher mean numbers of WT1-positive cells correlated with increasing atypia in melanocytes.
  • WT1 and HMB45 frequently showed diffuse and strong staining in atypical nevi, primary acquired melanosis with atypia, and malignant melanomas compared with benign lesions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Conjunctival Neoplasms / metabolism. Melanoma / metabolism. Neoplasm Proteins / metabolism. Nevus, Pigmented / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Child. Child, Preschool. Conjunctival Diseases / metabolism. Dysplastic Nevus Syndrome / metabolism. Dysplastic Nevus Syndrome / pathology. Female. Humans. Immunoenzyme Techniques. MART-1 Antigen. Male. Melanoma-Specific Antigens. Melanosis / metabolism. Melanosis / pathology. Middle Aged. S100 Proteins / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667332.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / S100 Proteins; 0 / WT1 Proteins
  •  go-up   go-down


41. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH: A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer; 2009 Jan 15;124(2):420-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes.
  • An abnormal nevus phenotype is associated with an increased risk of melanoma.
  • We report a pooled analysis conducted using individual nevus data from 15 case-control studies (5,421 melanoma cases and 6,966 controls).
  • Bayesian unconditional logistic random coefficients models were employed to study the risk associated with nevus characteristics.
  • Participants with whole body nevus counts in the highest of 4 population-based categories had a greatly increased risk of melanoma compared with those in the lowest category (pooled odds ratio (pOR) 6.9 (95% confidence interval (CI): 4.4, 11.2) for those aged<50 years and pOR 5.1 (95% CI: 3.6, 7.5) for those aged>or=50).
  • The pOR for presence compared with absence of any clinically atypical nevi was 4.0 (95% CI: 2.8, 5.8).
  • The pORs for 1-2 and >or=3 large nevi on the body compared with none were 2.9 (95% CI: 1.9, 4.3) and 7.1 (95% CI: 4.7, 11.6), respectively.
  • The relative heterogeneities among studies were small for most measures of nevus phenotype, except for the analysis of nevus counts on the arms, which may have been due to methodological differences among studies.
  • The pooled analysis also suggested that an abnormal nevus phenotype is associated most with melanomas on intermittently sun-exposed sites.
  • The presence of increased numbers of nevi, large nevi and clinically atypical nevi on the body are robust risk factors for melanoma showing little variation in relative risk among studies performed at different latitudes.
  • [MeSH-major] Melanoma / pathology. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):457-63 [10716963.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1593-9 [10789730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):509-13 [11352862.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):348-52 [11511314.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):806-12 [12783935.001]
  • [Cites] J Am Acad Dermatol. 1999 Apr;40(4):549-57 [10188672.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):28-44 [15617989.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] J Invest Dermatol. 2003 Jun;120(6):1087-93 [12787139.001]
  • [Cites] Br J Dermatol. 1982 Dec;107(6):621-9 [7171482.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):257-66 [6582314.001]
  • [Cites] Int J Cancer. 1985 Mar 15;35(3):297-300 [3972472.001]
  • [Cites] Br J Dermatol. 1985 Aug;113(2):167-74 [4027184.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Jun 14;292(6535):1555-9 [3087514.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] Int J Cancer. 1988 Aug 15;42(2):200-6 [3403065.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):387-95 [2369719.001]
  • [Cites] Int J Epidemiol. 1990 Dec;19(4):801-10 [2084006.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1164-7 [1764382.001]
  • [Cites] Am J Epidemiol. 1992 Jun 1;135(11):1301-9 [1626547.001]
  • [Cites] CMAJ. 1992 Aug 15;147(4):445-53 [1498755.001]
  • [Cites] Am J Epidemiol. 1994 Oct 15;140(8):691-9 [7942771.001]
  • [Cites] Am J Epidemiol. 1995 May 15;141(10):934-42 [7741123.001]
  • [Cites] Epidemiology. 1995 Sep;6(5):563-5 [8562639.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):17-23 [8847720.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):831-6 [8634653.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] Br J Cancer. 1998;77(3):505-10 [9472652.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):8-12 [9724086.001]
  • [Cites] J Invest Dermatol. 2005 Jan;124(1):56-62 [15654953.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1241-4 [15894679.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):144-9 [15761869.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):232-45 [16524953.001]
  • [Cites] Arch Dermatol Res. 2007 Jan;298(8):371-9 [17072629.001]
  • [Cites] Eur J Hum Genet. 2007 Jan;15(1):94-102 [17063143.001]
  • (PMID = 18792098.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059706-02; United States / NCI NIH HHS / CA / R01-CA52345; United Kingdom / Cancer Research UK / / A4994; United States / NCI NIH HHS / CA / R01 CA059706; United Kingdom / Cancer Research UK / / C588/A994; United States / NCI NIH HHS / CA / P0-1 CA42101
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS71103; NLM/ PMC2656967
  •  go-up   go-down


42. Olsen CM, Carroll HJ, Whiteman DC: Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila); 2010 Feb;3(2):233-45
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma.
  • We aimed to estimate the population attributable fraction (PAF) for melanoma associated with melanocytic nevi using relative risk estimates derived from a systematic review and meta-analysis.
  • Of 49 studies identified, 25 and 23, respectively, were included in meta-analyses of atypical and common nevi.
  • For people with > or =1 atypical nevi, the summary relative risk was 3.63 (95% confidence interval, 2.85-4.62), with a PAF of 0.25.
  • The relative risk increased by 1.017 (95% confidence interval, 1.014-1.020) for each common nevus; however, significant heterogeneity in risk estimates was observed.
  • We estimated that 42% of melanomas were attributable to having > or =25 common nevi (PAF 25-49 nevi = 0.15; PAF > or =50 nevi = 0.27), whereas PAFs for low nevus counts were modest (PAF 0-10 nevi = 0.04; PAF 11-24 nevi = 0.07).
  • We modeled PAF under scenarios of varying nevus prevalence; the highest melanoma burden was always among those with high nevus counts (PAF range of 0.31-0.62 for > or =25 common nevi).
  • Patients with > or =25 common nevi and/or > or =1 atypical nevi are a high-risk group, which might be targeted for identification, screening, and education.
  • [MeSH-major] Melanoma / epidemiology. Nevus, Pigmented / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20086181.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Risser J, Pressley Z, Veledar E, Washington C, Chen SC: The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol; 2007 Sep;57(3):428-34
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We sought to compare biopsy number in patients with multiple atypical nevi in their first year of care at our pigmented lesion clinic (PLC) between those who received total body skin examination alone and those who received total body skin examination and total body digital photography (TBDP).
  • We sought to identify predictors of biopsy number and number of dysplastic nevi diagnosed in patients with multiple atypical nevi.
  • Linear regression analysis revealed that the interaction term between a lack of both personal history of melanoma and severe dysplastic nevi (-0.930, P = .005) has a significant protective effect on the number of biopsies.
  • Similar regression analysis also showed that the interaction term between a lack of both personal history of melanoma and of severe dysplastic nevi (-1.209, P < .0001), increasing provider experience (-0.047, P = .029), and increased number of biopsies before the initial PLC (-0.028, P = .050) have a statistically significant protective effect on the number of dysplastic nevi diagnosed in the first year of PLC.
  • TBDP did not have an effect on the number of biopsies or on the number of dysplastic nevi diagnosed in the first year of care at the PLC.
  • Rather, our study supports the fact that a patient's positive history of melanoma and a history of severe dysplastic nevi have the most significant impact on provider biopsy behavior, resulting in a lower threshold to biopsy suggestive lesions.
  • [MeSH-major] Diagnosis, Computer-Assisted. Nevus / pathology. Photography. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy / statistics & numerical data. Dysplastic Nevus Syndrome / epidemiology. Dysplastic Nevus Syndrome / pathology. Female. Humans. Incidence. Linear Models. Male. Medical Records. Melanoma / etiology. Physical Examination / statistics & numerical data. Predictive Value of Tests. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2008 May;58(5):894-5 [18423263.001]
  • (PMID = 17624623.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23AR02185-01A1
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


44. Nading MA, Nanney LB, Boyd AS, Ellis DL: Estrogen receptor beta expression in nevi during pregnancy. Exp Dermatol; 2008 Jun;17(6):489-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor beta expression in nevi during pregnancy.
  • Estrogen levels increase during pregnancy and clinical evidence has long suggested that melanocytes are estrogen-responsive.
  • We hypothesized that nevi from pregnant patients would exhibit increased expression of estrogen receptor beta (ERbeta) and thus enhanced potential to respond to altered estrogen levels.
  • Normal, dysplastic and congenital nevi (n = 212) were collected from pregnant and non-pregnant women ranging from 18 to 45 years of age.
  • Immunohistochemical staining was performed on these nevi using antibodies specifically directed against estrogen receptor alpha (ERalpha) and ERbeta.
  • ERalpha was not observed in any lesions; thus, ERbeta was the predominant estrogen receptor in melanocytic cells from all types of nevi.
  • Enhanced positivity for ERbeta in normal nevi during pregnancy was noted, compared with non-pregnant controls including nevocytes residing in both the epidermal and dermal micro-environments (P = 0.005 and P = 0.001 respectively).
  • Nevi with increasingly melanocytic atypia showed increased ERbeta in nevocytes nested within the epidermis.
  • No additional increase in ERbeta in atypical nevi was observed during pregnancy.
  • For normal and congenital nevi, regardless of pregnancy status, dermally associated nevocytes tended to have greater ERbeta immunoreactivity.
  • Significant decreases in ERbeta immunoreactivity were observed in congenital nevi from pregnant women compared with normal and dysplastic nevi from pregnant women.
  • Our data suggest that nevi possess the capacity to be estrogen-responsive.
  • Factors such as pregnancy and degree of atypia are associated with enhanced ERbeta with the exception of congenital nevi where the melanocytes were unique in their response to pregnancy.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skin Res Technol. 2007 May;13(2):143-7 [17374054.001]
  • [Cites] Dermatol Surg. 2006 Dec;32(12):1497-504 [17199661.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):231-3 [10797338.001]
  • [Cites] Endocr Rev. 2000 Oct;21(5):457-87 [11041445.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4970-8 [11042684.001]
  • [Cites] J Am Acad Dermatol. 2001 Jul;45(1):1-19; quiz 19-22 [11423829.001]
  • [Cites] J Cutan Pathol. 2001 Sep;28(8):389-92 [11493375.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] J Invest Dermatol. 2002 Aug;119(2):471-4 [12190872.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):522-36 [12492494.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 May;17(3):349-51 [12702085.001]
  • [Cites] Cancer. 2003 May 1;97(9):2130-3 [12712462.001]
  • [Cites] Cancer. 2003 May 1;97(9):2248-53 [12712479.001]
  • [Cites] J Cutan Pathol. 2004 Jan;31(1):1-7 [14675278.001]
  • [Cites] Eur J Biochem. 2004 Nov;271(21):4178-88 [15511223.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4369-75 [15514378.001]
  • [Cites] Am J Dermatopathol. 1984 Summer;6 Suppl:89-91 [6528946.001]
  • [Cites] Arch Dermatol. 1985 Mar;121(3):350-4 [3977356.001]
  • [Cites] J Am Acad Dermatol. 1991 Sep;25(3):467-82 [1918487.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):876-83 [7662565.001]
  • [Cites] FEBS Lett. 1996 Aug 19;392(1):49-53 [8769313.001]
  • [Cites] Clin Dermatol. 1997 Jan-Feb;15(1):35-43 [9034654.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):378-82 [9091467.001]
  • [Cites] Endocrinology. 1998 Nov;139(11):4513-22 [9794460.001]
  • [Cites] Curr Opin Oncol. 1999 Mar;11(2):129-31 [10188078.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):2025-33 [10471056.001]
  • [Cites] Pediatrics. 1999 Oct;104(4 Pt 2):1042-5 [10506262.001]
  • [Cites] Cancer. 1951 Mar;4(2):324-34 [14821926.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):616-24 [15630700.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1217-26 [15712209.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):743-75; quiz 775-8 [15858465.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):505-13 [17158470.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:143-9 [17197073.001]
  • [Cites] Endocr Rev. 2005 May;26(3):465-78 [15857973.001]
  • [Cites] Am J Dermatopathol. 2005 Oct;27(5):456-65 [16148419.001]
  • [Cites] Obstet Gynecol. 2005 Oct;106(4):857-60 [16199647.001]
  • [Cites] Obstet Gynecol Clin North Am. 2005 Dec;32(4):559-68 [16310672.001]
  • [Cites] Ann Surg. 2006 May;243(5):693-8; discussion 698-700 [16633005.001]
  • [Cites] Dermatol Clin. 2006 Apr;24(2):199-204, vi [16677966.001]
  • [Cites] Exp Dermatol. 2006 Dec;15(12):971-80 [17083364.001]
  • [Cites] J Am Acad Dermatol. 2007 Jul;57(1):60-6 [17490783.001]
  • (PMID = 18177352.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR041943-150036; United States / NIAMS NIH HHS / AR / AR041943-150036; United States / NIAMS NIH HHS / AR / P30 AR41943; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / P30 CA68485-08; United States / NIAMS NIH HHS / AR / P30 AR041943
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  • [Other-IDs] NLM/ NIHMS150878; NLM/ PMC2766512
  •  go-up   go-down


45. Wang SQ, Dusza SW, Scope A, Braun RP, Kopf AW, Marghoob AA: Differences in dermoscopic images from nonpolarized dermoscope and polarized dermoscope influence the diagnostic accuracy and confidence level: a pilot study. Dermatol Surg; 2008 Oct;34(10):1389-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective was to evaluate whether diagnosis and diagnostic confidence changes when viewing dermoscopic images from NPDs and PDs.
  • Twenty-five pigmented lesions were shown in the study, consisting of 7 seborrheic keratoses (SK), 3 basal cell carcinomas, 2 atypical nevi, 5 malignant melanomas (MM), 3 dermatofibromas, 3 blue nevi, and 2 hemangiomas.
  • Significant differences in the diagnoses were observed for the SK, atypical nevus, and MM images.
  • CONCLUSIONS: Viewing lesions with NPD versus PD can affect the diagnosis and diagnostic confidence of physicians that are novices with dermoscopy.
  • Further studies including physicians at different expertise levels and a larger sample of lesions are needed to further explore the differences.
  • [MeSH-major] Dermoscopy / instrumentation. Skin Diseases / diagnosis
  • [MeSH-minor] Humans. Microscopy, Polarization. Pigmentation Disorders / diagnosis. Pilot Projects. Skin Neoplasms / diagnosis


46. Perry BN, Cohen C, Govindarajan B, Cotsonis G, Arbiser JL: Wilms tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol; 2006 Aug;142(8):1031-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
  • They range from nevi, which are clinically stable, to melanomas, which are notorious for distant metastasis and death.
  • Both nevi and melanomas arise from melanocytes, which are neural crest derivatives, and melanocyte precursors migrate from the paraspinal area to their eventual location at the dermoepidermal junction.
  • Atypical nevi have been clinically considered to be precursors of melanoma, and recently, biochemical abnormalities have been found that are present in both nevi and melanomas, including inactivation of the p16INK4a tumor suppressor gene and mutations in B-raf.
  • These mutations suggest not only that nevi and melanomas share a common origin but also that additional events are required for transformation to malignant melanoma.
  • OBSERVATIONS: We performed a Panomics protein array comparing a radial growth melanoma cell line with a vertical growth melanoma cell line and found that the transcription factor Wilms tumor 1 is highly expressed in the vertical growth cell line compared with the radial growth cell line.
  • Using immunohistochemical analysis, we compared expression of archival nevi and melanomas in a tissue microarray.
  • CONCLUSION: We found that Wilms tumor 1 is expressed in most melanomas but is nearly absent in nevi.
  • Immunohistochemical analysis for Wilms tumor 1 may be clinically useful in distinguishing nevi from melanoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. DNA-Binding Proteins / metabolism. Melanoma / diagnosis. Nevus, Pigmented / diagnosis. Nuclear Proteins / metabolism. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924053.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR 47901
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / WTAP protein, human
  •  go-up   go-down


47. Lange JR, Balch CM: Screening for cutaneous melanoma. Surg Oncol Clin N Am; 2005 Oct;14(4):799-811
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The idea of skin screening remains appealing for this common, visible malignancy which is eminently treatable when detected early.
  • Persons in kindreds of familial melanoma, and persons who have atypical mole syndrome, those who have a prior diagnosis of melanoma, or those who have diagnosed atypical nevi are all reasonable candidates for routine screening, based on lower-level evidence in the absence of randomized clinical trials targeting these groups.
  • [MeSH-major] Melanoma / diagnosis. Melanoma / prevention & control. Skin Neoplasms / diagnosis. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226692.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


48. Reutter JC, Long EM, Morrell DS, Thomas NE, Groben PA: Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol; 2007 Mar-Apr;24(2):135-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive post-chemotherapy in situ melanomas and dysplastic nevi.
  • A 22-year-old white man without a personal or family history of atypical nevi had received chemotherapy for pre-B-cell acute lymphocytic leukemia at age 17 that included L-asparaginase, prednisone, methotrexate, mercaptopurine, daunorubicin, and cytoxan.
  • Upon examination, two dark, atypical appearing plaques with irregular borders and numerous pink papules of varying shapes and sizes were noted on his chest, back, and abdomen.
  • Histology of specimens of both types of lesions revealed three moderately atypical compound dysplastic melanocytic nevi and three in situ melanomas.
  • The lesions with only features of dysplastic nevi exhibited dermal fibrosis, cytologic atypia, junctional shoulders, lentiginous spread, and focal pigmentation.
  • The lesions with in situ melanomas in addition demonstrated pagetoid spread, extension down adnexal structures, and more severe cytologic atypia.
  • Malignant melanoma has been associated with chronic immunosuppression, and benign nevi have been reported to erupt after chemotherapy.
  • We report an occurrence of multiple eruptive dysplastic nevi and in situ melanomas appearing shortly after completion of chemotherapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug Eruptions / etiology. Dysplastic Nevus Syndrome / chemically induced. Immunosuppressive Agents / adverse effects. Melanoma / chemically induced. Skin Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461808.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  •  go-up   go-down


49. Fernandes JD, Machado MC, Oliveira ZN: Increased melanocytic nevi in patients with inherited ichthyoses: report of a previously undescribed association. Pediatr Dermatol; 2010 Sep-Oct;27(5):453-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased melanocytic nevi in patients with inherited ichthyoses: report of a previously undescribed association.
  • Ichthyosis is a heterogeneous cornification disorder.
  • The objective of this study was to evaluate the clinical, dermoscopic, and histopathologic features of nevi and lentigines in 16 patients with autosomal recessive congenital ichthyosis-lamellar ichthyosis and nonbullous ichthyosiform congenital erythroderma.
  • Most patients (n = 13) reported no personal or familial history of melanoma or atypical nevi.
  • All of the patients had at least five atypical melanocytic lesions.
  • Ten of the 16 patients had at least one atypical nevus or lentigo.
  • This study suggests that increased atypical melanocytic nevi may be a feature of long-standing congenital ichthyoses.
  • As an unequivocal discrimination from malignant melanoma in vivo is not always possible, regular clinical follow-up of patients with ichthyosis and increased or unusual nevi is recommended.
  • [MeSH-major] Ichthyosis / epidemiology. Ichthyosis / pathology. Nevus, Pigmented / epidemiology. Nevus, Pigmented / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 20561241.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Cassarino DS, Miller WJ, Auerbach A, Yang A, Sherry R, Duray PH: The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients. J Cutan Pathol; 2006 May;33(5):335-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of gp100 and tyrosinase peptide vaccinations on nevi in melanoma patients.
  • This is the first study to examine the effects of such treatments on nevi.
  • DESIGN: We studied biopsies of 'clinically atypical' nevi from 10 patients before and after peptide vaccination.
  • However, there was a significant increase in both p53 and bcl-2 staining, and a trend toward decreased Ki-67 staining, in the nevi post-treatment.
  • Nevi were studied in order to assess the effects on benign melanocytes.
  • The increase in p53 and bcl-2 raises the possibility that vaccination with melanocytic antigens stimulates a response in benign melanocytes.
  • [MeSH-major] Cancer Vaccines. Melanoma / prevention & control. Membrane Glycoproteins / immunology. Monophenol Monooxygenase / immunology. Nevus / pathology. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640539.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cancer Vaccines; 0 / HLA Antigens; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / gp100 Melanoma Antigen; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


51. Fullen DR, Zhu W, Thomas D, Su LD: hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue. J Cutan Pathol; 2005 Nov;32(10):680-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have yielded conflicting results on whether human telomerase RNA (hTER) expression differs in nevi, atypical nevi and melanomas using polymerase chain reaction-based telomeric repeat amplification protocol or in situ hybridization assays.
  • METHODS: Paraffin-embedded sections from 12 acquired nevi, seven dysplastic nevi, 11 Spitz nevi, eight primary invasive melanomas, and three metastatic melanomas were studied for staining intensity (0-3+) and percentage of labeled cells with anti-hTERT.
  • Spitz nevi tended to have weaker hTERT staining (mean = 1.7) compared with acquired nevi (mean = 2.2), dysplastic nevi (mean = 2.4), primary melanomas (mean = 2.4), or metastatic melanomas (mean = 3).
  • CONCLUSIONS: Although telomerase activity was weaker in Spitz nevi, there was overlap with other nevi and primary invasive melanomas in our small series.
  • Thus, hTERT expression does not appear to be a reliable adjunct to the histological diagnosis of primary melanocytic lesions.
  • [MeSH-major] DNA-Binding Proteins / analysis. Melanocytes / enzymology. Melanoma / enzymology. Nevus / chemistry. Nevus, Epithelioid and Spindle Cell / enzymology. Nevus, Pigmented / enzymology. Telomerase / analysis
  • [MeSH-minor] Cell Nucleus / chemistry. Diagnosis, Differential. Dysplastic Nevus Syndrome / diagnosis. Dysplastic Nevus Syndrome / enzymology. Dysplastic Nevus Syndrome / pathology. Humans. Immunohistochemistry. Paraffin Embedding. Reproducibility of Results. Skin / enzymology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293180.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


52. Smith JH, Padnick-Silver L, Newlin A, Rhodes K, Rubinstein WS: Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology; 2007 Apr;114(4):774-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
  • METHODS: Evaluation of a large sibship via family history, complete eye and skin examinations, environmental risk factor questionnaire, and genetic testing, as well as a MEDLINE search of familial uveal melanoma kindreds.
  • MAIN OUTCOME MEASURES: Cutaneous and ocular nevi, benign and malignant neoplasms of skin and other sites, brief skin cancer risk assessment tool risk classification for cutaneous melanoma, DNA sequencing of p16INK4a and p14ARF genes, and citations on familial uveal melanoma.
  • Seven out of 10 siblings had a history of cutaneous and/or ocular nevi.
  • Of the 3 subjects without nevi, 2 had histories of eye or skin malignancies (1 uveal melanoma, 1 basal cell carcinoma).
  • Three of the 10 siblings had relevant ocular findings (2 choroidal nevi, 1 uveal melanoma).
  • CONCLUSIONS: Our results strengthen the association between uveal melanoma, atypical nevi, and cutaneous melanoma.
  • This relationship supports the recommendation that individuals with a personal or family history of uveal melanoma, particularly in combination with atypical nevi, should be regularly screened for uveal and cutaneous melanoma.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Melanoma / genetics. Nevus, Pigmented / genetics. Skin Neoplasms / genetics. Uveal Neoplasms / genetics

  • Genetic Alliance. consumer health - Melanoma, familial.
  • Genetic Alliance. consumer health - Ocular melanoma.
  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207529.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


53. Newton-Bishop JA, Chang YM, Iles MM, Taylor JC, Bakker B, Chan M, Leake S, Karpavicius B, Haynes S, Fitzgibbon E, Elliott F, Kanetsky PA, Harland M, Barrett JH, Bishop DT: Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomarkers Prev; 2010 Aug;19(8):2043-54
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom.
  • BACKGROUND: Increased number of melanocytic nevi is a potent melanoma risk factor.
  • We have carried out a large population-based case-control study to explore the environmental and genetic determinants of nevi and the relationship with melanoma risk.
  • METHODS: We report nevus phenotype in relation to differing patterns of sun exposure, inherited variation at loci shown in recent genome-wide association studies to be nevus genes, and risk.
  • RESULTS: Increased numbers of nevi were associated with holiday sun exposure, particularly on intermittently sun-exposed body sites (test for P(trend) < 0.0001).
  • Large nevi were also associated with holiday sun exposure (P = 0.002).
  • Single nucleotide polymorphisms (SNP) on chromosomes 9 and 22 were associated with increased numbers of nevi (P = 0.04 and P = 0.002 respectively) and larger nevi (P = 0.03 and P = 0.002), whereas that on chromosome 6 was associated only with large nevi (P = 0.01).
  • Melanoma risk was associated with increased nevus count, large nevi, and atypical nevi for tumors in all body sites (including rare sites) irrespective of age.
  • The risk persisted when adjusted for inheritance of nevus SNPs.
  • CONCLUSIONS: The at-risk nevus phenotype is associated with behaviors known to increase melanoma risk (holiday sun exposure).
  • Although SNPs on chromosomes 6, 9, and 22 were shown to be nevus genes, they explained only a small proportion of melanoma risk and nevus phenotype; therefore, several nevus genes likely remain to be identified.
  • IMPACT: This article confirms the importance of nevi in melanoma pathogenesis and increases understanding of their genetic determinants.
  • [MeSH-major] Environmental Exposure / adverse effects. Genetic Predisposition to Disease. Melanoma / etiology. Nevus / genetics. Skin Neoplasms / etiology. Sunburn / complications

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):457-63 [10716963.001]
  • [Cites] Eur J Cancer. 2009 Dec;45(18):3271-81 [19615888.001]
  • [Cites] J Invest Dermatol. 2001 Aug;117(2):348-52 [11511314.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):375-9 [12209963.001]
  • [Cites] Melanoma Res. 2002 Oct;12(5):405-16 [12394181.001]
  • [Cites] J Clin Epidemiol. 2002 Nov;55(11):1075-81 [12507670.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 4;95(11):806-12 [12783935.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6483-8 [14695152.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1164-7 [1764382.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):328-30 [7581459.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1605-11 [8664138.001]
  • [Cites] Hum Mol Genet. 1996 Oct;5(10):1663-6 [8894704.001]
  • [Cites] Stat Med. 1996 Oct 15;15(19):1987-97 [8896134.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):8-12 [9724086.001]
  • [Cites] Am J Hum Genet. 1999 Aug;65(2):483-92 [10417291.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8 [15533235.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):28-44 [15617989.001]
  • [Cites] J Invest Dermatol. 2005 Jan;124(1):56-62 [15654953.001]
  • [Cites] J Am Acad Dermatol. 2005 May;52(5):786-92 [15858467.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):193-9 [15947871.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2040-59 [16125929.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):91-5 [16755289.001]
  • [Cites] Br J Cancer. 2006 Aug 21;95(4):496-505 [16880792.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2753-60 [18366057.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1269-74 [18394881.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):420-8 [18792098.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):50-9 [18615111.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):937-44 [19035450.001]
  • [Cites] Int J Epidemiol. 2009 Jun;38(3):814-30 [19359257.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):915-9 [19578365.001]
  • [Cites] Occup Med (Lond). 2009 Sep;59(6):437-9 [19578076.001]
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1049
  • (PMID = 20647408.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA083115; United Kingdom / Cancer Research UK / / C8216/A6129; United Kingdom / Cancer Research UK / / A6129; United States / NCI NIH HHS / CA / R01 CA83115; United Kingdom / Cancer Research UK / / A4994; United Kingdom / Cancer Research UK / / A10589; United Kingdom / Cancer Research UK / / C588/A4994; United States / NCI NIH HHS / CA / R01 CA083115-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS214319; NLM/ PMC2923062
  •  go-up   go-down


54. Mahé E, Beauchet A, Aegerter P, Saiag P: Neonatal blue-light phototherapy does not increase nevus count in 9-year-old children. Pediatrics; 2009 May;123(5):e896-900
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal blue-light phototherapy does not increase nevus count in 9-year-old children.
  • OBJECTIVE: One of the most important risk factors for melanoma is the number of acquired common and atypical nevi in childhood.
  • The role played by neonatal blue-light phototherapy in the increasing incidence of common and atypical melanocytic nevi in childhood or adolescence has been discussed recently with discordant results.
  • PATIENTS AND METHODS: We designed a multicenter study to assess the effects of neonatal blue-light phototherapy on nevus count in a cohort of 9-year-old children.
  • We counted back and arm nevi as a function of size in 828 children included in a French photoprotection educational campaign.
  • History of neonatal phototherapy, phototype, skin, hair and eye color, and sunburn were assessed through questionnaires to which both parents and children responded, and a nevus count was performed by trained nurses blinded to phototherapy history.
  • RESULTS: Mean nevus count was 16.7 per child.
  • Neonatal phototherapy had no effect on the nevus count irrespective of nevi location, nevi size, or phototype of the children.
  • A light phototype, skin, and hair color; blue/green eyes; and history of sunburn were closely correlated with an increase in nevus count.
  • CONCLUSIONS: This study found no evidence for a major role of blue-light phototherapy on nevus count in 9-year-old children.
  • It underlines the dominant effect of phototype characteristics and history of sunburn in childhood on the early development of melanocytic nevi.
  • [MeSH-major] Nevus, Pigmented / epidemiology. Phototherapy. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403483.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Uribe P, Andrade L, Gonzalez S: Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol; 2006 Jan;126(1):161-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
  • The mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase signaling pathway can be activated through mutations of V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) oncogene, frequently found in melanoma (60%), common nevi (CN) (73-82%), and atypical nevi (AN) (52-80%).
  • MAPK activation has been reported between 0 and 22% in nevi, and 86% of primary melanoma, without any knowledge of BRAF mutational status.
  • BRAF mutation does not seem to be sufficient to produce MAPK activation in melanocytic nevi, and it is suggested that other events are needed to induce MAPK activation, that is, B-Raf overexpression, inhibition of MAPK phosphatases, or suppression of RAF kinase inhibitors.
  • [MeSH-major] Extracellular Signal-Regulated MAP Kinases / metabolism. Nevus, Pigmented / enzymology. Proto-Oncogene Proteins B-raf / genetics. Skin Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417232.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


56. Pastar Z, Lipozencić J, Kovacević S, Canović S, Didović-Torbarina A, Vukasović A: Neurofibromatosis type 1 associated with dysplastic nevus syndrome. Acta Dermatovenerol Croat; 2009;17(2):118-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1 associated with dysplastic nevus syndrome.
  • Neurofibromatosis type 1 (NF-1) is an autosomal dominant disorder that primarily affects the development and growth of neural cell tissues.
  • It causes tumors to grow on nerves and produces other abnormalities such as skin changes and bone deformities.
  • Dysplastic nevus syndrome (DNS) represents multiple atypical nevi associated with polygenetic inheritance pattern and may rarely occur together with NF-1.
  • We describe a case of NF-1 type A with DNS presenting with multiple neural tumors, cafe-au-lait spots, hamartomas in globus pallidus and pigmented melanocytic iris hamartomas (Lisch nodules).
  • The importance of close follow up of nevi in such patients with NF-1 and DNS for the development of melanoma as well as other NF-1 associated skin disorders and with multidisciplinary approach to other associated diseases is highlighted.
  • [MeSH-major] Dysplastic Nevus Syndrome / complications. Neurofibromatosis 1 / complications
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Genetic Linkage. Humans. Male. Pedigree


57. Arndt S, Bosserhoff AK: TANGO is a tumor suppressor of malignant melanoma. Int J Cancer; 2006 Dec 15;119(12):2812-20
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our study we revealed that TANGO was downregulated or lost in 9 melanoma cell lines when compared to normal melanocytes and in most of the 8 tumor samples analyzed.
  • These results were confirmed in situ by immunohistochemistry on 10 paraffin-embedded sections of human malignant melanoma primary tumors and melanoma skin metastases.
  • A small reduction of TANGO was also seen in different benign and atypical nevi when compared to normal skin.
  • For functional analysis of TANGO we evaluated TANGO re-expressing melanoma cell clones and antisense TANGO cell clones with a complete loss of TANGO.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 17044017.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ARNT protein, human; 0 / DNA, Antisense; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 138391-32-9 / Aryl Hydrocarbon Receptor Nuclear Translocator
  •  go-up   go-down


58. Seidenari S, Pellacani G, Grana C: Pigment distribution in melanocytic lesion images: a digital parameter to be employed for computer-aided diagnosis. Skin Res Technol; 2005 Nov;11(4):236-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigment distribution in melanocytic lesion images: a digital parameter to be employed for computer-aided diagnosis.
  • Our aim was to automatically assess pigment distribution in images referring to MMs, atypical nevi (AN) and clearly benign nevi (BN), and to evaluate the diagnostic capability of numerical parameters describing a non homogeneous distribution of pigmentation.
  • For a D score equal to 0, corresponding to the best diagnostic accuracy (86.6%), a sensitivity of 87.5% and a specificity of 85.7% were obtained.
  • CONCLUSION: This original evaluation method for digital pigment distribution, based on mathematical description and comparison of colours in different image blocks, provides numerical parameters to be implemented in image analysis programs for computer-aided MM diagnosis.
  • [MeSH-major] Melanins / metabolism. Melanoma / metabolism. Melanoma / pathology. Nevus / metabolism. Nevus / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Colorimetry / methods. Dermoscopy / methods. Humans. Image Interpretation, Computer-Assisted / methods. Microscopy, Fluorescence / methods. Microscopy, Video / methods. Reproducibility of Results. Sensitivity and Specificity. Signal Processing, Computer-Assisted. Skin Pigmentation. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221139.001).
  • [ISSN] 0909-752X
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Melanins
  •  go-up   go-down


59. Strömberg S, Agnarsdóttir M, Magnusson K, Rexhepaj E, Bolander A, Lundberg E, Asplund A, Ryan D, Rafferty M, Gallagher WM, Uhlen M, Bergqvist M, Ponten F: Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma. J Proteome Res; 2009 Apr;8(4):1639-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective expression of Syntaxin-7 protein in benign melanocytes and malignant melanoma.
  • To search for proteins expressed in human melanocytes and melanoma, we employed an antibody-based proteomics strategy to screen for protein expression in tissue microarrays containing normal tissues, cancer tissues and cell lines.
  • The protein was further characterized regarding subcellular localization, specificity, tissue distribution pattern and potential as a diagnostic and prognostic marker using cell lines and tissue microarrays containing normal skin, melanocytic nevi and primary and metastatic melanoma.
  • STX7 was expressed in normal melanocytes, various benign melanocytic nevi, atypical nevi and malignant melanoma.
  • [MeSH-major] Melanocytes / metabolism. Melanoma / metabolism. Qa-SNARE Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714869.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Qa-SNARE Proteins
  •  go-up   go-down


60. Pho L, Grossman D, Leachman SA: Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol; 2006 Mar;18(2):173-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Certain variants in a low-penetrance gene, MC1R, the melanocortin 1 receptor gene, increase melanoma risk to a lesser extent and act as a genetic modifier when cosegregating with a deleterious p16 gene.
  • To date, the clinical phenotypes of increased number of atypical nevi and nevi body distribution are independent risk factors for melanoma risk, regardless of family history.
  • The atypical mole syndrome cannot reliably predict melanoma germline mutations but increases melanoma risk in p16 mutation carriers.
  • [MeSH-major] Melanoma / genetics. Neoplastic Syndromes, Hereditary / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Cyclin-Dependent Kinase 4 / genetics. Genes, Tumor Suppressor. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Nevus / epidemiology. Nevus / genetics. Phenotype. Receptor, Melanocortin, Type 1 / genetics. Risk Factors. Skin Pigmentation / genetics. Sunlight / adverse effects

  • Genetic Alliance. consumer health - Melanoma, familial.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462187.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Melanocortin, Type 1; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Number-of-references] 78
  •  go-up   go-down


61. Rubegni P, Cevenini G, Burroni M, Bono R, Sbano P, Biagioli M, Risulo M, Nami N, Perotti R, Miracco C, Fimiani M: Objective follow-up of atypical melanocytic skin lesions: a retrospective study. Arch Dermatol Res; 2010 Sep;302(7):551-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective follow-up of atypical melanocytic skin lesions: a retrospective study.
  • Various authors have suggested that information from longitudinal observation (follow-up) of dynamic changes in atypical melanocytic pigmented skin lesions (MPSL) could enable identification of early malignant melanoma escaping initial observation due to an absence of specific clinical and dermoscopic features.
  • The aim of our retrospective study was to determine the existence of numerical variables regarding changes in MPSL that could be useful to differentiate early melanomas and atypical nevi.
  • Digital dermoscopy analyzers (DB-Mips System) were used to evaluate dermoscopic images of 94 equivocal pigmented skin lesions under observation for 6-12 months and then excised because of changes across time (29 melanomas and 65 nevi).
  • When objective pigmented skin lesion parameters were considered together with their objective changes over 6-12 months, a decisive increase in discrimination capacity was obtained.
  • Analysis of the parameters of our model and statistical analysis enabled us to interpret/identify the most significant factors of modification and differentiation of lesions, providing quantitative insights into the diagnosis of equivocal MPSL and demonstrating the utility of objective/numerical follow-up.
  • [MeSH-major] Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Dermoscopy. Diagnosis, Differential. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20411393.001).
  • [ISSN] 1432-069X
  • [Journal-full-title] Archives of dermatological research
  • [ISO-abbreviation] Arch. Dermatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Lynch HT, Fusaro RM, Lynch JF: Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control. Future Oncol; 2007 Apr;3(2):169-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.
  • Oncologists who are aware of the progress in hereditary cancer syndrome diagnosis, and, in particular, of how this effort may be effectively facilitated through a comprehensive family history in concert with molecular genetic studies, are in the envious position of designing highly targeted screening and management programs for the membership of these cancer-prone families.
  • The familial atypical multiple mole melanoma-pancreatic cancer (FAMMM-PC) syndrome, on the other hand, provides another model with cancer-control potential.
  • Given its phenotypic features of multiple atypical nevi, high total body mole count and cutaneous malignant melanoma, coupled with the integral association of PC in a subset of FAMMM kindreds with the CDKN2A germline mutation, this may result in a perhaps lower level of diagnostic certainty when compared with the Lynch syndrome.
  • This knowledge may impact upon progress in the earlier diagnosis of melanoma and provide an impetus for creative diagnostic methods in PC, a disease that, at this time, demonstrates a mortality rate virtually identical to its incidence rate.
  • [MeSH-major] Genetic Predisposition to Disease. Molecular Biology. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics
  • [MeSH-minor] Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Disease Management. Disease Progression. Dysplastic Nevus Syndrome / diagnosis. Dysplastic Nevus Syndrome / genetics. Humans. Mutation. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381417.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1U01 CA 86389
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  • [Number-of-references] 69
  •  go-up   go-down


63. Jackson S, Harland M, Turner F, Taylor C, Chambers PA, Randerson-Moor J, Swerdlow AJ, dos Santos Silva I, Beswick S, Bishop DT, Newton Bishop JA: No Evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):913-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No Evidence for BRAF as a melanoma/nevus susceptibility gene.
  • Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi.
  • Polymorphisms or other variants in the BRAF gene may therefore act as candidate low-penetrance genes for nevus/melanoma susceptibility.
  • In addition, we found that there was no association between the BRAF genotype and mean total number of banal or atypical nevi in either the cases or controls.
  • [MeSH-major] Genetic Predisposition to Disease. Melanoma / genetics. Nevus / genetics. Polymorphism, Genetic. Proto-Oncogene Proteins B-raf / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15824163.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


64. Nikolaou VA, Sypsa V, Stefanaki I, Gogas H, Papadopoulos O, Polydorou D, Plaka M, Tsoutsos D, Dimou A, Mourtzoukou E, Korfitis V, Hatziolou E, Antoniou C, Hatzakis A, Katsambas A, Stratigos AJ: Risk associations of melanoma in a Southern European population: results of a case/control study. Cancer Causes Control; 2008 Sep;19(7):671-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk associations of melanoma in a Southern European population: results of a case/control study.
  • We investigated the association of melanoma with phenotypic and solar indices in this darker skin population residing in an environment of high ambient ultraviolet radiation.
  • Information on history of sun exposure patterns and cutaneous reaction to sunlight was obtained and a clinical evaluation of pigmentary traits, pigmented lesions, and actinic keratoses was performed.
  • RESULTS: In the multivariate analysis, fair skin (OR: 4.63, for fair skin versus light brown, 95% CI: 1.54-13.92), intermittent sun exposure during childhood (OR: 3.33, >2 weeks/year of sun exposure versus < or =2 weeks/year 95% CI: 1.37-8.09), and outdoor leisure activities (OR: 2.74, 95% CI: 1.28-5.89), but not skin phototype or sunburns, were positively related to the risk of melanoma.
  • In addition to an elevated count of common melanocytic nevi (OR: 6.27, > or =10 nevi versus no nevi, 95% CI: 1.65-23.76) and the presence of clinically atypical nevi (OR: 2.84, 95% CI: 1.16-6.98), solar lentigenes were an independent risk factor of melanoma (OR: 4.33, 95% CI: 1.67-11.22).
  • CONCLUSIONS: Intermittent sun exposure of moderate intensity during childhood/adolescence and outdoor leisural activities, in conjunction with a more resistant skin phenotype to acute sunburns and a strong association with nevi and solar lentigenes was a prominent determinant of melanoma risk in our population.
  • [MeSH-major] Melanoma / epidemiology. Nevus / complications. Skin Neoplasms / epidemiology. Sunlight / adverse effects
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Greece / epidemiology. Humans. Male. Middle Aged. Risk Factors. Skin Pigmentation. Sunburn / epidemiology. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307049.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Nagore E, Pereda C, Botella-Estrada R, Requena C, Guillén C: Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility. Cancer Causes Control; 2009 Feb;20(1):115-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acral lentiginous melanoma presents distinct clinical profile with high cancer susceptibility.
  • BACKGROUND: Acral lentiginous melanoma (ALM) is a distinct histological variant of cutaneous melanoma that presents a genomic profile different from the other variants.
  • This group was compared with a group composed of 932 patients with the remaining three most frequent cutaneous melanoma variants.
  • RESULTS: The ALM differed significantly from other variants: in an older age at diagnosis (65.52 vs. 51.79 years), a lower number of common (88.2 vs. 55.8%) and atypical nevi (95.0 vs. 80.2%), a predisposing genetic trait to cancer (22.2 vs. 7.1% had a personal history of other non-cutaneous malignancies and 58.1 vs. 36.4% had at least one first degree relative with non-cutaneous neoplasia) and lower number of sunburns (88.2 vs. 47.4% remembered none).
  • Also, the tumors were thicker (mean of 2.94 vs. 2.03 mm), more frequently ulcerated (74.2 vs. 23.9%) and with perineural invasion (8.0 vs. 1.5%), had lower degree of inflammatory infiltrate (36.8 vs. 7.5% was absent) and were less frequently associated with a previous melanocytic lesion (8.3 vs. 32.6%).
  • In comparison with the other frequent variants we have shown that ALM has some important differences which emphasize that it is a distinct entity more probably related to certain cancer susceptibility but unrelated to familial melanoma, tendency to developing nevus or sun exposure.
  • [MeSH-major] Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acral Lentiginous Melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758972.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Haenssle HA, Korpas B, Hansen-Hagge C, Buhl T, Kaune KM, Johnsen S, Rosenberger A, Schön MP, Emmert S: Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch Dermatol; 2010 Mar;146(3):257-64
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Six hundred eighty-eight patients prospectively categorized into defined melanoma risk groups and followed up (mean, 44.3 months) by clinical examinations, dermoscopy, and, for atypical nevi, sequential digital dermoscopy.
  • RESULTS: Odds ratios from a multivariate logistic regression analysis indicated a highly increased melanoma risk for patients with familial atypical mole and multiple melanoma (FAMMM) syndrome, atypical mole syndrome (AMS), or previous melanoma.
  • Each digitally documented atypical lesion (range, 1-17 lesions per patient) denoted a significant 10% increase in melanoma risk.
  • Patients with multiple common nevi and no additional risk factors had no benefit from sequential digital dermoscopy.
  • [MeSH-major] Dermoscopy / methods. Image Processing, Computer-Assisted / methods. Melanoma / diagnosis. Patient Selection. Risk Assessment / methods. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231495.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Roaten JB, Partrick DA, Pearlman N, Gonzalez RJ, Gonzalez R, McCarter MD: Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg; 2005 Jan;40(1):232-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review of patients younger than 21 years (N = 20) undergoing SLNBX for melanoma or other melanocytic skin lesions at the University of Colorado Health Science Center between 1996 and 2003 was conducted.
  • CONCLUSIONS: Sentinel lymph node biopsy can be successfully and safely performed in pediatric patients for melanoma and atypical nevi.
  • Completion lymph node dissection for microscopic disease is a morbid procedure with uncertain benefit to pediatric or adult patients with a positive SLNBX result.
  • Long-term follow-up data are needed before SLNBX can become a standard of care in pediatric melanoma or as a diagnostic tool to distinguish the atypical Spitz nevus from melanoma.
  • [MeSH-major] Melanoma / pathology. Nevus, Pigmented / pathology. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868590.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K12 CA86913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


68. Nielsen K, Harbst K, Måsbäck A, Jönsson G, Borg A, Olsson H, Ingvar C: Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Melanoma Res; 2010 Aug;20(4):266-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
  • Phenotypic characteristics were examined in melanoma-prone southern Swedish CDKN2A (p16-113insArg/p14ARF-128insSer) mutation families, in relation to the CDKN2A genotype, nevi, clinically atypical nevi (CAN) and melanoma.
  • Individuals from eight melanoma-prone families, with index patients carrying the CDKN2A mutation, were offered skin examinations and genotyping (CDKN2A and MC1R).
  • Median age at diagnosis was 36 years.
  • A positive mutation status (CDKN2A) was correlated to one or more CAN (P=0.007) but neither to blue eyes, red hair colour, heavy freckling nor high number of nevi.
  • For mutation carriers, median total naevus count was 24 and interquartile range was 12-47 (mean 31); whereas for the whole cohort, median total naevus count was 12 and interquartile range was 5-25 (mean 22).
  • No participant fulfilled the atypical mole syndrome phenotype criteria.
  • Melanomas were diagnosed only in mutation carriers, and melanoma diagnosis was statistically correlated to the presence of one or more CAN and red hair colour, supporting the possible synergistic effect of a MC1R mutation on increased risk of melanoma in patients with a CDKN2A mutation.
  • The atypical mole syndrome phenotype was, however, not verified in the studied families and total naevus counts were low.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Dysplastic Nevus Syndrome / genetics. Germ-Line Mutation. Melanoma / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526219.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


69. Dusza SW, Delgado R, Busam KJ, Marghoob AA, Halpern AC: Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study. J Drugs Dermatol; 2006 Jan;5(1):56-62
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study.
  • OBJECTIVE: To assess the clinical and histologic effects of topical imiquimod therapy on dysplastic nevi, and to determine the feasibility of using in vivo confocal microscopy (CSLM) to non-invasively monitor histological response of dysplastic nevi to imiquimod therapy.
  • PATIENTS: The study population comprised of 10 patients with clinically dysplastic (atypical) nevi and at least 8 large nevi, (> or =5 mm) on their trunk.
  • MAIN OUTCOME MEASURE: Clinical response as gauged by comparison of baseline and week 20 1:1 standardized photographs for all study nevi and histological assessment of each patient's 4 largest study nevi at completion of therapy.
  • RESULTS: There were no obvious clinical changes in the size and morphology of the study nevi.
  • Subtle changes in nevus color could not be assessed due to imperfect spectral registration of images over the course of the study.
  • Histologically, 4 of 14 treated nevi and 0 of 14 untreated nevi p=0.03 showed a significant relative reduction of junctional and intraepidermal nevocytes accompanied by papillary dermal fibroses and variable inflammation suggestive of partial regression.
  • Non-invasive CSLM imaging of study nevi demonstrated previously reported in vivo features of dysplastic nevi. but the imaging equipment and protocol utilized proved inconsistent across lesions and time.
  • CONCLUSIONS: The histological changes seen in a subset of treated nevi suggest a possible role for the use of topical immune response modifiers for the treatment of dysplastic nevi with the intent of melanoma chemoprevention.
  • Targeting of dysplastic nevi and intermediate endpoints for melanoma chemoprevention with more intense and/or prolonged treatment regimens with imiquimod or the use of other immune response modifiers seems promising.
  • Technical improvements are required for the use of non-invasive CSLM imaging in lieu of invasive histology for the study of topical nevus therapies.
  • [MeSH-major] Aminoquinolines / administration & dosage. Dysplastic Nevus Syndrome / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468293.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


70. Carli P, Ghigliotti G, Gnone M, Chiarugi A, Crocetti E, Astorino S, Berti UA, Broganelli P, Carcaterra A, Corradin MT, Pellacani G, Piccolo D, Risulo M, Stanganelli I, De Giorgi V: Baseline factors influencing decisions on digital follow-up of melanocytic lesions in daily practice: an Italian multicenter survey. J Am Acad Dermatol; 2006 Aug;55(2):256-62
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Predictors of a short follow-up interval (<or=3 months) compared with a 6-month interval were investigated by means of logistic regression analysis.
  • Determinants of a short follow-up interval, adopted in 40.8% of patients, were the personal history of melanoma (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.09-5.99) and the presence of atypical nevi (at least one atypical nevus (OR 4.54, 95% CI 2.45-8.42).
  • Unexpectedly, the dermoscopic atypia of the lesion (TDS >4.75) was associated only with a marginal effect on the scheduled duration of follow-up interval (OR 1.34, 95% CI 0.97-1.86).
  • [MeSH-major] Image Processing, Computer-Assisted. Mass Screening / methods. Melanoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844508.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


71. Borbola K, Bánfalvi T, Fejos Z, Liszkay G, Papp A, Horváth B, Gilde K: [Etiologic factors of malignant melanoma in young adults]. Orv Hetil; 2005 Jul 10;146(28):1481-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant melanoma is the most aggressive type of skin cancers, involving the cutis and the mucosa.
  • Skin phototype, number of nevi, presence of congenital nevi (especially giant congenital nevi) and non-melanoma skin cancer in previous history refer to increased risk.
  • METHOD: A total of 70 new, histologically verified melanoma patient under 30 years were examined between 1993-2003 with a retrospective study.
  • RESULTS: 5% of patients had giant congenital nevi, although in half of the patients (19/40) more than 20 moles were found.
  • On the basis of patients' histories 57.5% of melanomas developed on a nevus existing from birth or childhood.
  • 30% of melanomas developed on a pigmented brown alteration which rose on the normal skin.
  • About 1/3 of patients had fair skin type and almost all patients (38/40) suffered from erythematous sunburn at first sunbath.
  • In young adulthood the main risk factors were the number of atypical nevi and repeated or severe sunburns in childhood.
  • The skin type was also an important risk factor.
  • [MeSH-major] Melanoma / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adult. Female. Humans. Male. Nevus / complications. Risk Factors. Skin Pigmentation. Sunburn / complications. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130442.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


72. Yousefi M, Payne JR, Barnhill RL: Alopecia areata associated with regression of cutaneous melanoma. Int J Dermatol; 2006 Mar;45(3):314-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 41-year-old white female with a past medical history of hypothyroidism and alopecia universalis presented on January 24, 2002 with a recently changing mole.
  • She indicated changes in size and color of the superior aspect of a mole that had been present for more than 8 years.
  • No family or previous personal history of skin cancers, including melanoma or atypical nevi, was reported.
  • On diagnosis of alopecia universalis, she was initially treated with oral prednisone for 1 year and topical minoxidil for 3 months.
  • She denied other previous skin conditions.
  • During the initial physical examination, she presented with phototype II skin with two adjacent pigmented lesions on her left foot within a 1.3 cm square.
  • The left posterior proximal lesion showed malignant melanoma, with a Breslow depth of 0.4 mm, anatomic level II, marked lymphocytic response and partial regression (Fig. 2).
  • The left posterior distal lesion showed malignant melanoma in situ, arising in a lentiginous compound nevus, with architectural disorder and cytological atypia.
  • [MeSH-major] Alopecia Areata / complications. Melanoma / pathology. Skin / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Alopecia Areata.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533238.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Alam M, Posten W, Martini MC, Wrone DA, Rademaker AW: Aesthetic and functional efficacy of subcuticular running epidermal closures of the trunk and extremity: a rater-blinded randomized control trial. Arch Dermatol; 2006 Oct;142(10):1272-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: A consecutive sample of 36 adult patients (ages 18-65 years), each referred for concurrent elliptical excision of at least 2 clinically atypical nevi of the trunk and/or extremity, were included in the study.
  • The best overall appearance was with a subcuticular running polyglactin 910 suture left in place, and the next best was with a subcuticular running polypropylene suture left in place; differences across groups persisted but decreased in intensity at 9 months.
  • CONCLUSION: While scar width does not appear to vary significantly based on choice of epidermal closure, bilayered closures of the trunk and extremity have better overall appearance and less associated erythema at 3 and 9 months after surgery with the use of a subcuticular running polyglactin 910 suture left in place.
  • [MeSH-major] Nevus / surgery. Skin Neoplasms / surgery. Suture Techniques

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043181.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


74. Alam M, Pon K, Van Laborde S, Kaminer MS, Arndt KA, Dover JS: Clinical effect of a single pulsed dye laser treatment of fresh surgical scars: randomized controlled trial. Dermatol Surg; 2006 Jan;32(1):21-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effect of a single pulsed dye laser treatment of fresh surgical scars: randomized controlled trial.
  • Included patients underwent elliptical excision for atypical nevi of the trunk and/or extremities, with at least one resulting scar of at least 5 cm in length or two scars of at least 2.5 cm in length.
  • Treatment scars received a single one-pass treatment with a 595 nm pulsed dye laser (Vbeam, Candela Corporation, Wayland, MA, USA) at the time of suture removal (ie, 2 weeks after excision) at the following parameters: 7 J/cm2 fluence, 7 mm spot size, 1.5-millisecond pulse duration, and 30-millisecond spray, 20-millisecond delay of dynamic cooling.
  • RESULTS: Immediate purpura was induced from the laser treatment Six weeks after laser treatment, no significant difference was found in the clinical appearance of surgical scars treated with a single pulsed dye laser treatment on suture removal day versus those surgical scars not treated with laser.
  • [MeSH-major] Cicatrix / radiotherapy. Low-Level Light Therapy. Nevus / surgery. Postoperative Complications. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • MedlinePlus Health Information. consumer health - Scars.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393594.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


75. Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK: Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol; 2007 Mar;143(3):379-85
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of atypical nevi with imiquimod 5% cream.
  • To our knowledge, imiquimod has not been previously used to treat atypical nevi (AN).
  • Two were consistent with atypical compound nevus on excisional biopsy and demonstrated inflammation, while the third showed congenital features and demonstrated minimal inflammation.
  • The AN were initially interpreted as displaying more severe histologic atypia on excisional biopsy than was present at baseline.
  • Immunohistochemical studies revealed that the AN but not the congenital-like nevus exhibited increased staining for CD4(+) and CD8(+) cells and for a surrogate marker of interferon alpha expression.
  • A differential inflammatory response was observed between the AN and the congenital-like nevus.
  • The character of the inflammatory infiltrate was similar to that observed with halo nevi.
  • Uncertainties remain concerning imiquimod use for chemoprevention of AN, and the posttreatment histologic features may be misinterpreted as severe melanocytic atypia or melanoma.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Nevus / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372103.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Dosage Forms; 99011-02-6 / imiquimod
  •  go-up   go-down


76. de Snoo FA, Kroon MW, Bergman W, ter Huurne JA, Houwing-Duistermaat JJ, van Mourik L, Snels DG, Breuning MH, Willemze R, Frants RR, Gruis NA: From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients. J Am Acad Dermatol; 2007 May;56(5):748-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From sporadic atypical nevi to familial melanoma: risk analysis for melanoma in sporadic atypical nevus patients.
  • BACKGROUND: Atypical nevi (AN), present in either a familial or a sporadic setting, are strong indicators of increased melanoma risk.
  • Six of 167 patients were carriers of a CDKN2A mutation.
  • At the end of follow-up, 10 of 136 patients with sporadic AN reported being a member of a melanoma family.
  • LIMITATIONS: This study was conducted in an area with a founder mutation in many of its melanoma families; therefore the results may not be applicable to other populations.
  • [MeSH-major] Dysplastic Nevus Syndrome / genetics. Melanoma / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Melanoma, familial.
  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276542.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Niemiec P, Zak I: [Vascular NAD(P)H oxidases--role in the pathogenesis of atherosclerosis]. Postepy Biochem; 2005;51(1):1-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vascular NAD(P)H oxidases--role in the pathogenesis of atherosclerosis].
  • [Transliterated title] Naczyniowe oksydazy NAD(P)H--znaczenie w patogenezie miazdzycy.
  • Vascular NAD(P)H oxidases are multicomponent enzymes found in vascular smooth muscle cells and endothelial cells.
  • Vascular NAD(P)H oxidases are predominant sources of superoxide in the vasculature.
  • Active forms of NAD(P)H oxidases are associated with plasma membrane and consist of at least six components, namely: NOX, p22phox peptides and p47phox, p67phox, p40phox and Rac.
  • Angiotensin II is the most important activator of NAD(P)H oxidases in vasculature.
  • Moreover, reactive oxygen species produced by NAD(P)H oxidases may be involved in endothelial cells apoptosis, oxidation of low density lipoproteins and vascular myocytes hypertrophy and proliferation.
  • Specific inhibitors of NAD(P)H oxidases may be useful experimental tools for atherosclerosis research and may have potential therapeutic significance in the future.

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209336.001).
  • [ISSN] 0032-5422
  • [Journal-full-title] Postepy biochemii
  • [ISO-abbreviation] Postepy Biochem.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 11062-77-4 / Superoxides; 11128-99-7 / Angiotensin II; EC 1.6.3.1 / NADPH Oxidase
  • [Number-of-references] 92
  •  go-up   go-down


78. Billington RA, Genazzani AA, Travelli C, Condorelli F: NAD depletion by FK866 induces autophagy. Autophagy; 2008 Apr;4(3):385-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD depletion by FK866 induces autophagy.
  • NAD is a multifunctional molecule involved in both metabolic processes and signaling pathways.
  • Such signalling pathways consume NAD which is replenished via one of several biosynthesis pathways.
  • We show that influx of NAD across the plasma membrane may be able to contribute to the homeostasis of intracellular NAD levels.
  • Indeed, extracellular application of NAD was able to replete NAD levels that had been lowered pharmacologically using the novel drug FK866 and was also able to rescue cells from FK866-induced cell death.
  • A marked lag between the drop in NAD levels and cell death prompted us to investigate the mechanism of cell death.
  • Furthermore, this autophagic phenotype could be reverted by the addition of NAD to the extracellular medium.
  • [MeSH-major] Acrylamides / pharmacology. Antineoplastic Agents / pharmacology. Autophagy / drug effects. NAD / physiology. Piperidines / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227641.001).
  • [ISSN] 1554-8635
  • [Journal-full-title] Autophagy
  • [ISO-abbreviation] Autophagy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Antineoplastic Agents; 0 / Apoptosis Inducing Factor; 0 / Microtubule-Associated Proteins; 0 / N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; 0 / Piperidines; 0 / light chain 3, human; 0U46U6E8UK / NAD; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


79. Penberthy WT, Tsunoda I: The importance of NAD in multiple sclerosis. Curr Pharm Des; 2009;15(1):64-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of NAD in multiple sclerosis.
  • During chronic CNS inflammation, nicotinamide adenine dinucleotide (NAD) concentrations are altered by (T helper) Th1-derived cytokines through the coordinated induction of both indoleamine 2,3-dioxygenase (IDO) and the ADP cyclase CD38 in pathogenic microglia and lymphocytes.
  • While IDO activation may keep auto-reactive T cells in check, hyper-activation of IDO can leave neuronal CNS cells starving for extracellular sources of NAD.
  • Existing data indicate that glia may serve critical functions as an essential supplier of NAD to neurons during times of stress.
  • Administration of pharmacological doses of non-tryptophan NAD precursors ameliorates pathogenesis in animal models of MS.
  • This resistance is due to increased efficiency of NAD biosynthesis that delays stress-induced depletion of axonal NAD and ATP.
  • In this review, we contrast the role of NAD in EAE versus TMEV demyelinating pathogenesis to increase our understanding of the pharmacotherapeutic potential of NAD signal transduction pathways.
  • A comprehensive review of immunomodulatory control of NAD biosynthesis and degradation in MS pathogenesis is presented.
  • Distinctive pharmacological approaches designed for NAD-complementation or targeting NAD-centric proteins (SIRT1, SIRT2, PARP-1, GPR109a, and CD38) are outlined towards determining which approach may work best in the context of clinical application.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2007 Aug 4;370(9585):389-97 [17679016.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5505-20 [17694090.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):540-6 [17596147.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24574-82 [17604275.001]
  • [Cites] N Engl J Med. 2007 Aug 30;357(9):927-9 [17660531.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2570-82 [17710230.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):946-50 [17803959.001]
  • [Cites] Nat Rev Immunol. 2007 Oct;7(10):817-23 [17767193.001]
  • [Cites] Regen Med. 2007 Sep;2(5):817-29 [17907933.001]
  • [Cites] Cardiovasc Drug Rev. 2007 Fall;25(3):235-60 [17919258.001]
  • [Cites] Med Sci (Paris). 2007 Oct;23(10):840-4 [17937892.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(21):7475-85 [17785446.001]
  • [Cites] Cell Mol Life Sci. 2007 Oct;64(19-20):2542-63 [17611712.001]
  • [Cites] FASEB J. 2007 Nov;21(13):3629-39 [17585054.001]
  • [Cites] PLoS Biol. 2007 Oct 2;5(10):e263 [17914902.001]
  • [Cites] PLoS Biol. 2007 Oct;5(10):e257 [17896864.001]
  • [Cites] Am J Pathol. 2007 Nov;171(5):1563-75 [17823280.001]
  • [Cites] Cell Metab. 2007 Nov;6(5):363-75 [17983582.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7827-39 [18025229.001]
  • [Cites] Mol Pharmacol. 2007 Dec;72(6):1508-21 [17872969.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12884-92 [18032661.001]
  • [Cites] J Neuroimmune Pharmacol. 2007 Sep;2(3):270-5 [18040861.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8807-14 [17923681.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(1):30-9 [17954562.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 1;366(1):174-9 [18054327.001]
  • [Cites] PLoS One. 2007;2(12):e1331 [18159229.001]
  • [Cites] J Biol Chem. 2008 Jan 4;283(1):202-12 [17981805.001]
  • [Cites] Life Sci. 2008 Jan 16;82(3-4):205-9 [18078960.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2008;48:79-106 [17705685.001]
  • [Cites] Immunol Lett. 2008 Jan 29;115(2):153-9 [18082271.001]
  • [Cites] J Neuroimmunol. 2008 Jan;193(1-2):12-23 [18077006.001]
  • [Cites] J Biomol Screen. 2008 Jan;13(1):54-61 [18057180.001]
  • [Cites] Nat Rev Drug Discov. 2008 Feb;7(2):143-55 [18239670.001]
  • [Cites] Neurochem Int. 2008 Mar-Apr;52(4-5):751-60 [18029056.001]
  • [Cites] Free Radic Biol Med. 2008 Feb 15;44(4):527-37 [17997992.001]
  • [Cites] Int J Cardiol. 2008 Feb 29;124(2):172-8 [17395297.001]
  • [Cites] Cell Metab. 2008 Feb;7(2):104-12 [18249170.001]
  • [Cites] Cell Motil Cytoskeleton. 2008 Mar;65(3):179-82 [18044719.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):785-99 [18156156.001]
  • [Cites] Nat Clin Pract Rheumatol. 2008 Mar;4(3):136-44 [18200008.001]
  • [Cites] Autophagy. 2008 Apr;4(3):286-9 [18094610.001]
  • [Cites] Biochem J. 2008 Apr 1;411(1):63-70 [18215126.001]
  • [Cites] Biochem J. 2008 Apr 1;411(1):e1-3 [18333834.001]
  • [Cites] PLoS One. 2008;3(3):e1759 [18335035.001]
  • [Cites] Biochem J. 2008 Apr 15;411(2):279-85 [18215119.001]
  • [Cites] J Leukoc Biol. 2008 Apr;83(4):804-16 [18252866.001]
  • [Cites] Cell Stem Cell. 2007 Aug 16;1(2):135-6 [18371345.001]
  • [Cites] Cell Stem Cell. 2008 Mar 6;2(3):241-51 [18371449.001]
  • [Cites] Am J Cardiol. 2008 Apr 17;101(8A):20B-26B [18375237.001]
  • [Cites] Neurochem Int. 2008 May;52(6):1297-303 [18328600.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):385-94 [18344989.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):373-4 [18379594.001]
  • [Cites] Neuron. 2008 Apr 10;58(1):10-4 [18400158.001]
  • [Cites] Mol Cell Biol. 2008 May;28(9):2860-71 [18299389.001]
  • [Cites] Arch Neurol. 2008 Apr;65(4):452-6 [18413466.001]
  • [Cites] Cancer Biol Ther. 2007 Dec;6(12):1833-6 [18087218.001]
  • [Cites] Curr Opin Neurol. 2008 Jun;21(3):242-7 [18451705.001]
  • [Cites] Exp Neurol. 2008 May;211(1):214-26 [18346732.001]
  • [Cites] Nutr Rev. 2008 May;66(5):250-5 [18454811.001]
  • [Cites] Pharmacol Res. 2008 Apr;57(4):318-23 [18434188.001]
  • [Cites] Br J Pharmacol. 2002 Nov;137(6):761-70 [12411406.001]
  • [Cites] Springer Semin Immunopathol. 2002;24(2):105-25 [12503060.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:65-70 [12505286.001]
  • [Cites] Brain Pathol. 2003 Jan;13(1):23-33 [12580542.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):366-74 [12590258.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):327-8 [12610543.001]
  • [Cites] Nat Med. 2003 Mar;9(3):352-5 [12563315.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):688-94 [12700753.001]
  • [Cites] Trends Pharmacol Sci. 2003 May;24(5):228-32 [12767721.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2863-72 [12960308.001]
  • [Cites] Biochem Pharmacol. 2003 Sep 15;66(6):1033-6 [12963490.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1269-74 [14502282.001]
  • [Cites] Cell Mol Life Sci. 2003 Sep;60(9):1990-7 [14523559.001]
  • [Cites] J Virol. 2003 Nov;77(22):12252-65 [14581562.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1896-906 [14734775.001]
  • [Cites] Mult Scler. 2004 Feb;10(1):26-34 [14760949.001]
  • [Cites] J Virol. 2004 Mar;78(5):2632-6 [14963171.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):116-26 [14975592.001]
  • [Cites] J Immunol. 2004 Apr 1;172(7):4100-10 [15034022.001]
  • [Cites] Biochem Pharmacol. 2004 Feb 1;67(3):411-9 [15037193.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):618-29 [15056470.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18895-902 [14960594.001]
  • [Cites] Cell. 2004 May 14;117(4):495-502 [15137942.001]
  • [Cites] Adv Exp Med Biol. 2003;527:113-8 [15206723.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Jul;24(7):728-43 [15241181.001]
  • [Cites] Mol Microbiol. 2004 Aug;53(4):1003-9 [15306006.001]
  • [Cites] Science. 2004 Aug 13;305(5686):1010-3 [15310905.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Sep;310(3):1053-61 [15159442.001]
  • [Cites] Nutrition. 2004 Sep;20(9):778-82 [15325687.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2500-20 [15353303.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):245-313 [17237347.001]
  • [Cites] J Neuroinflammation. 2007;4:6 [17254325.001]
  • [Cites] Neurochem Res. 2007 Feb;32(2):187-95 [16933150.001]
  • [Cites] Mult Scler. 2007 Jan;13(1):33-40 [17294609.001]
  • [Cites] Neuroscience. 2007 Mar 2;145(1):11-9 [17218064.001]
  • [Cites] J Neurosci. 2007 Feb 21;27(8):1933-41 [17314289.001]
  • [Cites] J Biol Chem. 2007 Mar 2;282(9):6823-32 [17197703.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1351-6 [17322921.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 20;355(4):1075-80 [17335774.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):209-18 [17187374.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):219-27 [17387730.001]
  • [Cites] Curr Drug Metab. 2007 Apr;8(3):197-200 [17430106.001]
  • [Cites] Curr Drug Metab. 2007 Apr;8(3):245-66 [17430113.001]
  • [Cites] Genes Dev. 2007 Apr 15;21(8):920-8 [17437997.001]
  • [Cites] Autoimmunity. 2007 Mar;40(2):148-60 [17453713.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1695-712 [17456775.001]
  • [Cites] Eur J Immunol. 2007 May;37(5):1290-301 [17407101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7217-22 [17438283.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):695-705 [17465726.001]
  • [Cites] Nat Med. 2007 May;13(5):579-86 [17417651.001]
  • [Cites] Brain Pathol. 2007 Jan;17(1):45-55 [17493037.001]
  • [Cites] Gene. 2007 Jul 1;396(1):203-13 [17499941.001]
  • [Cites] Diabetologia. 2007 Jul;50(7):1523-31 [17508197.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 3;359(3):665-71 [17560549.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):305-12 [17579050.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):1007-11 [17581586.001]
  • [Cites] Neurochem Int. 2007 Jun;50(7-8):954-8 [17222947.001]
  • [Cites] Med Hypotheses. 2007;69(3):618-28 [17349750.001]
  • [Cites] Expert Rev Mol Med. 2007;9(20):1-19 [17637110.001]
  • [Cites] J Neurosci. 2007 Jul 18;27(29):7717-30 [17634366.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3602-9 [17652729.001]
  • [Cites] Glia. 2007 Sep;55(12):1251-62 [17659524.001]
  • [Cites] Glia. 2007 Sep;55(12):1280-6 [17659530.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 21;346(1):188-92 [16750163.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):130-7 [16785507.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9685-90 [16769901.001]
  • [Cites] Blood. 2006 Jul 1;108(1):228-37 [16522817.001]
  • [Cites] Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):284-94 [16544364.001]
  • [Cites] Free Radic Biol Med. 2006 Jul 15;41(2):311-7 [16814112.001]
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8484-91 [16914673.001]
  • [Cites] Curr Neurovasc Res. 2006 Aug;3(3):203-13 [16918384.001]
  • [Cites] Expert Rev Mol Med. 2006;8(20):1-27 [16942634.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1545-53 [16632544.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 20;349(2):533-9 [16956582.001]
  • [Cites] J Neurochem. 2006 Oct;99(1):165-76 [16987244.001]
  • [Cites] J Neurosci. 2006 Sep 20;26(38):9794-804 [16988050.001]
  • [Cites] Dev Biol. 2006 Oct 1;298(1):118-31 [16875686.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5639-46 [17015752.001]
  • [Cites] Nat Biotechnol. 2006 Oct;24(10):1179-80 [17033640.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(8):2169-76 [17042794.001]
  • [Cites] Front Biosci. 2007;12:2728-34 [17127275.001]
  • [Cites] J Neurosci. 2006 Dec 13;26(50):12904-13 [17167081.001]
  • [Cites] J Antimicrob Chemother. 2007 Jan;59(1):74-9 [17079237.001]
  • [Cites] Nat Rev Neurosci. 2007 Jan;8(1):57-69 [17180163.001]
  • [Cites] J Immunol. 2007 Jan 1;178(1):95-102 [17182544.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jan;320(1):458-64 [17021258.001]
  • [Cites] Adv Exp Med Biol. 2007;590:171-83 [17191385.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):214-26 [17200195.001]
  • [Cites] Trends Biochem Sci. 2007 Jan;32(1):12-9 [17161604.001]
  • [Cites] Arch Biochem Biophys. 1999 Dec 1;372(1):1-7 [10562410.001]
  • [Cites] Am Heart J. 1999 Dec;138(6 Pt 1):1082-7 [10577438.001]
  • [Cites] J Cell Biol. 1999 Dec 13;147(6):1123-8 [10601327.001]
  • [Cites] Neurosci Lett. 2000 Mar 10;281(2-3):111-4 [10704755.001]
  • [Cites] Eur J Biochem. 2000 Mar;267(6):1550-64 [10712584.001]
  • [Cites] Am J Public Health. 2000 May;90(5):727-38 [10800421.001]
  • [Cites] Development. 2000 Jun;127(12):2653-62 [10821763.001]
  • [Cites] Biochim Biophys Acta. 2000 Jun 26;1486(1):84-96 [10856715.001]
  • [Cites] Mutat Res. 2000 Jun 30;460(1):1-15 [10856830.001]
  • [Cites] Brain Pathol. 2000 Jul;10(3):402-18 [10885659.001]
  • [Cites] J Neurobiol. 2000 Jul;44(1):7-19 [10880128.001]
  • [Cites] Redox Rep. 2000;5(2-3):101-4 [10939283.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):925-31 [10951359.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):898-904 [11006365.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):938-52 [11006371.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Rheumatology (Oxford). 2001 Mar;40(3):329-35 [11285382.001]
  • [Cites] J Neuroimmunol. 2001 Jul 2;117(1-2):78-86 [11431007.001]
  • [Cites] Neuropediatrics. 2000 Dec;31(6):314-7 [11508552.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1296-7 [11701918.001]
  • [Cites] Nat Neurosci. 2001 Dec;4(12):1199-206 [11770485.001]
  • [Cites] Mol Med. 2001 Nov;7(11):761-6 [11788790.001]
  • [Cites] Infect Immun. 2002 Feb;70(2):859-68 [11796621.001]
  • [Cites] Free Radic Biol Med. 2002 Feb 15;32(4):314-8 [11841921.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2508-15 [11859145.001]
  • [Cites] Herpes. 2001 Nov;8(3):60-3 [11867021.001]
  • [Cites] Neuroreport. 2002 Feb 11;13(2):213-6 [11893912.001]
  • [Cites] Br J Nutr. 2002 Feb;87(2):115-9 [11895163.001]
  • [Cites] Brain. 2002 Jun;125(Pt 6):1297-308 [12023318.001]
  • [Cites] CNS Drugs. 2002;16(6):405-18 [12027786.001]
  • [Cites] Neuropsychopharmacology. 2002 Aug;27(2):309-18 [12093605.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2002;50(3):187-96 [12098934.001]
  • [Cites] J Neuroimmunol. 2002 Aug;129(1-2):186-96 [12161035.001]
  • [Cites] Pharmacol Biochem Behav. 2002 Nov;73(4):901-10 [12213537.001]
  • [Cites] Trends Neurosci. 2002 Oct;25(10):532-7 [12220882.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):375-429 [12223530.001]
  • [Cites] Mol Med. 2002 May;8(5):283-9 [12359959.001]
  • [Cites] J Neuroimmunol. 2008 Jul 15;197(2):140-6 [18555539.001]
  • [Cites] Physiol Rev. 2008 Jul;88(3):841-86 [18626062.001]
  • [Cites] Biosci Biotechnol Biochem. 2008 Jul;72(7):1667-72 [18603814.001]
  • [Cites] Annu Rev Nutr. 2008;28:115-30 [18429699.001]
  • [Cites] Biochem Pharmacol. 2008 Aug 15;76(4):443-52 [18547543.001]
  • [Cites] Free Radic Biol Med. 2008 Sep 1;45(5):726-31 [18554520.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):24571-83 [18599483.001]
  • [Cites] Cell Cycle. 2008 Sep 15;7(18):2821-5 [18797187.001]
  • [Cites] Exp Cell Res. 2008 Oct 1;314(16):3069-74 [18687325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14447-52 [18794531.001]
  • [Cites] Phytother Res. 2008 Oct;22(10):1367-71 [18688788.001]
  • [Cites] J Leukoc Biol. 2008 Oct;84(4):940-8 [18678605.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6384-401 [18710944.001]
  • [Cites] J Cell Biochem. 2008 Oct 15;105(3):905-12 [18759251.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15599-604 [18829436.001]
  • [Cites] J Nutr Biochem. 2008 Nov;19(11):746-53 [18436439.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2016-22 [18669886.001]
  • [Cites] Brain. 2008 Nov;131(Pt 11):3081-91 [18790823.001]
  • [Cites] Atherosclerosis. 2009 Jan;202(1):68-75 [18550065.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Mar;41(3):467-71 [18282734.001]
  • [Cites] Cardiovasc Res. 2009 Feb 15;81(3):582-91 [18719074.001]
  • [Cites] Cell Metab. 2008 May;7(5):365-75 [18460328.001]
  • [Cites] J Neurosci Res. 2005 Apr 1;80(1):66-74 [15723383.001]
  • [Cites] Brain Res. 2005 May 17;1044(1):8-15 [15862784.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):421-40 [15864271.001]
  • [Cites] Methods. 2005 Jun;36(2):117-28 [15893938.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1449-57 [15931380.001]
  • [Cites] J Neurol Sci. 2005 Jun 15;233(1-2):93-7 [15896807.001]
  • [Cites] J Physiol Biochem. 2004 Dec;60(4):245-52 [15957242.001]
  • [Cites] Shock. 2005 Jul;24(1):59-65 [15988322.001]
  • [Cites] J Neurosci Res. 2005 Jul 1;81(1):1-8 [15920740.001]
  • [Cites] J Neurosci Res. 2005 Jul 15;81(2):190-8 [15931673.001]
  • [Cites] J Neuroimmunol. 2005 Aug;165(1-2):83-91 [15958276.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):266-71 [16015332.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26649-52 [15929991.001]
  • [Cites] FASEB J. 2005 Aug;19(10):1347-9 [15939737.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):349-55 [16043516.001]
  • [Cites] Neuroscientist. 2005 Aug;11(4):308-22 [16061518.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1755-61 [15905186.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3075-83 [16116196.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2375-81 [15947091.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):271-85 [16181120.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4623-35 [16079181.001]
  • [Cites] Neurotoxicology. 2005 Oct;26(5):847-55 [15923038.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2004 Dec;1(2):84-9 [16265311.001]
  • [Cites] Science. 2005 Nov 4;310(5749):850-5 [16272121.001]
  • [Cites] Inflamm Res. 2005 Nov;54(11):435-50 [16307217.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3634-40 [16322797.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43121-30 [16207712.001]
  • [Cites] Adv Neurol. 2006;98:77-89 [16400828.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):82-90 [16139256.001]
  • [Cites] Biochem Pharmacol. 2006 Feb 28;71(5):646-56 [16386710.001]
  • [Cites] Hum Mol Genet. 2006 Feb 15;15(4):625-35 [16403805.001]
  • [Cites] Int J Cardiol. 2006 Apr 4;108(2):143-54 [15978685.001]
  • [Cites] No To Shinkei. 2006 Feb;58(2):141-4 [16519110.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 21;342(4):1312-8 [16516847.001]
  • [Cites] Brain Res. 2006 Feb 16;1073-1074:25-37 [16448631.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2846-54 [16339401.001]
  • [Cites] Curr Med Chem. 2006;13(8):967-77 [16611078.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):873-7 [16628003.001]
  • [Cites] Ann Pharmacother. 2006 Jun;40(6):1158-61 [16684809.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jun;5(6):493-506 [16732220.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 14;345(4):1386-92 [16730329.001]
  • [Cites] Neuron. 2006 Jun 15;50(6):819-21 [16772165.001]
  • [Cites] Int J Dermatol. 1983 Jan-Feb;22(1):44-5 [6832880.001]
  • [Cites] Biochemistry. 1983 Oct 25;22(22):5188-94 [6317018.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Feb;81(3):908-12 [6422465.001]
  • [Cites] J Clin Invest. 1986 Apr;77(4):1312-20 [2937805.001]
  • [Cites] Infect Immun. 1986 Aug;53(2):347-51 [3089936.001]
  • [Cites] Lancet. 1987 Apr 18;1(8538):893-5 [2882294.001]
  • [Cites] Neurology. 1987 Jul;37(7):1097-102 [3110648.001]
  • [Cites] Int J Tissue React. 1987;9(4):317-24 [3114164.001]
  • [Cites] Lancet. 1987 Oct 17;2(8564):920 [2889118.001]
  • [Cites] J Neuroimmunol. 1989 Dec;25(2-3):151-9 [2685040.001]
  • [Cites] Postgrad Med. 1990 Jan;87(1):163-7, 170 [2296564.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):874-81 [1690352.001]
  • [Cites] Arch Biochem Biophys. 1990 Nov 15;283(1):40-5 [2146924.001]
  • [Cites] J Neurocytol. 1990 Aug;19(4):494-503 [1700810.001]
  • [Cites] Acta Neuropathol. 1990;80(5):521-6 [2251909.001]
  • [Cites] J Neurosci. 1991 Oct;11(10):3146-54 [1941078.001]
  • [Cites] Adv Exp Med Biol. 1991;294:675-8 [1837697.001]
  • [Cites] J Neurol Sci. 1992 Jun;109(2):140-7 [1634896.001]
  • [Cites] J Neuroimmunol. 1992 Oct;40(2-3):225-30 [1430153.001]
  • [Cites] Br J Dermatol. 1993 May;128(5):578-80 [8504053.001]
  • [Cites] J Am Coll Nutr. 1993 Aug;12(4):412-6 [8409103.001]
  • [Cites] J Neurosci. 1993 Oct;13(10):4354-60 [8410191.001]
  • [Cites] Science. 1993 Oct 29;262(5134):695-700 [8235590.001]
  • [Cites] J Neurol. 1993 Dec;241(2):108-14 [8138825.001]
  • [Cites] J Neurosci. 1994 Jun;14(6):3915-21 [8207495.001]
  • [Cites] Intern Med. 1994 Feb;33(2):82-6 [8019047.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jun;55(6):673-86 [8642393.001]
  • [Cites] Neurology. 1996 Apr;46(4):907-11 [8780061.001]
  • [Cites] Neurology. 1996 Sep;47(3):829-34 [8797491.001]
  • [Cites] Nat Med. 1997 Jan;3(1):73-6 [8986744.001]
  • [Cites] J Nutr. 1997 Jan;127(1):117-21 [9040554.001]
  • [Cites] J Exp Med. 1997 Oct 6;186(7):1041-9 [9314553.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1089-95 [9334719.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Nov;17(11):1143-51 [9390645.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):611-9 [9466588.001]
  • [Cites] J Neurochem. 1998 Apr;70(4):1759-63 [9523595.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1324-33 [9694721.001]
  • [Cites] Science. 1998 Aug 21;281(5380):1191-3 [9712583.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Aug;57(8):758-67 [9720491.001]
  • [Cites] J Infect Dis. 1998 Sep;178(3):875-8 [9728563.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3435-47 [9842886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15769-74 [9861045.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):957-64 [9916720.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):335-45 [9922314.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1363-72 [10224276.001]
  • [Cites] Clin Exp Dermatol. 1999 May;24(3):167-9 [10354170.001]
  • [Cites] J Ment Sci. 1952 Jan;98(410):130-42 [14898212.001]
  • [Cites] J Clin Exp Psychopathol. 1957 Apr-Jun;18(2):131-58 [13439009.001]
  • [Cites] Lancet. 1962 Feb 10;1(7224):316-9 [14482545.001]
  • [Cites] Can Med Assoc J. 1959 Aug 15;81:235-8 [14402370.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50754-63 [15381699.001]
  • [Cites] Am J Forensic Med Pathol. 2004 Dec;25(4):342-4 [15577526.001]
  • [Cites] J Immunol. 2005 Feb 15;174(4):1971-9 [15699125.001]
  • [Cites] Nat Med. 2005 Mar;11(3):312-9 [15711557.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3748-54 [15356121.001]
  • [Cites] Toxicology. 2005 Apr 15;209(2):135-47 [15767026.001]
  • [Cites] BMC Genomics. 2008;9:171 [18412984.001]
  • [Cites] Dev Cell. 2008 May;14(5):661-73 [18477450.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jun;67(6):543-54 [18520773.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):92-103 [18566373.001]
  • [Cites] Autoimmunity. 2008 Aug;41(5):405-13 [18568646.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):2-13 [18535182.001]
  • [Cites] Genes Dev. 2008 Jul 1;22(13):1753-7 [18550784.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2562-73 [18568076.001]
  • [Cites] Microbes Infect. 2004 Jul;6(9):806-12 [15374002.001]
  • [Cites] Nat Rev Immunol. 2004 Oct;4(10):762-74 [15459668.001]
  • [Cites] Steroids. 2004 Sep;69(10):653-9 [15465110.001]
  • [Cites] J Endocrinol Invest. 2004 Jul-Aug;27(7):695-707 [15505998.001]
  • [Cites] Nat New Biol. 1971 Nov 10;234(45):62-4 [5288733.001]
  • [Cites] J Neural Transm. 1973;34(3):205-14 [4146521.001]
  • [Cites] Nutr Rev. 1975 Jan;33(1):15-7 [1089213.001]
  • [Cites] J Neural Transm. 1975;37(4):297-304 [1206393.001]
  • [Cites] Acta Neuropathol. 1978 Nov 15;44(2):91-102 [213928.001]
  • [Cites] J Nutr. 1979 Apr;109(4):654-62 [34678.001]
  • [Cites] J Neurochem. 1979 Oct;33(4):895-904 [158635.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Mar;44(3):209-15 [7229643.001]
  • (PMID = 19149604.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R21 NS059724; United States / NINDS NIH HHS / NS / R21 NS059724-01A2; United States / NINDS NIH HHS / NS / R21NS059724
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0U46U6E8UK / NAD
  • [Number-of-references] 346
  • [Other-IDs] NLM/ NIHMS96557; NLM/ PMC2651433
  •  go-up   go-down


80. Lin H, Kwan AL, Dutcher SK: Synthesizing and salvaging NAD: lessons learned from Chlamydomonas reinhardtii. PLoS Genet; 2010 Sep 09;6(9):e1001105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesizing and salvaging NAD: lessons learned from Chlamydomonas reinhardtii.
  • The essential coenzyme nicotinamide adenine dinucleotide (NAD+) plays important roles in metabolic reactions and cell regulation in all organisms.
  • Bacteria, fungi, plants, and animals use different pathways to synthesize NAD+.
  • Our molecular and genetic data demonstrate that in the unicellular green alga Chlamydomonas NAD+ is synthesized from aspartate (de novo synthesis), as in plants, or nicotinamide, as in mammals (salvage synthesis).
  • The de novo pathway requires five different enzymes: L-aspartate oxidase (ASO), quinolinate synthetase (QS), quinolate phosphoribosyltransferase (QPT), nicotinate/nicotinamide mononucleotide adenylyltransferase (NMNAT), and NAD+ synthetase (NS).
  • Sequence similarity searches, gene isolation and sequencing of mutant loci indicate that mutations in each enzyme result in a nicotinamide-requiring mutant phenotype in the previously isolated nic mutants.
  • NMNAT, which is also in the de novo pathway, and nicotinamide phosphoribosyltransferase (NAMPT) constitute the nicotinamide-dependent salvage pathway.
  • A mutation in NAMPT (npt1-1) has no obvious growth defect and is not nicotinamide-dependent.
  • When the de novo pathway is inactive, the salvage pathway is essential to Chlamydomonas for the synthesis of NAD+.
  • Our results suggest that Chlamydomonas is an excellent model system to study NAD+ metabolism and cell longevity.
  • [MeSH-major] Chlamydomonas reinhardtii / metabolism. NAD / biosynthesis
  • [MeSH-minor] Amino Acid Sequence. Animals. Aspartic Acid / metabolism. Base Sequence. Biological Evolution. Biosynthetic Pathways / drug effects. Biosynthetic Pathways / genetics. Gene Expression Regulation / drug effects. Gene Expression Regulation, Plant / drug effects. Genes, Plant / genetics. Mammals. Molecular Sequence Data. Mutagenesis, Insertional / drug effects. Mutation / genetics. Niacinamide / pharmacology. Nicotinamide-Nucleotide Adenylyltransferase / metabolism. Phenotype. Plant Proteins / genetics. Plant Proteins / metabolism. Pyridines / pharmacology. Time Factors. Transcription, Genetic / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genetics. 2007 Jun;176(2):913-25 [17435233.001]
  • [Cites] Plant Cell. 2008 Oct;20(10):2909-25 [18978034.001]
  • [Cites] PLoS Genet. 2006 Oct 13;2(10):e167 [17040130.001]
  • [Cites] Nature. 2008 Feb 14;451(7180):783-8 [18273011.001]
  • [Cites] Mol Biol Cell. 1998 Jun;9(6):1293-308 [9614175.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2570-80 [10521401.001]
  • [Cites] Structure. 2005 Sep;13(9):1385-96 [16154095.001]
  • [Cites] Cell. 2006 Jan 27;124(2):315-29 [16439206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11647-52 [16868079.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1075-80 [16618798.001]
  • [Cites] J Bacteriol. 2005 Apr;187(8):2774-82 [15805524.001]
  • [Cites] Plant J. 2007 Feb;49(4):694-703 [17270012.001]
  • [Cites] Front Biosci. 2004 May 1;9:1577-86 [14977569.001]
  • [Cites] Nature. 2008 Mar 27;452(7186):492-6 [18337721.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1095-107 [17889652.001]
  • [Cites] J Bacteriol. 1999 Sep;181(17):5509-11 [10464228.001]
  • [Cites] Cell. 2007 May 4;129(3):473-84 [17482543.001]
  • [Cites] Science. 2007 Oct 12;318(5848):245-50 [17932292.001]
  • [Cites] Cell Metab. 2007 Nov;6(5):363-75 [17983582.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):10841-5 [17307730.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1011-8 [17457050.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):4011-9 [8196640.001]
  • [Cites] Chem Biol. 2003 Dec;10(12):1195-204 [14700627.001]
  • [Cites] J Mol Biol. 2000 Jul 21;300(4):1005-16 [10891285.001]
  • [Cites] Mol Biol Cell. 1999 Oct;10(10):3507-20 [10512883.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Curr Pharm Des. 2009;15(1):20-8 [19149599.001]
  • [Cites] J Mol Biol. 2007 Oct 26;373(3):755-63 [17868694.001]
  • [Cites] Cell. 2007 Sep 7;130(5):797-810 [17803904.001]
  • [Cites] Proteomics. 2004 Jun;4(6):1581-90 [15174128.001]
  • [Cites] FEMS Microbiol Rev. 2001 Jan;25(1):15-37 [11152939.001]
  • [Cites] Science. 2009 May 1;324(5927):654-7 [19286518.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 1999 Dec 23;99(7):735-45 [10619427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15150-5 [17823244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):829-33 [17213307.001]
  • [Cites] Plant Physiol. 2006 Jul;141(3):851-7 [16698895.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5505-20 [17694090.001]
  • [Cites] Z Vererbungsl. 1959;90(1):74-82 [13660246.001]
  • [Cites] Genetics. 1965 Jun;51(6):931-45 [17248263.001]
  • [Cites] Science. 2001 Jul 20;293(5529):510-4 [11441146.001]
  • [Cites] Genetics. 2002 Jan;160(1):181-200 [11805055.001]
  • [Cites] Cell. 2004 May 14;117(4):495-502 [15137942.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):599-604 [18923395.001]
  • [Cites] Genetics. 1991 Jul;128(3):549-61 [1874415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2216-20 [8134376.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8 [10873683.001]
  • [Cites] Plant Cell. 2008 Mar;20(3):502-7 [18359853.001]
  • [Cites] Genetics. 1962 May;47:531-43 [13889019.001]
  • [Cites] Trends Biochem Sci. 2007 Jan;32(1):12-9 [17161604.001]
  • [Cites] Mol Cells. 2009 Nov 30;28(5):407-15 [19936627.001]
  • [Cites] Cell Metab. 2007 Oct;6(4):280-93 [17908557.001]
  • [Cites] Bioessays. 2003 Jul;25(7):683-90 [12815723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7705-10 [17460045.001]
  • [Cites] Plant Physiol. 2007 Jul;144(3):1508-19 [17468215.001]
  • [Cites] J Bacteriol. 1975 Dec;124(3):1615-7 [127787.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8524-30 [11751893.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):918-30 [18334618.001]
  • [Cites] Cell. 2008 Jul 25;134(2):317-28 [18662546.001]
  • [Cites] Science. 2009 Apr 10;324(5924):191-2 [19359572.001]
  • [Cites] Anal Biochem. 1990 Dec;191(2):396-400 [2085185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4678-83 [12682299.001]
  • [Cites] Trends Genet. 2007 Aug;23(8):413-8 [17559965.001]
  • [Cites] Development. 2009 Nov;136(21):3637-46 [19820182.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):221-9 [11602359.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):158-64 [19001417.001]
  • [Cites] Cell. 2010 Jan 22;140(2):280-93 [20141841.001]
  • [Cites] J Cell Sci. 2009 Feb 15;122(Pt 4):489-98 [19174463.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2297-313 [10888669.001]
  • [Cites] Cell. 2008 Nov 28;135(5):907-18 [19041753.001]
  • [Cites] Science. 1989 Dec 15;246(4936):1503-4 [17756009.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):887-91 [18344983.001]
  • [Cites] Nature. 2009 Oct 15;461(7266):947-55 [19829375.001]
  • [Cites] PLoS Biol. 2006 Nov;4(12):e416 [17132048.001]
  • [Cites] Genetics. 2009 Nov;183(3):885-96 [19720863.001]
  • [Cites] Eukaryot Cell. 2003 Apr;2(2):362-79 [12684385.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18326-35 [15753098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15998-6003 [15520384.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] BMC Genomics. 2009;10:210 [19422688.001]
  • [Cites] Genetics. 1995 Oct;141(2):543-9 [8647391.001]
  • [Cites] Bioinformatics. 2007 Nov 1;23(21):2947-8 [17846036.001]
  • [Cites] Genetics. 1990 Dec;126(4):875-88 [1981764.001]
  • [Cites] J Hered. 1991 Jul-Aug;82(4):295-301 [1880392.001]
  • (PMID = 20838591.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM032843; United States / NIGMS NIH HHS / GM / R01 GM032843-25A2; United States / NHGRI NIH HHS / HG / HG-00249; United States / NIGMS NIH HHS / GM / GM-32842; United States / NHGRI NIH HHS / HG / R01 HG000249
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Proteins; 0 / Pyridines; 00QT8FX306 / 3-acetylpyridine; 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide; 30KYC7MIAI / Aspartic Acid; EC 2.7.7.1 / Nicotinamide-Nucleotide Adenylyltransferase
  • [Other-IDs] NLM/ PMC2936527
  •  go-up   go-down


81. Billington RA, Travelli C, Ercolano E, Galli U, Roman CB, Grolla AA, Canonico PL, Condorelli F, Genazzani AA: Characterization of NAD uptake in mammalian cells. J Biol Chem; 2008 Mar 7;283(10):6367-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of NAD uptake in mammalian cells.
  • Recent evidence has shown that NAD(P) plays a variety of roles in cell-signaling processes.
  • Surprisingly, the presence of NAD(P) utilizing ectoenzymes suggests that NAD(P) is present extracellularly.
  • Indeed, nanomolar concentrations of NAD have been found in plasma and other body fluids.
  • Although very high concentrations of NAD have been shown to enter cells, it is not known whether lower, more physiological concentrations are able to be taken up.
  • Here we show that two mammalian cell types are able to transport low NAD concentrations effectively.
  • Furthermore, extracellular application of NAD was able to counteract FK866-induced cell death and restore intracellular NAD(P) levels.
  • We propose that NAD uptake may play a role in physiological NAD homeostasis.
  • [MeSH-major] NAD / metabolism. NADP / metabolism. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180302.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylamides; 0 / N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; 0 / Piperidines; 0U46U6E8UK / NAD; 53-59-8 / NADP
  •  go-up   go-down


82. Ying W: NAD+ and NADH in neuronal death. J Neuroimmune Pharmacol; 2007 Sep;2(3):270-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD+ and NADH in neuronal death.
  • Increasing evidence has suggested that NAD+ and NADH mediate not only energy metabolism and mitochondrial functions, but also calcium homeostasis, aging, and cell death.
  • This article is written to provide an overview about the information suggesting significant roles of NAD+ and NADH in neuronal death in certain neurological diseases.
  • Our latest studies have suggested that intranasal administration with NAD+ can profoundly decrease ischemic brain damage.
  • These observations suggest that NAD+ administration may be a novel therapeutic strategy for some neurological diseases.
  • [MeSH-major] NAD / physiology. Neurons / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Restor Neurol Neurosci. 2000;16(2):135-142 [12671216.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21302-8 [10807908.001]
  • [Cites] Drugs Exp Clin Res. 2004;30(1):27-33 [15134388.001]
  • [Cites] Exp Neurol. 2002 Oct;177(2):407-18 [12429187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10 ):5774-9 [10318960.001]
  • [Cites] EMBO J. 2003 May 1;22(9):1953-8 [12727863.001]
  • [Cites] FEBS J. 2005 Sep;272(18):4565-75 [16156779.001]
  • [Cites] Annu Rev Biochem. 2004;73:417-35 [15189148.001]
  • [Cites] Brain Res. 2004 Mar 12;1000(1-2):32-9 [15053949.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18426-33 [12626504.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1729-40 [14657223.001]
  • [Cites] Front Biosci. 2007 Jan 01;12 :2728-34 [17127275.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 5;308(4):809-13 [12927790.001]
  • [Cites] J Neurochem. 2005 Nov;95(3):715-23 [16104849.001]
  • [Cites] J Neurosci Res. 2005 Jul 15;81(2):190-8 [15931673.001]
  • [Cites] Curr Alzheimer Res. 2005 Oct;2(4):403-8 [16248845.001]
  • [Cites] J Neural Transm (Vienna). 1996;103(10):1187-93 [9013405.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1815-26 [16294211.001]
  • [Cites] Biochem J. 2006 Jun 15;396(3):419-29 [16526943.001]
  • [Cites] Front Biosci. 2006 Sep 01;11:3129-48 [16720381.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16(3):712-9 [15677308.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Nov;17(11):1143-51 [9390645.001]
  • [Cites] Radiat Res. 1985 Jan;101(1):4-15 [3155867.001]
  • [Cites] Eur J Biochem. 2000 Mar;267(6):1550-64 [10712584.001]
  • [Cites] Pharmacol Biochem Behav. 2004 May;78(1):179-83 [15159148.001]
  • [Cites] J Alzheimers Dis. 2004 Apr;6(2):147-57 [15096698.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10 ):3887-9 [16505364.001]
  • [Cites] Stroke. 2002 Apr;33(4):1101-6 [11935067.001]
  • [Cites] J Neurochem. 2002 Oct;83(1):186-92 [12358742.001]
  • [Cites] Exp Dermatol. 2004 Mar;13(3):170-8 [14987257.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):43121-30 [16207712.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):1067-78 [14985416.001]
  • [Cites] Pharmacol Res. 2005 Jul;52(1):100-8 [15911338.001]
  • [Cites] Acta Neurol Scand Suppl. 1993;146:32-5 [8101414.001]
  • [Cites] J Bioenerg Biomembr. 2004 Aug;36(4):381-6 [15377876.001]
  • [Cites] Nat Rev Neurosci. 2005 Nov;6(11):889-98 [16224497.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1089-95 [9334719.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):216-23 [15562437.001]
  • [Cites] Science. 2004 Aug 13;305(5686):1010-3 [15310905.001]
  • [Cites] Br J Pharmacol. 2004 Sep;143(1):186-92 [15302683.001]
  • [Cites] Med Hypotheses. 1996 Oct;47(4):307-13 [8910880.001]
  • [Cites] J Neurosci. 1998 Jun 15;18(12):4439-50 [9614221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12227-32 [11593040.001]
  • [Cites] Neuroscientist. 2002 Feb;8(1):22-32 [11843096.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4439-44 [12154052.001]
  • [Cites] Exp Cell Res. 2001 Aug 1;268(1):7-13 [11461113.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):349-50 [15793589.001]
  • [Cites] Ann N Y Acad Sci. 1996 Jun 15;786:120-34 [8687014.001]
  • [Cites] J Neurochem. 2002 Aug;82(4):894-902 [12358795.001]
  • [Cites] Brain Res. 1996 Aug 12;729(2):264-9 [8876997.001]
  • [Cites] Neuroreport. 2000 May 15;11(7):1385-8 [10841343.001]
  • [Cites] Med Hypotheses. 1997 Feb;48(2):143-8 [9076696.001]
  • [Cites] Biochem J. 1999 Sep 1;342 ( Pt 2):249-68 [10455009.001]
  • [Cites] Free Radic Biol Med. 2002 Nov 15;33(10 ):1372-9 [12419469.001]
  • [Cites] Neuroreport. 2005 Aug 1;16(11):1209-12 [16012350.001]
  • [Cites] FASEB J. 2005 Apr;19(6):558-66 [15791006.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):375-429 [12223530.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18895-902 [14960594.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):349-55 [16043516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7136-41 [16627622.001]
  • [Cites] Front Biosci. 2007 Jan 01;12:1863-88 [17127427.001]
  • [Cites] Science. 1994 Feb 4;263(5147):687-9 [8080500.001]
  • (PMID = 18040861.001).
  • [ISSN] 1557-1904
  • [Journal-full-title] Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
  • [ISO-abbreviation] J Neuroimmune Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD
  • [Number-of-references] 50
  •  go-up   go-down


83. Shi F, Li Y, Li Y, Wang X: Molecular properties, functions, and potential applications of NAD kinases. Acta Biochim Biophys Sin (Shanghai); 2009 May;41(5):352-61
BioCyc. gene/protein/disease-specific - nadK .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular properties, functions, and potential applications of NAD kinases.
  • NAD kinase catalyzes the phosphorylation of NAD(H) to form NADP(H), using ATP as phosphoryl donor.
  • It is the only key enzyme leading to the de novo NADP(+)/NADPH biosynthesis.
  • Coenzymes such as NAD(H) and NADP(H) are known for their important functions.
  • Recent studies have partially demonstrated that NAD kinase plays a crucial role in the regulation of NAD(H)/NADP(H) conversion.
  • Here, the molecular properties, physiologic functions, and potential applications of NAD kinase are discussed.
  • [MeSH-major] Bacterial Proteins / metabolism. NAD / metabolism. NADP / metabolism. Phosphotransferases (Alcohol Group Acceptor) / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430699.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0U46U6E8UK / NAD; 53-59-8 / NADP; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.23 / NAD kinase
  • [Number-of-references] 73
  •  go-up   go-down


84. Gazzaniga F, Stebbins R, Chang SZ, McPeek MA, Brenner C: Microbial NAD metabolism: lessons from comparative genomics. Microbiol Mol Biol Rev; 2009 Sep;73(3):529-41, Table of Contents
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbial NAD metabolism: lessons from comparative genomics.
  • NAD is a coenzyme for redox reactions and a substrate of NAD-consuming enzymes, including ADP-ribose transferases, Sir2-related protein lysine deacetylases, and bacterial DNA ligases.
  • Microorganisms that synthesize NAD from as few as one to as many as five of the six identified biosynthetic precursors have been identified.
  • De novo NAD synthesis from aspartate or tryptophan is neither universal nor strictly aerobic.
  • Salvage NAD synthesis from nicotinamide, nicotinic acid, nicotinamide riboside, and nicotinic acid riboside occurs via modules of different genes.
  • Nicotinamide salvage genes nadV and pncA, found in distinct bacteria, appear to have spread throughout the tree of life via horizontal gene transfer.
  • [MeSH-major] Bacteria. Genomics. NAD / metabolism

  • COS Scholar Universe. author profiles.
  • BioCyc. gene/protein/disease-specific - pncA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2001 Feb;183(4):1168-74 [11157928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3083-8 [19204287.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(6):1241-8 [11442824.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] Structure. 2002 Jan;10(1):69-79 [11796112.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3698-707 [11704676.001]
  • [Cites] Yeast. 2002 Feb;19(3):215-24 [11816029.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):497-502 [11823852.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18881-90 [11884393.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33291-9 [12068016.001]
  • [Cites] Extremophiles. 2002 Aug;6(4):275-81 [12215812.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45099-107 [12297502.001]
  • [Cites] J Bacteriol. 2002 Dec;184(24):6906-17 [12446641.001]
  • [Cites] Cell. 2002 Nov 27;111(5):747-56 [12464185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15908-13 [12456892.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8804-8 [12496312.001]
  • [Cites] Mol Microbiol. 2003 Apr;48(1):77-84 [12657046.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1572-4 [12912839.001]
  • [Cites] J Bacteriol. 2003 Sep;185(17):5220-33 [12923095.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33049-55 [12771147.001]
  • [Cites] Chem Biol. 2003 Dec;10(12):1195-204 [14700627.001]
  • [Cites] Infect Immun. 2004 Feb;72(2):1143-6 [14742562.001]
  • [Cites] Trends Biochem Sci. 2004 Mar;29(3):111-8 [15003268.001]
  • [Cites] Science. 2004 Apr 2;304(5667):66-74 [15001713.001]
  • [Cites] J Bacteriol. 2004 May;186(9):2862-71 [15090528.001]
  • [Cites] Cell. 2004 May 14;117(4):495-502 [15137942.001]
  • [Cites] J Biol Chem. 1967 Feb 10;242(3):385-92 [4290215.001]
  • [Cites] J Exp Med. 1969 Jan 1;129(1):1-21 [4304436.001]
  • [Cites] J Bacteriol. 1994 Jun;176(11):3400-2 [8195100.001]
  • [Cites] Science. 1995 Jul 28;269(5223):496-512 [7542800.001]
  • [Cites] Nat Med. 1996 Jun;2(6):662-7 [8640557.001]
  • [Cites] Eur J Biochem. 1996 Jul 15;239(2):427-33 [8706750.001]
  • [Cites] J Bacteriol. 1998 Jun;180(12):3218-21 [9620974.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 5;273(2):793-8 [10873683.001]
  • [Cites] FEBS Lett. 1999 Feb 12;444(2-3):222-6 [10050763.001]
  • [Cites] FEBS Lett. 1999 Jul 16;455(1-2):13-7 [10428462.001]
  • [Cites] J Bacteriol. 1999 Sep;181(17):5509-11 [10464228.001]
  • [Cites] J Biol Chem. 1951 Apr;189(2):889-99 [14832305.001]
  • [Cites] J Biol Chem. 1958 Aug;233(2):488-92 [13563526.001]
  • [Cites] J Biol Chem. 1958 Aug;233(2):493-500 [13563527.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D34-8 [15608212.001]
  • [Cites] Nat Genet. 2005 Feb;37(2):153-9 [15640799.001]
  • [Cites] Science. 2005 May 6;308(5723):866-70 [15774723.001]
  • [Cites] Structure. 2005 Sep;13(9):1239-40 [16154080.001]
  • [Cites] Structure. 2005 Sep;13(9):1385-96 [16154095.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5691-702 [16214803.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36334-41 [16118205.001]
  • [Cites] Science. 2006 Mar 3;311(5765):1283-7 [16513982.001]
  • [Cites] J Bacteriol. 2006 Apr;188(8):3012-23 [16585762.001]
  • [Cites] Plant Physiol. 2006 Jul;141(3):851-7 [16698895.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D224-8 [17202162.001]
  • [Cites] Trends Biochem Sci. 2007 Jan;32(1):12-9 [17161604.001]
  • [Cites] Biochemistry. 2007 Apr 24;46(16):4912-22 [17402747.001]
  • [Cites] Cell. 2007 May 4;129(3):473-84 [17482543.001]
  • [Cites] Mol Microbiol. 2007 Oct;66(1):14-25 [17725566.001]
  • [Cites] PLoS Biol. 2007 Oct 2;5(10):e263 [17914902.001]
  • [Cites] Structure. 2008 Feb;16(2):196-209 [18275811.001]
  • [Cites] Nucleic Acids Res. 2008 Apr;36(6):2047-59 [18276643.001]
  • [Cites] Nucleic Acids Res. 2008 Apr;36(6):2032-46 [18276644.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19329-41 [18490451.001]
  • [Cites] Annu Rev Nutr. 2008;28:115-30 [18429699.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):158-64 [19001417.001]
  • [Cites] Genome Biol. 2001;2(1):REVIEWS0001 [11380987.001]
  • (PMID = 19721089.001).
  • [ISSN] 1098-5557
  • [Journal-full-title] Microbiology and molecular biology reviews : MMBR
  • [ISO-abbreviation] Microbiol. Mol. Biol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC2738131
  •  go-up   go-down


85. Chen YG, Kowtoniuk WE, Agarwal I, Shen Y, Liu DR: LC/MS analysis of cellular RNA reveals NAD-linked RNA. Nat Chem Biol; 2009 Dec;5(12):879-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LC/MS analysis of cellular RNA reveals NAD-linked RNA.
  • This technique revealed NAD-linked RNA in Escherichia coli and Streptomyces venezuelae.
  • Subsequent characterization showed that NAD is a 5' modification of RNA, cannot be installed in vitro through aberrant transcriptional initiation, is only found among smaller cellular RNAs and is present at a surprisingly high abundance of approximately 3,000 copies per cell.
  • [MeSH-major] Escherichia coli / chemistry. NAD / isolation & purification. RNA, Bacterial / isolation & purification. RNA, Fungal / isolation & purification. RNA, Transfer / isolation & purification. Streptomyces / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jun;5(6):451-63 [15173824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 12;106(19):7768-73 [19416889.001]
  • [Cites] Nature. 1975 Jan 31;253(5490):374-5 [163011.001]
  • [Cites] J Mol Evol. 1976 Mar 29;7(2):101-4 [1263263.001]
  • [Cites] J Mol Evol. 1978 Jun 20;11(2):163-8 [671563.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jan;77(1):201-4 [6153795.001]
  • [Cites] J Bacteriol. 1984 Jun;158(3):769-76 [6373741.001]
  • [Cites] Methods Enzymol. 1990;193:796-824 [1706064.001]
  • [Cites] Nucleic Acids Res. 1994 Jun 25;22(12):2183-96 [7518580.001]
  • [Cites] J Mol Evol. 1995 Jun;40(6):551-8 [7643406.001]
  • [Cites] Proteins. 1998 Sep 1;32(4):414-24 [9726413.001]
  • [Cites] J Biol Chem. 1958 Mar;231(1):241-57 [13538965.001]
  • [Cites] Nature. 1950 Aug 5;166(4214):237-8 [15439258.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):e2 [15640439.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):387-90 [11201752.001]
  • [Cites] Annu Rev Biochem. 2001;70:39-80 [11395402.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 1;31(3):e8 [12560511.001]
  • [Cites] J Am Chem Soc. 2004 Apr 28;126(16):5044-5 [15099068.001]
  • [Cites] Mol Microbiol. 2005 Oct;58(2):456-66 [16194232.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):79-90 [17612492.001]
  • [Cites] J Am Chem Soc. 2008 Nov 19;130(46):15611-26 [18956864.001]
  • [Cites] Biol Cell. 2009 Feb;101(2):117-31 [19076068.001]
  • [Cites] Cell. 2009 Feb 20;136(4):615-28 [19239884.001]
  • [Cites] Science. 2004 Sep 10;305(5690):1601-5 [15319493.001]
  • (PMID = 19820715.001).
  • [ISSN] 1552-4469
  • [Journal-full-title] Nature chemical biology
  • [ISO-abbreviation] Nat. Chem. Biol.
  • [Language] eng
  • [Databank-accession-numbers] PubChem-Substance/ 85195596/ 85195597/ 85195598/ 85195599
  • [Grant] United States / NIGMS NIH HHS / GM / R01GM065865; United States / NIGMS NIH HHS / GM / R01 GM065865-05A1; United States / Howard Hughes Medical Institute / / ; United States / NIGMS NIH HHS / GM / R01 GM065865-06S1; United States / NIGMS NIH HHS / GM / R01 GM065865-06; United States / NIGMS NIH HHS / GM / R01 GM065865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Fungal; 0U46U6E8UK / NAD; 9014-25-9 / RNA, Transfer
  • [Other-IDs] NLM/ NIHMS140940; NLM/ PMC2842606
  •  go-up   go-down


86. Ansari HR, Raghava GP: Identification of NAD interacting residues in proteins. BMC Bioinformatics; 2010;11:160
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of NAD interacting residues in proteins.
  • Nicotinamide adenine dinucleotide (NAD+ or NAD) is one of the most commonly used organic cofactors in living cells, which plays a critical role in cellular metabolism, storage and regulatory processes.
  • In the past, several NAD binding proteins (NADBP) have been reported in the literature, which are responsible for a wide-range of activities in the cell.
  • Attempts have been made to derive a rule for the binding of NAD+ to its target proteins.
  • Thus a sequence and non-similarity based method is needed to characterize the NAD binding sites to help in the annotation.
  • In this study attempts have been made to predict NAD binding proteins and their interacting residues (NIRs) from amino acid sequence using bioinformatics tools.
  • RESULTS: We extracted 1556 proteins chains from 555 NAD binding proteins whose structure is available in Protein Data Bank.
  • Then we removed all redundant protein chains and finally obtained 195 non-redundant NAD binding protein chains, where no two chains have more than 40% sequence identity.
  • In this study all models were developed and evaluated using five-fold cross validation technique on the above dataset of 195 NAD binding proteins.
  • Gly, Tyr, Thr, His) in NAD interaction, residues like Ala, Glu, Leu, Lys are not preferred.
  • A support vector machine (SVM) based method has been developed using various window lengths of amino acid sequence for predicting NAD interacting residues and obtained maximum Matthew's correlation coefficient (MCC) 0.47 with accuracy 74.13% at window length 17.
  • CONCLUSION: For the first time a sequence-based method has been developed for the prediction of NAD binding proteins and their interacting residues, in the absence of any prior structural information.
  • The present model will aid in the understanding of NAD+ dependent mechanisms of action in the cell.
  • [MeSH-major] NAD / chemistry. Proteins / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D195-200 [18842629.001]
  • [Cites] Protein Sci. 2003 May;12(5):923-9 [12717015.001]
  • [Cites] Bioinformatics. 2009 May 1;25(9):1192-4 [19251774.001]
  • [Cites] BMC Bioinformatics. 2009;10:105 [19358699.001]
  • [Cites] BMC Bioinformatics. 2008;9:312 [18637174.001]
  • [Cites] Curr Opin Struct Biol. 2003 Jun;13(3):389-95 [12831892.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D129-33 [14681376.001]
  • [Cites] Proteins. 2004 Apr 1;55(1):83-90 [14997542.001]
  • [Cites] Nature. 1976 Aug 19;262(5570):726 [183143.001]
  • [Cites] FASEB J. 1996 Sep;10(11):1257-69 [8836039.001]
  • [Cites] Mol Microbiol. 1996 Aug;21(4):667-74 [8878030.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Bioinformatics. 1999 Apr;15(4):327-32 [10320401.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):349-55 [16043516.001]
  • [Cites] Science. 2005 Aug 12;309(5737):1093-6 [16099990.001]
  • [Cites] Proteins. 2005 Nov 1;61(2):318-24 [16106377.001]
  • [Cites] Protein Eng Des Sel. 2006 Feb;19(2):67-75 [16403825.001]
  • [Cites] Bioinformatics. 2006 Jul 1;22(13):1658-9 [16731699.001]
  • [Cites] Curr Protein Pept Sci. 2006 Oct;7(5):395-406 [17073692.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D515-20 [17082206.001]
  • [Cites] Protein Pept Lett. 2007;14(6):575-80 [17627599.001]
  • [Cites] BMC Bioinformatics. 2007;8:337 [17854501.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D618-22 [17720712.001]
  • [Cites] Proteins. 2008 Apr;71(1):189-94 [17932917.001]
  • [Cites] J R Soc Interface. 2009 Feb 6;6(31):129-47 [19019817.001]
  • (PMID = 20353553.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0U46U6E8UK / NAD
  • [Other-IDs] NLM/ PMC2853471
  •  go-up   go-down


87. Ying W: NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci; 2007;12:1863-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD+ and NADH in brain functions, brain diseases and brain aging.
  • Numerous studies have suggested that NAD+ and NADH mediate multiple major biological processes, including calcium homeostasis, energy metabolism, mitochondrial functions, cell death and aging.
  • In particular, NAD+ and NADH have emerged as novel, fundamental regulators of calcium homeostasis.
  • It appears that most of the components in the metabolic pathways of NAD+ and NADH, including poly(ADP-ribose), ADP-ribose, cyclic ADP-ribose, O-acetyl-ADP-ribose, nicotinamide and kynurenine, can produce significant biological effects.
  • This exquisiteness of NAD+ and NADH metabolism could epitomize the exquisiteness of life, through which we may grasp the intrinsic harmony life has evolved to produce.
  • The exquisiteness also suggests a central regulatory role of NAD+ and NADH in life.
  • It is tempted to propose that NAD+ and NADH, together with ATP and Ca2+, constitute a Central Regulatory Network of life.
  • Increasing evidence has also suggested that NAD+ and NADH play important roles in multiple biological processes in brains, such as neurotransmission and learning and memory.
  • NAD+ and NADH may also mediate brain aging and the tissue damage in various brain illnesses.
  • Our latest studies have suggested that NADH can be transported across the plasma membranes of astrocytes, and that NAD+ administration can markedly decrease ischemic brain injury.
  • Based on this information, it is proposed that NAD+ and NADH are fundamental mediators of brain functions, brain senescence and multiple brain diseases.
  • Because numerous properties of NAD+ and NADH remain unclear, future studies regarding NAD+ and NADH may expose some fundamental mechanisms underlying brain functions, brain pathologies and brain aging.
  • [MeSH-major] Aging / physiology. Brain / physiology. Brain Diseases / etiology. NAD / physiology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127427.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD
  • [Number-of-references] 282
  •  go-up   go-down


88. Huang X, El-Sayed IH, Yi X, El-Sayed MA: Gold nanoparticles: catalyst for the oxidation of NADH to NAD(+). J Photochem Photobiol B; 2005 Nov 1;81(2):76-83
Hazardous Substances Data Bank. GOLD, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gold nanoparticles: catalyst for the oxidation of NADH to NAD(+).
  • Nicotinamide adenine dinucleotide is an important coenzyme involved in the production of ATP, the fuel of energy, in every cell.
  • It alternates between the oxidized form NAD(+) and the reduced form dihydronicotinamide adenine dinucleotide (NADH) and serves as a hydrogen and electron carrier in the cellular respiratory processes.
  • In the present work, the catalytic effect of gold nanoparticles on the oxidization of NADH to NAD(+) was investigated.
  • The intensity of the 340 nm absorption band of NADH was found to decrease while that of the 260 nm band of NAD(+) was found to increase as the concentration of gold nanoparticles increased.
  • This gives a strong support that the conversion of NADH to NAD(+) is occurring on the surface of the gold nanoparticles, i.e.
  • [MeSH-major] Gold / chemistry. NAD / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125965.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 7440-57-5 / Gold
  •  go-up   go-down


89. Poncet-Montange G, Assairi L, Arold S, Pochet S, Labesse G: NAD kinases use substrate-assisted catalysis for specific recognition of NAD. J Biol Chem; 2007 Nov 23;282(47):33925-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD kinases use substrate-assisted catalysis for specific recognition of NAD.
  • Here we describe the crystal structures of the NAD kinase (LmNADK1) from Listeria monocytogenes in complex with its substrate NAD, its product NADP, or two synthesized NAD mimics.
  • We identified one of the NAD mimics, di-adenosine diphosphate, as a new substrate for LmNADK1, whereas we showed that the closely related compound di-5'-thioadenosine is a novel non-natural inhibitor for this enzyme.
  • Indeed, sequence/structure comparison and directed mutagenesis have previously shown that NAD kinases (NADKs) and the distantly related 6-phosphofructokinases share the same catalytically important GGDGT motif.
  • Although this acidic residue chelates the catalytic Mg(2+) ion in 6-phosphofructokinases, it activates the phospho-acceptor (NAD) in NADKs.
  • [MeSH-minor] Amino Acid Motifs / genetics. Amino Acid Substitution. Aspartic Acid / chemistry. Aspartic Acid / genetics. Aspartic Acid / metabolism. Catalysis. Crystallography, X-Ray. Diacylglycerol Kinase / chemistry. Diacylglycerol Kinase / genetics. Diacylglycerol Kinase / metabolism. Magnesium / chemistry. Magnesium / metabolism. Mutation, Missense. NAD / chemistry. NAD / metabolism. Phosphofructokinase-1 / chemistry. Phosphofructokinase-1 / genetics. Phosphofructokinase-1 / metabolism. Structure-Activity Relationship. Substrate Specificity / genetics

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686780.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2I1W/ 2I29/ 2I2A/ 2I2B/ 2I2C/ 2I2D/ 2I2E/ 2I2F/ 2Q5F
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0U46U6E8UK / NAD; 30KYC7MIAI / Aspartic Acid; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / sphingosine kinase; EC 2.7.1.107 / Diacylglycerol Kinase; EC 2.7.1.11 / Phosphofructokinase-1; EC 2.7.1.23 / NAD kinase; I38ZP9992A / Magnesium
  •  go-up   go-down


90. Benarroch D, Shuman S: Characterization of mimivirus NAD+-dependent DNA ligase. Virology; 2006 Sep 15;353(1):133-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of mimivirus NAD+-dependent DNA ligase.
  • Here we produced, purified, and characterized mimivirus DNA ligase (MimiLIG), an NAD+-dependent nick joining enzyme homologous to bacterial LigA and entomopoxvirus DNA ligase.
  • MimiLIG is a 636-aa polypeptide composed of an N-terminal NAD+ specificity module (domain Ia), linked to nucleotidyltransferase, OB-fold, helix-hairpin-helix, and BRCT domains, but it lacks the tetracysteine Zn-binding module found in all bacterial LigA enzymes.
  • MimiLIG requires conserved domain Ia residues Tyr36, Asp46, Tyr49, and Asp50 for its initial reaction with NAD+ to form the ligase-AMP intermediate, but not for the third step of phosphodiester formation at a preadenylylated nick.
  • The DeltaBRCT mutant of MimiLIG was impaired in sealing at a preadenylylated nick.
  • We propose that eukaryal DNA viruses acquired the NAD+-dependent ligases by horizontal transfer from a bacterium and that MimiLIG predates entomopoxvirus ligase, which lacks both the tetracysteine and BRCT domains.
  • We speculate that the dissemination of NAD+-dependent ligase from bacterium to eukaryotic virus might have occurred within an amoebal host.

  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844179.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 6.5.1.- / DNA Ligases; EC 6.5.1.2 / DNA ligase (NAD); K848JZ4886 / Cysteine
  •  go-up   go-down


91. Cvetić T, Veljović-Jovanović S, Vucinić Z: Characterization of NAD-dependent malate dehydrogenases from spinach leaves. Protoplasma; 2008;232(3-4):247-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of NAD-dependent malate dehydrogenases from spinach leaves.
  • Spinach leaves were used to extract isoforms of NAD-dependent malate dehydrogenase (NAD-MDH) (EC 1.1.1.37), either soluble or bound to microsomal, plasma, or chloroplast envelope membranes.
  • All fractions were subjected to isoelectric focusing analysis, which showed that purified chloroplast envelopes contain an NAD-MDH isoform tightly bound to the membranes, since treatment with 0.5 or 1% Triton X-100 was not able to release the enzyme from the envelopes.
  • In contrast, plasma membranes released an isoform with a pI of 3.5 following treatment with 0.5% Triton X-100.
  • The most abundant soluble leaf isoform had a pI of 9, while the chloroplast stroma contained an isoform with a pI of 5.3.
  • Kinetic analysis of oxaloacetate (OAA)-dependent NADH oxidation in different fractions gave different Km values for both substrates, the envelope- and plasma membrane-bound NAD-MDH exhibiting the highest affinities for OAA.
  • Our results indicate that the chloroplast envelope contains a specifically attached NAD-MDH isoform that could provide direct coupling between chloroplast and cytosol adenylate pools.
  • [MeSH-minor] Biomarkers / metabolism. Hydrogen-Ion Concentration. Isoenzymes / metabolism. Kinetics. NAD. Subcellular Fractions / enzymology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Genet. 1997 Jun;35(5-6):155-64 [9332710.001]
  • [Cites] Plant Physiol. 1983 Jun;72(2):402-8 [16663015.001]
  • [Cites] J Biol Chem. 1973 Oct 25;248(20):7215-22 [4147558.001]
  • [Cites] Plant Physiol. 1998 Nov;118(3):715-23 [9808715.001]
  • [Cites] Proc Natl Acad Sci U S A. 1955 Jun 15;41(6):327-38 [16589675.001]
  • [Cites] Mol Cell Proteomics. 2003 May;2(5):325-45 [12766230.001]
  • [Cites] Biochim Biophys Acta. 1992 Jun 19;1100(3):217-34 [1610875.001]
  • [Cites] Biochem Biophys Res Commun. 1971 May 21;43(4):703-9 [4397919.001]
  • [Cites] Plant Physiol. 1991 Jul;96(3):971-9 [16668283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1597-602 [11038604.001]
  • [Cites] Planta. 1991 Jun;184(3):319-26 [24194148.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Biochem J. 1984 Oct 15;223(2):543-5 [6497861.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):27927-33 [9774405.001]
  • (PMID = 18239847.001).
  • [ISSN] 0033-183X
  • [Journal-full-title] Protoplasma
  • [ISO-abbreviation] Protoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Isoenzymes; 0U46U6E8UK / NAD; EC 1.1.1.37 / Malate Dehydrogenase
  •  go-up   go-down


92. Brenner C: Evolution of NAD biosynthetic enzymes. Structure; 2005 Sep;13(9):1239-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of NAD biosynthetic enzymes.
  • Two research groups have solved crystal structures of nicotinic acid phosphoribosyltransferase (PRTase) and made the argument that PRTases in three distinct pathways of nicotinamide adenine dinucleotide (NAD) biosynthesis evolved from a common ancestor (Shin et al., 2005 and Chappie et al., 2005).
  • [MeSH-major] Evolution, Molecular. NAD / biosynthesis. Pentosyltransferases / chemistry. Pentosyltransferases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Structure. 2005 Sep;13(9):1385-96 [16154095.001]
  • [CommentOn] J Biol Chem. 2005 May 6;280(18):18326-35 [15753098.001]
  • (PMID = 16154080.001).
  • [ISSN] 0969-2126
  • [Journal-full-title] Structure (London, England : 1993)
  • [ISO-abbreviation] Structure
  • [Language] eng
  • [Publication-type] Comment; News
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD; EC 2.4.2.- / Pentosyltransferases; EC 6.3.4.21 / nicotinate phosphoribosyltransferase
  •  go-up   go-down


93. Gerdes SY, Kurnasov OV, Shatalin K, Polanuyer B, Sloutsky R, Vonstein V, Overbeek R, Osterman AL: Comparative genomics of NAD biosynthesis in cyanobacteria. J Bacteriol; 2006 Apr;188(8):3012-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomics of NAD biosynthesis in cyanobacteria.
  • Biosynthesis of NAD(P) cofactors is of special importance for cyanobacteria due to their role in photosynthesis and respiration.
  • Despite significant progress in understanding NAD(P) biosynthetic machinery in some model organisms, relatively little is known about its implementation in cyanobacteria.
  • A detailed reconstruction of the NAD(P) metabolic subsystem using the SEED genomic platform (http://theseed.uchicago.edu/FIG/index.cgi) helped us accurately annotate respective genes in the entire set of 13 cyanobacterial species with completely sequenced genomes available at the time.
  • Comparative analysis of operational variants implemented in this divergent group allowed us to elucidate both conserved (de novo and universal pathways) and variable (recycling and salvage pathways) aspects of this subsystem.
  • Focused genetic and biochemical experiments confirmed several conjectures about the key aspects of this subsystem. (i) The product of the slr1691 gene, a homolog of Escherichia coli gene nadE containing an additional nitrilase-like N-terminal domain, is a NAD synthetase capable of utilizing glutamine as an amide donor in vitro. (ii) The product of the sll1916 gene, a homolog of E. coli gene nadD, is a nicotinic acid mononucleotide-preferring adenylyltransferase.
  • This gene is essential for survival and cannot be compensated for by an alternative nicotinamide mononucleotide (NMN)-preferring adenylyltransferase (slr0787 gene). (iii) The product of the slr0788 gene is a nicotinamide-preferring phosphoribosyltransferase involved in the first step of the two-step non-deamidating utilization of nicotinamide (NMN shunt). (iv) The physiological role of this pathway encoded by a conserved gene cluster, slr0787-slr0788, is likely in the recycling of endogenously generated nicotinamide, as supported by the inability of this organism to utilize exogenously provided niacin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Soc Trans. 1996 Aug;24(3):729-33 [8878835.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5125-34 [8895556.001]
  • [Cites] DNA Res. 1996 Jun 30;3(3):109-36 [8905231.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1453-62 [9278503.001]
  • [Cites] Gene. 1997 Sep 15;197(1-2):GC11-26 [9332394.001]
  • [Cites] J Bacteriol. 1997 Dec;179(24):7718-23 [9401030.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5691-702 [16214803.001]
  • [Cites] Nature. 2003 Aug 28;424(6952):1042-7 [12917642.001]
  • [Cites] Mol Microbiol. 2003 Sep;49(6):1577-93 [12950922.001]
  • [Cites] Trends Biotechnol. 2003 Nov;21(11):504-11 [14573364.001]
  • [Cites] DNA Res. 2003 Aug 31;10(4):137-45 [14621292.001]
  • [Cites] Cell Mol Life Sci. 2004 Jan;61(1):19-34 [14704851.001]
  • [Cites] J Struct Biol. 1999 Oct;127(3):279-82 [10544053.001]
  • [Cites] Eur J Biochem. 2000 Mar;267(6):1550-64 [10712584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6658-63 [10841563.001]
  • [Cites] J Mol Microbiol Biotechnol. 1999 Aug;1(1):127-8 [10941793.001]
  • [Cites] J Bacteriol. 2001 Jan;183(1):292-300 [11114929.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):406-12 [11027696.001]
  • [Cites] Vitam Horm. 2001;61:103-19 [11153263.001]
  • [Cites] Methods Enzymol. 2001;330:134-57 [11210495.001]
  • [Cites] J Bacteriol. 2001 Feb;183(4):1168-74 [11157928.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(6):1241-8 [11442824.001]
  • [Cites] In Silico Biol. 1999;1(2):93-108 [11471247.001]
  • [Cites] DNA Res. 2001 Oct 31;8(5):205-13; 227-53 [11759840.001]
  • [Cites] Science. 2002 Mar 8;295(5561):1895-7 [11847309.001]
  • [Cites] Int J Med Microbiol. 2002 Feb;291(6-7):523-9 [11890553.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):13148-54 [11788603.001]
  • [Cites] Plant Mol Biol. 2002 May;49(1):107-18 [12008895.001]
  • [Cites] Proteins. 2002 Jul 1;48(1):1-14 [12012333.001]
  • [Cites] J Bacteriol. 2002 Aug;184(16):4555-72 [12142426.001]
  • [Cites] Protein Expr Purif. 2002 Aug;25(3):547-57 [12182838.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33291-9 [12068016.001]
  • [Cites] DNA Res. 2002 Aug 31;9(4):123-30 [12240834.001]
  • [Cites] J Bacteriol. 2002 Dec;184(24):6906-17 [12446641.001]
  • [Cites] Science. 2002 Nov 22;298(5598):1616-20 [12446909.001]
  • [Cites] Trends Biochem Sci. 2003 Jan;28(1):41-8 [12517451.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):164-71 [12519973.001]
  • [Cites] Eur J Immunol. 2002 Nov;32(11):3225-34 [12555668.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13503-11 [12574164.001]
  • [Cites] Res Microbiol. 2003 Apr;154(3):157-64 [12706503.001]
  • [Cites] Bioessays. 2003 Jul;25(7):683-90 [12815723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10020-5 [12917486.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33049-55 [12771147.001]
  • [Cites] Nature. 2003 Aug 28;424(6952):1037-42 [12917641.001]
  • [Cites] Curr Opin Microbiol. 2004 Apr;7(2):115-9 [15063846.001]
  • [Cites] Curr Med Chem. 2004 Apr;11(7):873-85 [15078171.001]
  • [Cites] Methods Enzymol. 1985;113:297-302 [3003498.001]
  • [Cites] J Bacteriol. 1990 May;172(5):2313-9 [2110139.001]
  • [Cites] Genome Res. 1998 Mar;8(3):203-10 [9521924.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9699-704 [9689144.001]
  • [Cites] FEBS Lett. 1999 Feb 12;444(2-3):222-6 [10050763.001]
  • [Cites] Curr Opin Plant Biol. 1998 Jun;1(3):217-23 [10066592.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1999;73:135-82, xi [10218108.001]
  • [Cites] J Bacteriol. 1999 Jul;181(13):3994-4003 [10383967.001]
  • [Cites] Genetics. 1999 Aug;152(4):1299-305 [10430560.001]
  • [Cites] J Bacteriol. 1999 Sep;181(17):5509-11 [10464228.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30540-9 [10521436.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50754-63 [15381699.001]
  • [Cites] Bioinformatics. 2005 Feb 1;21(3):293-306 [15347579.001]
  • [Cites] Res Microbiol. 2005 Mar;156(2):173-7 [15748981.001]
  • [Cites] Bioinformatics. 2005 Jun;21 Suppl 1:i478-86 [15961494.001]
  • [Cites] J Bacteriol. 1990 Jun;172(6):3138-45 [2160938.001]
  • [Cites] Arch Microbiol. 1992;157(4):336-42 [1590707.001]
  • [Cites] Mol Cell Biol. 1994 Feb;14(2):1431-7 [8289818.001]
  • [Cites] J Bacteriol. 1994 Jun;176(11):3400-2 [8195100.001]
  • [Cites] Biochemistry. 1994 Nov 22;33(46):13662-7 [7947774.001]
  • [Cites] J Bacteriol. 1995 Jun;177(12):3527-33 [7768863.001]
  • [Cites] Science. 1995 Jul 28;269(5223):496-512 [7542800.001]
  • [Cites] Biochemistry. 1995 Oct 17;34(41):13431-6 [7577930.001]
  • [Cites] Anal Biochem. 1995 Jun 10;228(1):64-8 [8572289.001]
  • (PMID = 16585762.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI059146; United States / NIAID NIH HHS / AI / 1R01 AI 059146-01A2
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 0U46U6E8UK / NAD; 1094-61-7 / Nicotinamide Mononucleotide; 25X51I8RD4 / Niacinamide; 2679MF687A / Niacin; 321-02-8 / nicotinate mononucleotide; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.7.7.- / Nucleotidyltransferases; EC 2.7.7.42 / glutamine-synthetase adenylyltransferase; EC 6.3.1.- / Amide Synthases; EC 6.3.1.5 / NAD+ synthase
  • [Other-IDs] NLM/ PMC1446974
  •  go-up   go-down


94. Denu JM: Vitamins and aging: pathways to NAD+ synthesis. Cell; 2007 May 4;129(3):453-4
Saccharomyces Genome Database. Saccharomyces Genome Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamins and aging: pathways to NAD+ synthesis.
  • Recent genetic evidence reveals additional salvage pathways for NAD(+) synthesis.
  • In this issue, Belenky et al. (2007) report that nicotinamide riboside, a new NAD(+) precursor, regulates Sir2 deacetylase activity and life span in yeast.
  • The ability of nicotinamide riboside to enhance life span does not depend on calorie restriction.
  • [MeSH-major] Aging / metabolism. Histone Deacetylases / metabolism. NAD / biosynthesis. Niacinamide / analogs & derivatives. Saccharomyces cerevisiae / metabolism. Silent Information Regulator Proteins, Saccharomyces cerevisiae / metabolism. Sirtuins / metabolism. Vitamins / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cell. 2007 May 4;129(3):473-84 [17482543.001]
  • (PMID = 17482537.001).
  • [ISSN] 0092-8674
  • [Journal-full-title] Cell
  • [ISO-abbreviation] Cell
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Silent Information Regulator Proteins, Saccharomyces cerevisiae; 0 / Vitamins; 0U46U6E8UK / NAD; 1341-23-7 / nicotinamide-beta-riboside; 25X51I8RD4 / Niacinamide; EC 3.5.1.- / SIR2 protein, S cerevisiae; EC 3.5.1.- / Sirtuin 2; EC 3.5.1.- / Sirtuins; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


95. Ma B, Pan SJ, Zupancic ML, Cormack BP: Assimilation of NAD(+) precursors in Candida glabrata. Mol Microbiol; 2007 Oct;66(1):14-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assimilation of NAD(+) precursors in Candida glabrata.
  • The yeast pathogen Candida glabrata is a nicotinamide adenine dinucleotide (NAD(+)) auxotroph and its growth depends on the environmental supply of vitamin precursors of NAD(+). C. glabrata salvage pathways defined in this article allow NAD(+) to be synthesized from three compounds - nicotinic acid (NA), nicotinamide (NAM) and nicotinamide riboside (NR).
  • The second is a novel pathway in which NR is degraded by the nucleosidases Pnp1 and Urh1, with a minor role for Meu1, and ultimately converted to NAD(+) via the nicotinamidase Pnc1 and the Preiss-Handler pathway.
  • Using C. glabrata mutants whose growth depends exclusively on the external NA or NR supply, we also show that C. glabrata utilizes NR and to a lesser extent NA as NAD(+) sources during disseminated infection.
  • [MeSH-major] Candida glabrata / metabolism. Metabolic Networks and Pathways. NAD / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725566.001).
  • [ISSN] 0950-382X
  • [Journal-full-title] Molecular microbiology
  • [ISO-abbreviation] Mol. Microbiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 2P01DK49720; United States / NIAID NIH HHS / AI / 5R01AI046223-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 1341-23-7 / nicotinamide-beta-riboside; 25X51I8RD4 / Niacinamide; 2679MF687A / Niacin; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.- / nicotinamide riboside kinase; EC 3.2.2.- / N-Glycosyl Hydrolases; EC 3.5.1.19 / Nicotinamidase
  •  go-up   go-down


96. Dudev T, Lim C: Factors controlling the mechanism of NAD(+) non-redox reactions. J Am Chem Soc; 2010 Nov 24;132(46):16533-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors controlling the mechanism of NAD(+) non-redox reactions.
  • β-Nicotinamide adenine dinucleotide (NAD(+)) is an indispensable coenzyme or substrate for enzymes involved in catalyzing redox and non-redox reactions.
  • ADP-ribosylating enzymes catalyze cleavage of the nicotinamide-glycosyl bond of NAD(+) and addition of a nucleophilic group from their substrate proteins to the N-ribose anomeric carbon of NAD(+).
  • Although the role of the nicotinamide-ribose fragment in the mechanism of NAD(+) hydrolysis has been examined, the role of the doubly negatively charged, flexible, and chemically reactive NAD(+) diphosphate moiety in the reaction process has largely been neglected.
  • In this study, we endeavor to fill in these gaps and elucidate the role of these factors in controlling the NAD(+) nicotinamide-glycosyl bond cleavage.
  • Using density functional theory combined with continuum dielectric methods, we modeled both S(N)1 and S(N)2 reaction pathways and assessed the role of the diphosphate group in stabilizing the (i) NAD(+) ground state, (ii) oxocarbocation intermediate, (iii) reaction product, and (iv) nucleophile.
  • [MeSH-major] NAD / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047075.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0U46U6E8UK / NAD
  •  go-up   go-down


97. Borradaile NM, Pickering JG: NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des; 2009;15(1):110-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD(+), sirtuins, and cardiovascular disease.
  • The sirtuin (SIRT) family of NAD(+)-dependent protein deacetylases and ADP-ribosyltransferases have emerged as exciting targets for CVD management that can impact the cardiovascular system both directly and indirectly, the latter by modulating whole body metabolism.
  • SIRT1-4 regulate the activities of a variety of transcription factors, coregulators, and enzymes that improve metabolic control in adipose tissue, liver, skeletal muscle, and pancreas, particularly during obesity and aging.
  • Because SIRT activity depends on cellular NAD+ availability, enzymes involved in NAD+ biosynthesis, including nicotinamide phosphoribosyltransferase (Nampt), may also be valuable pharmaceutical targets for managing CVD.
  • Herein we review the actions of the SIRT proteins on the cardiovascular system and consider the potential of modulating SIRT activity and NAD+ availability to control CVD.
  • [MeSH-major] Cardiovascular Diseases / metabolism. NAD / metabolism. Sirtuins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19149606.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0U46U6E8UK / NAD; EC 3.5.1.- / Sirtuins
  • [Number-of-references] 100
  •  go-up   go-down


98. Fukuwatari T, Shibata K: Consideration of diurnal variations in human blood NAD and NADP concentrations. J Nutr Sci Vitaminol (Tokyo); 2009 Jun;55(3):279-81
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consideration of diurnal variations in human blood NAD and NADP concentrations.
  • The sum of the urinary excretion of nicotinamide and its catabolites, which are metabolites of NAD and NADP, were observed to have clear diurnal variations in human urine.
  • Then, we examined whether NAD and NADP in blood also showed the diurnal variation.
  • In addition, we examined whether diurnal variations were affected by the intakes of dietary nicotinamide or not.
  • As a result, neither the NAD nor the NADP content of the blood shows the diurnal variation regardless of the administered amount of nicotinamide.
  • The concentrations of NAD and NADP did not increase according to the intake of nicotinamide.
  • The existence of a mechanism by which NAD and the NADP levels of the blood are constantly maintained by the adjustment of the amount of excretion to the urinary bladder, was suggested.
  • [MeSH-major] Circadian Rhythm / physiology. NAD / blood. NADP / blood

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19602837.001).
  • [ISSN] 1881-7742
  • [Journal-full-title] Journal of nutritional science and vitaminology
  • [ISO-abbreviation] J. Nutr. Sci. Vitaminol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0U46U6E8UK / NAD; 25X51I8RD4 / Niacinamide; 53-59-8 / NADP
  •  go-up   go-down


99. Wang J, He Z: NAD and axon degeneration: from the Wlds gene to neurochemistry. Cell Adh Migr; 2009 Jan-Mar;3(1):77-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAD and axon degeneration: from the Wlds gene to neurochemistry.
  • The phenotype is attributed to the overexpression of a chimeric protein Wlds which contains a short fragment of the ubiquitin assembly protein UFD2 and the full-length nicotinamide adenine dinucleotide (NAD) synthetic enzyme Nicotinamide mononucleotide adenylyl-transferase-1 (Nmnat-1).
  • Together with a significant number of subsequential reports, this finding highlighted the substantial role of nicotinamide adenine dinucleotide (NAD) in the process of axon degeneration.
  • Here we reviewed the history of axon degeneration research from a neurochemical standpoint and discuss the potential involvement of NAD synthesis, NAD consumption and NAD-dependent proteins and small molecules in axon degeneration.
  • [MeSH-major] Axons / pathology. NAD / metabolism. Nerve Tissue Proteins / genetics. Nervous System / metabolism. Nervous System / pathology. Wallerian Degeneration / metabolism. Wallerian Degeneration / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8484-91 [16914673.001]
  • [Cites] J Neurosci. 2006 Sep 20;26(38):9794-804 [16988050.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(8):2163-8 [17074042.001]
  • [Cites] J Neurosci Res. 2006 Dec;84(8):1799-807 [17022038.001]
  • [Cites] Cell Death Differ. 2007 Jan;14(1):116-27 [16645633.001]
  • [Cites] PLoS Biol. 2006 Nov;4(12):e416 [17132048.001]
  • [Cites] Annu Rev Neurosci. 2005;28:127-56 [16022592.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):349-55 [16043516.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36334-41 [16118205.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1075-84 [16371511.001]
  • [Cites] Neuron. 2006 Jun 15;50(6):869-81 [16772169.001]
  • [Cites] Neuron. 2006 Jun 15;50(6):883-95 [16772170.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):406-12 [11027696.001]
  • [Cites] FEBS Lett. 2001 Mar 9;492(1-2):95-100 [11248244.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7225-32 [11063748.001]
  • [Cites] Bioessays. 2001 Jun;23(6):543-8 [11385634.001]
  • [Cites] Nature. 2001 Jul 26;412(6845):449-52 [11473321.001]
  • [Cites] J Physiol. 2001 Aug 1;534(Pt 3):627-39 [11483696.001]
  • [Cites] Neuron. 2001 Sep 27;31(6):957-71 [11580896.001]
  • [Cites] J Biotechnol. 2001 Dec 28;92(2):81-7 [11640979.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Ann Neurol. 2001 Dec;50(6):773-9 [11761475.001]
  • [Cites] Nat Neurosci. 2001 Dec;4(12):1199-206 [11770485.001]
  • [Cites] Neuron. 2001 Dec 20;32(6):1013-26 [11754834.001]
  • [Cites] Gene. 2002 Feb 6;284(1-2):23-9 [11891043.001]
  • [Cites] Science. 2002 May 3;296(5569):868-71 [11988563.001]
  • [Cites] Neurosci Lett. 2002 Aug 9;328(2):150-4 [12133577.001]
  • [Cites] J Neurochem. 2001 Jan;76(2):321-31 [11208895.001]
  • [Cites] J Cell Biol. 2002 Aug 19;158(4):647-57 [12186850.001]
  • [Cites] J Physiol. 2002 Sep 15;543(Pt 3):739-55 [12231635.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):835-40 [12359228.001]
  • [Cites] Cell. 2002 Oct 18;111(2):209-18 [12408865.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45099-107 [12297502.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):297-304 [12504083.001]
  • [Cites] Eur J Immunol. 2002 Nov;32(11):3225-34 [12555668.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13503-11 [12574164.001]
  • [Cites] J Neurochem. 2003 Jun;85(5):1148-58 [12753074.001]
  • [Cites] Bioessays. 2003 Jul;25(7):683-90 [12815723.001]
  • [Cites] Neuron. 2003 Jun 19;38(6):871-85 [12818174.001]
  • [Cites] Neuron. 2003 Jul 17;39(2):217-25 [12873380.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7436-42 [14612543.001]
  • [Cites] Neurochem Int. 2004 Apr;44(5):361-9 [14643754.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2011-5 [14976264.001]
  • [Cites] Anal Biochem. 2004 Sep 1;332(1):90-9 [15301953.001]
  • [Cites] Science. 2004 Aug 13;305(5686):1010-3 [15310905.001]
  • [Cites] J Biol Chem. 1966 Jan 10;241(1):188-91 [4285133.001]
  • [Cites] Biochim Biophys Acta. 1971 Apr 29;238(1):82-5 [4325158.001]
  • [Cites] J Biol Chem. 1989 Jan 25;264(3):1608-15 [2912976.001]
  • [Cites] J Neuropathol Exp Neurol. 1991 May;50(3):192-204 [2022963.001]
  • [Cites] Biochem Pharmacol. 1992 Sep 1;44(5):947-53 [1530662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9717-20 [8415768.001]
  • [Cites] Mol Cell Endocrinol. 1994 Jan;98(2):125-31 [8143921.001]
  • [Cites] Eur J Neurosci. 1994 Apr 1;6(4):516-24 [8025707.001]
  • [Cites] Dev Biol. 1994 Sep;165(1):63-72 [8088451.001]
  • [Cites] J Neurocytol. 1995 May;24(5):333-40 [7650538.001]
  • [Cites] J Neurosci. 1995 Oct;15(10):6445-52 [7472407.001]
  • [Cites] Biochimie. 1995;77(5):394-8 [8527495.001]
  • [Cites] Trends Neurosci. 1995 Nov;18(11):489-96 [8592758.001]
  • [Cites] Neurosci Lett. 1995 Oct 27;199(3):163-6 [8577388.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3699-705 [8631983.001]
  • [Cites] J Neurochem. 1996 Sep;67(3):1259-67 [8752134.001]
  • [Cites] Exp Cell Res. 1999 Jun 15;249(2):396-403 [10366439.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):273-9 [10381378.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):47-51 [10471497.001]
  • [Cites] J Physiol. 1960 Jan;150:145-68 [13800902.001]
  • [Cites] Science. 2005 Feb 25;307(5713):1282-8 [15731448.001]
  • [Cites] Mol Cell Neurosci. 2005 Mar;28(3):430-9 [15737734.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Aug 3;359(3):665-71 [17560549.001]
  • [Cites] Nature. 2008 Apr 17;452(7189):887-91 [18344983.001]
  • [Cites] Biochem J. 1996 Oct 15;319 ( Pt 2):613-7 [8912702.001]
  • [Cites] Biochem J. 1997 Mar 15;322 ( Pt 3):909-17 [9148768.001]
  • [Cites] Nature. 1998 Sep 24;395(6700):395-8 [9759731.001]
  • [Cites] Free Radic Biol Med. 1998 Oct;25(6):694-702 [9801070.001]
  • [Cites] Mol Cell Neurosci. 1999 Sep;14(3):180-98 [10576889.001]
  • [Cites] J Neurosci. 2000 Feb 15;20(4):1333-41 [10662823.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Eur J Biochem. 2000 Mar;267(6):1550-64 [10712584.001]
  • [Cites] Prog Neurobiol. 2000 Oct;62(3):273-95 [10840150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11377-82 [11027338.001]
  • [Cites] Science. 2000 Dec 1;290(5497):1717-21 [11099404.001]
  • [Cites] Acta Neuropathol. 1971;5:Suppl 5:3-16 [5562691.001]
  • [Cites] J Neural Transm. 1978;42(1):37-43 [641543.001]
  • [Cites] Eur J Biochem. 1987 Apr 1;164(1):197-203 [3830181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 May;84(10):3491-5 [3472219.001]
  • [Cites] Genetics. 1987 May;116(1):9-22 [3297920.001]
  • [Cites] Toxicology. 1987 Oct 30;46(2):125-39 [3313811.001]
  • [Cites] Exp Cell Res. 1988 Jul;177(1):103-8 [3391236.001]
  • [Cites] Nat Med. 2005 May;11(5):572-7 [15821747.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):401-13 [14556717.001]
  • (PMID = 19372760.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0U46U6E8UK / NAD
  • [Number-of-references] 94
  • [Other-IDs] NLM/ PMC2675153
  •  go-up   go-down


100. Till S, Ladurner AG: Sensing NAD metabolites through macro domains. Front Biosci (Landmark Ed); 2009;14:3246-58
Saccharomyces Genome Database. Saccharomyces Genome Database .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensing NAD metabolites through macro domains.
  • Many macro domains, including those of the human histone macroH2A1.1, bind NAD metabolites such as ADP-ribose, suggesting that macro domains may function in the recognition of this and related molecules.
  • The presence of a metabolite-binding function in a repressive chromatin component opens new potential connections between chromosome structure, gene silencing and cellular metabolism.
  • Current evidence suggests that macro domains also represent a novel tool for studying NAD metabolites and may be an attractive drug target for the treatment of diseases.
  • [MeSH-major] NAD / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273270.001).
  • [ISSN] 1093-4715
  • [Journal-full-title] Frontiers in bioscience (Landmark edition)
  • [ISO-abbreviation] Front Biosci (Landmark Ed)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0U46U6E8UK / NAD; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Number-of-references] 68
  •  go-up   go-down






Advertisement